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Abstract 
Type 1 diabetes (T1D) results from autoimmune destruction of pancreatic β cells. The 
current treatment for the fatal insulin-deficiency in T1D is injection of exogenous insulin. Despite 
the dramatic increase in survival from the use of exogenous insulin, complications develop from 
imperfect glycemic control and exogenous insulin does not rectify the underlying cause of disease, 
the diabetogenic autoimmune response. Hence, there is a need for an effective therapy that impedes 
the progress of the pathogenic autoimmune response. β cell-reactive CD8+ and CD4+ T cells are 
important mediators of T1D development and progression, and CD8+ T cells directly destroy β 
cells. For an effective immunotherapy, diabetogenic CD8+ T cells must therefore be inactivated. 
Using the model antigen, ovalbumin (OVA), it has been shown that targeting OVA expression to 
antigen-presenting cells (APC) inactivates cognate CD8+ T cells. It is not known whether this 
inactivation would also occur for T cells recognising disease-relevant, β-cell antigens in 
autoimmune-prone NOD (non-obese diabetic) mice where genetic immune tolerance defects exist. 
In the NOD mouse model of T1D, insulin is the primary β-cell antigen that elicits disease. As such, 
I have investigated T-cell tolerance to insulin in an adoptive transfer setting in which TCR 
transgenic (G9) CD8+ T cells specific for insulin B15-23 (InsB15-23) were transferred to transgenic 
mice over-expressing proinsulin in APC. Subsequently, I examined the effect of introducing 
transgenic proinsulin expression on diabetes development in wild type NOD mice. 
When transferred to mice transgenically expressing proinsulin, naïve G9 T cells proliferated 
extensively prior to undergoing rapid deletion. In proinsulin transgenic recipients, the remaining 
population of G9 T cells displayed reduced T-cell receptor (TCR) expression and bound less InsB15-
23-loaded, H2-K
d-tetramer compared to G9 T cells that had been transferred to non-transgenic NOD 
recipients. Interestingly, TCR down-regulation represented that which occurred for OVA-specific 
CD8+ T cells transferred to mice expressing OVA in APC in a non-autoimmune prone strain. 
Importantly, naïve G9 T cells did not expand or produce the important effector cytokine, interferon 
(IFN)-γ, in response to InsB15-23 immunisation after transfer to proinsulin transgenic mice. These 
data confirm naïve G9 T cells undergo rapid deletion and inactivation after transfer to mice 
transgenically-expressing proinsulin, despite genetic tolerance defects in NOD mice. Memory CD8+ 
T cells (Tmem) perpetuate β-cell autoimmunity and pose a distinct barrier to immunotherapy. It was 
pertinent to determine whether inactivation of insulin-specific CD8+ Tmem also occurs after 
transfer to mice expressing proinsulin in APC. To test inactivation of insulin-specific CD8+ Tmem, 
G9 Tmem were generated using an in vitro culture method. Cultured G9 Tmem were validated by 
assessing phenotypic markers and cytokine production. Similarly to naïve G9 T cells, G9 Tmem 
proliferated extensively and most G9 Tmem were rapidly deleted after transfer to mice over-
expressing proinsulin in APC. The remaining, non-deleted population of G9 Tmem was infrequent 
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and exhibited reduced TCR expression. Furthermore, G9 Tmem did not expand or produce IFN-γ in 
response to InsB15-23 immunisation, consistent with functional inactivation. These results 
demonstrate transgenic proinsulin expression in APC overcomes genetic defects in NOD mice to 
induce tolerance in insulin-specific CD8+ Tmem. 
From the data described above, transgenic proinsulin expression is tolerogenic for insulin-
specific CD8+ T cells. This has therapeutic potential to alter diabetes development by inactivating 
potentially diabetogenic T cells. The next step was to investigate the effect on diabetes development 
of introducing transgenic proinsulin expression to non-transgenic NOD mice using bone marrow 
(BM)/haematopoietic stem and progenitor cell (HSPC) transfer facilitated by low-dose irradiation. 
Expanding regulatory T cells (Treg) concurrently with antigen-encoding BM/HSPC transfer may be 
beneficial in impeding diabetes progression. To determine the therapeutic window in which 
inducing tolerance to insulin might protect NOD mice from diabetes development, proinsulin 
transgenic BM/HSPC were transferred to NOD recipients at defined disease stages in conjunction 
with administration of a Treg-boosting interleukin (IL)-2 complex. Proinsulin transgenic BM did 
not significantly alter disease course when transferred to 10- and 16-week old NOD recipients. 
Interestingly, an increase in overall diabetes incidence was observed after proinsulin transgenic BM 
transfer to 6-week old NOD recipients, yet this increased diabetes incidence was not observed when 
proinsulin-encoding HSPC were transferred. Finally, treatment with an IL-2 complex reduced 
diabetes incidence in 3-week old recipients of NOD HSPC. The present study provides important 
proof-of-concept regarding rapid inactivation of naïve and memory CD8+ T cells recognising a 
diabetes-relevant, β-cell antigen that is, insulin, by transgenic expression of proinsulin in APC. 
Furthermore, this study demonstrates transfer of proinsulin-encoding BM and treatment with a 
Treg-boosting IL-2 complex alter diabetes development in an age-dependent manner.  
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1.1 Introduction 
Autoimmune disease occurs when an immune response is mounted against an individual’s 
own cells or tissues, representing a breakdown of immune tolerance mechanisms that usually 
moderate these undesirable immune responses. Autoimmune diseases are generally characterized as 
systemic or organ-specific. Systemic autoimmune diseases affect multiple organs or target sites 
within an individual such as the joints, skin and vasculature in systemic lupus erythematosus (SLE) 
or the kidneys and lungs in systemic sclerosis. Organ-specific autoimmune diseases are the result of 
a single organ or tissue being targeted, and classic examples are type 1 diabetes (T1D), in which 
pancreatic β cells are targeted, or Graves disease, where follicular cells of the thyroid gland are 
affected. The pathogenesis of organ-specific autoimmune disease usually involves T-cell attack and 
destruction of target tissues. A thorough understating of how to interrupt pathogenic T-cell 
responses could lead to effective therapies for T-cell mediated autoimmune diseases.  
 
1.2 T cells and the generation of immunological memory 
T cells are a subset of adaptive immune cells which develop in the thymus. In the periphery, 
T cells can be characterised into two broad populations based on the presence of the surface 
molecules CD4 and CD8. CD8+ T cells, as cytotoxic T lymphocytes (CTL), mediate cytotoxicity of 
pathogen-infected and potentially tumourigenic cells, while CD4+ T cells provide ‘help’ to elicit 
CD8+ T cell cytotoxicity as well as antibody production by B cells. The capacity to generate 
immunological memory is an important characteristic of T cells and the adaptive immune system as 
a whole. Naïve CD8+ T cells, by way of the T-cell receptor (TCR), recognise their cognate peptide 
antigen presented in the context of multiple histocompatibility complex (MHC) class I molecules on 
the surface of an antigen presenting cell (APC). Upon encounter with peptide/MHC class I 
complexes in the presence of co-stimulation, CD8+ T cells expand and differentiate [reviewed in 
(Williams & Bevan, 2007)]. Most CD8+ T cells differentiate into short-lived effector T cells, 
capable of driving inflammation through the production of proinflammatory cytokines such as 
interferon (IFN)-γ and tumour necrosis factor (TNF)-α. These short-lived CD8+ effector T cells are 
also able to directly lyse target cells via cytotoxic mediators including granzyme B/perforin and 
Fas/Fas ligand (FasL) (Li et al., 2014; Lowin et al., 1994). A small proportion (5-10%) of the initial 
activated T-cell pool will differentiate into a long-lived memory population (Kaech et al., 2002), 
capable of mounting a rapid response after secondary antigen challenge, and it is this rapid 
secondary response of memory T cells (Tmem) which underlies vaccination. Human and murine 
Tmem can be classified into two broad subsets based on phenotype and function: central memory 
and effector memory T cells. Central memory T cells (TCM) express high levels of the lymph node 
(LN)-homing receptor, CD62L, and chemokine receptor 7 (CCR7) and as such, generally reside in 
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LN. In contrast, effector memory T cells (TEM) express low levels of CD62L and do not express 
CCR7, but possess cytotoxic activity and can migrate to non-lymphoid tissue (Sallusto et al., 1999; 
Wherry et al., 2003).  
 
1.3 T-cell tolerance  
The immune system must not only prevent the individual from attack by pathogens, but also 
protect self-tissue from misdirected immune responses. Tolerance mechanisms act as checkpoints to 
balance the need to prevent deleterious autoimmune responses without impairing protective 
immunity As a consequence, autoimmune disease results when immune tolerance mechanisms 
break down.  
 
1.3.1 Central tolerance 
Central tolerance occurs in the thymus for T cells and during T-cell development, immature 
CD4+CD8+ T cells are positively selected in the thymic cortex by finely-tuned levels of TCR 
signalling. Thymocytes with very low levels of TCR signalling die by neglect and those with TCR 
signalling above this threshold progress to negative selection (Starr et al., 2003). Negative selection 
is deletion, via apoptosis, of thymocytes that strongly interact with self-antigen presented by MHC 
(Klein et al., 2014). Many tissue-specific antigens are expressed in the thymus (Derbinski et al., 
2001) and the autoimmune regulator (Aire) gene has been implicated in controlling thymic 
expression of self-antigens (Anderson et al., 2002). Humans with autoimmune polyglandular 
syndrome type 1 (APS1) display multi-organ endocrinology and this syndrome has been attributed 
to a mutation in AIRE (Peterson & Peltonen, 2005). Furthermore, Aire-deficient mice display 
similar autoimmune phenotypes to APS1 patients (Anderson et al., 2002; Metzger & Anderson, 
2011). Therefore, Aire-dependent thymic antigen expression is crucial for effective negative 
selection of thymocytes and in the absence of Aire, an increase in self-reactive T cells is observed in 
the periphery which may lead to development of autoimmune disease. Some thymocytes with an 
intermediate to high self-reactivity are designated to develop into regulatory T cells (Treg) 
(Stritesky et al., 2013) and thymocytes with low affinity for self are released into the periphery 
(Stritesky et al., 2012). 
 
1.3.2 Peripheral tolerance 
While negative selection in the thymus greatly reduces the frequency of circulating, 
potentially autoreactive mature T cells, this tolerance mechanism is incomplete as not all self-
antigens are expressed in the thymus and low-affinity self-reactive T cells can escape central 
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tolerance, thus peripheral checkpoints are required to prevent autoimmune disease. Peripheral 
tolerance mechanisms can be classified as cell-intrinsic or cell-extrinsic.  
 
1.3.2.1 Cell-intrinsic peripheral tolerance mechanisms 
Cell-intrinsic deletion or induction of functional unresponsiveness in a T cell requires an 
antigen-specific interaction of the T cell with an APC. To generate immunity, T-cell activation 
requires TCR recognition of peptide/MHC complex on APC and a second co-stimulatory signal 
such as ligation of CD28 on the T cell and CD80/CD86 present on the APC. The result of an 
‘unproductive’ encounter, in the absence of a co-stimulatory signal, between a T cell and an APC 
presenting the T cell’s cognate antigen is deletion of that T cell, or the T cell existing in an 
unresponsive state (Bonifaz et al., 2002; Hawiger et al., 2001; Steptoe et al., 2007). In studies 
employing administration of peptide to induce tolerance, it has been shown that lower peptide doses 
favour deletion, rather than unresponsiveness, of cognate T cells (Redmond et al., 2005) and 
peptides with low TCR affinity also favour deletional T-cell tolerance (Smith et al., 2014). During 
deletional tolerance, there is an initial period of T-cell proliferation but this ultimately leads to death 
of the self-reactive T cells via apoptosis (Davey et al., 2002; Kenna et al., 2008; Kurts et al., 1997). 
Proliferation of self-reactive CD8+ T cells preceding their deletion has been demonstrated upon 
interaction with Aire-expressing cells that reside outside of the thymus, in secondary lymphoid 
organs (Gardner et al., 2008). Using TCR transgenic mice in which CD8+ T cells recognise 
hemagglutinin (HA), HA-specific CD8+ (clone 4) T cells proliferated before being deleted in 
pancreatic LN (pLN) of transgenic mice expressing HA in pancreatic islets (Hernandez et al., 
2001). In mice expressing the model antigen, ovalbumin (OVA), in the pancreas only high levels of 
OVA expression led to deletion of transferred OVA-specific CD8+ (OT-I) T cells, as opposed to 
OT-I T-cell ignorance when low levels of OVA were expressed (Kurts et al., 1999).  
The Bcl-2 family member, Bim, has been implicated in the apoptotic pathway of deletional 
tolerance, in that Bim can activate the proapoptotic proteins, Bax and Bak, thereby initiating 
mitochondrial cell death (Czabotar et al., 2009; Gavathiotis et al., 2008). For example, Bim-
deficient CD8+ T cells recognising OVA were not deleted in response to cross-presented OVA, 
unlike their wild type counterparts (Davey et al., 2002). Furthermore, inhibition of deletion in 
response to cross-presented antigen has been demonstrated for Bim-deficient CD8+ T cells 
recognising HA (Redmond et al., 2008). Another pathway of T-cell death is dependent on the death 
receptor CD95 (Fas) and the role of CD95 in antigen-specific T-cell deletion is less clear, that is, 
CD95-deficient OT-I T cells were not deleted when OVA was expressed in islets (Kurts et al., 
1998), while CD95-deficient clone 4 T cells were deleted when HA was expressed in islets 
(Redmond et al., 2008). Transcriptional analyses have shown CD8+ T cells undergoing deletional 
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tolerance exhibited a distinct gene profile from T cells undergoing immunogenic activation, with 
down-regulation of granzyme A, as well as rapid up-regulation of Bim and up-regulation of 
programmed death 1 (PD-1) (Parish et al., 2009). Deletional tolerance of CD8+ T cells by targeting 
antigen to steady-state dendritic cells (DC), was demonstrated to be independent of the PD-1/PD-
ligand 1 (PD-L1) pathway (Mukherjee et al., 2013), and may represent different T-cell tolerance 
outcomes depending on the antigen encounter. Targeting antigen to non-APC, such as, erythrocytes, 
has been shown to induce T-cell tolerance by cross-presentation of antigen by DC and subsequent 
deletion of cognate CD8+ and CD4+ T cells (Kontos et al., 2013). Therefore, T-cell deletion in the 
periphery has been demonstrated in multiple model systems and is important in maintaining 
tolerance to self, and in the absence of such deletional pathways, autoimmune disease can result.  
Anergy occurs when T cells persist in an unresponsive state following antigen encounter in 
the absence of a co-stimulatory signal and this state was initially characterised in vitro (Harding et 
al., 1992; Jenkins & Schwartz, 1987; Lamb et al., 1983). The anergic state is characterized by 
reduced TCR signalling and interleukin (IL)-2 expression (Schwartz, 2003). Altered signalling 
pathways underlie T-cell anergy in that T cells lacking the E3 ubiquitin ligases, Itch or Cbl-b, are 
resistant to anergy (Heissmeyer et al., 2004), probably due to the requirement for such ubiquitin 
ligases to degrade TCR signalling proteins. Furthermore, microarray analyses revealed early growth 
response gene 2 (Egr-2) and Egr-3 as negative regulators of TCR signalling, possibly through 
association with Cbl-b (Safford et al., 2005). T-cell unresponsiveness can occur not only from a T 
cell/APC interaction in the absence of co-stimulation, but also in the presence of co-inhibitory 
molecules, for example PD-1 and cytotoxic T lymphocyte antigen-4 (CTLA-4). CTLA-4 has been 
shown to compete with CD28 for binding of its ligand CD80 (van der Merwe et al., 1997), thereby 
inducing unresponsiveness, rather than activation, of the interacting T cell. In a study using 
administration of peptide to explore T-cell tolerance, CD8+ T-cell unresponsiveness was reversed 
by PD-1 blockade (Tsushima et al., 2007). Despite studies implicating the PD-1/PD-L1 inhibitory 
pathway in T-cell deletion and unresponsiveness, this pathway has been more extensively 
investigated in, and thought to be a hallmark of, T-cell exhaustion in chronic viral infection (Day et 
al., 2006; Trautmann et al., 2006) and tumour settings (Fourcade et al., 2012; Woo et al., 2012). The 
transcription factor nuclear factor of activated T cells (NFAT) has recently been shown to bind to 
genes associated with exhaustion which, for example, encode PD-1 and T cell immunoglobin and 
mucin domain-containing 3 (TIM-3), thereby controlling CD8+ T-cell exhaustion and possibly other 
forms of T-cell unresponsiveness dependent on co-inhibitory molecules (Martinez et al., 2015) The 
importance of peripheral tolerance mechanisms is evident as autoreactive T cells often exist in 
healthy individuals (Danke et al., 2004). It is this ability of APC to induce T cell-specific tolerance 
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that makes them an attractive tool for immunotherapy in autoimmune diseases where peripheral 
tolerance mechanisms are perturbed.  
 
1.3.2.2 Cell-extrinsic peripheral tolerance mechanisms 
Cell-extrinsic peripheral tolerance mechanisms can be mediated by cells with regulatory 
properties capable of suppressing effector T cells. There are a range of T-cell types with regulatory 
abilities including conventional Treg, T helper 3 (Th3) and type 1 regulatory T cells (Tr1). 
Conventional Treg, as characterised by CD4, CD25 and forkhead box P3 (Foxp3) transcription 
factor expression are important in maintaining peripheral tolerance and thereby preventing 
development of autoimmune disease (Hori et al., 2003; Sakaguchi et al., 1995). Treg can act 
through contact-dependent or contact-independent mechanisms (Shalev et al., 2011). Contact-
dependent mechanisms include ligation of CTLA-4 on the surface of Treg with CD80/CD86 which 
acts to inhibit co-stimulation and cytokine secretion of DC to impair effector T-cell activation 
(Oderup et al., 2006). Treg, via CTLA—4, can induce production of indoleamine 2, 3-dioxygenase 
(IDO) by DC which suppresses T-cell function by depletion of tryptophan (Fallarino et al., 2003). 
Also, Treg can lyse effector T cells by release of perforin and granzymes (Cao et al., 2007; 
Grossman et al., 2004; Oderup et al., 2006). Contact-independent mechanisms of Treg function 
include secretion of regulatory cytokines interleukin (IL)-10 (Asseman et al., 1999), IL-35 (Collison 
et al., 2007) and transforming growth factor (TGF)-β (Joetham et al., 2007) as well as limiting 
expansion of effector T cells by IL-2 deprivation (McNally et al., 2011).  
Two subsets of Foxp3+ Treg occur in mice and humans; thymic-derived natural Treg (nTreg) and 
peripherally induced Treg (iTreg). nTreg develop in the thymus as a result of agonist self-peptide 
selection (Jordan et al., 2001). During reduced immunogenic conditions, conventional T cells can 
convert to iTreg in the presence of TGF-β and retinoic acid, with this process occurring 
predominantly in the gut (Chen et al., 2003; Peng et al., 2004). Emphasising the importance of Treg 
in autoimmune disease is ‘immune dysregulation, polyendocrinopathy, enteropathy, X-linked’ 
(IPEX) syndrome in which patients have mutations in the FOXP3 gene (Katoh et al., 2013), 
resulting in defective Treg and development of multiple autoimmune diseases within the first few 
years of life (Chatila et al., 2000; Powell et al., 1982).  
 
1.4 Type 1 diabetes  
T1D is an autoimmune disease mediated by T cells, resulting in destruction of insulin-
producing β cells in the pancreatic islets of Langerhans (Chatenoud et al., 1994). Insulin is a 
hormone secreted exclusively by pancreatic β cells and allows for cellular up-take of glucose from 
the blood. As such, T1D is characterised by hyperglycemia as well as impaired lipid and protein 
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metabolism. The endocrine symptoms of T1D are due to the lack of insulin in T1D patients and 
currently, injection of exogenous insulin is required for survival. However, injection of insulin is 
not a cure and imperfect control of blood glucose levels renders patients susceptible to chronic 
complications including retinopathy, neuropathy and nephropathy, as well as cerebrovascular and 
cardiovascular disease (Bjornstad et al., 2015). These complications are the prime cause of 
amputations and reduced lifespan in T1D patients. 
T1D afflicts more than 90 000 individuals in Australian (2011) and is usually diagnosed in 
childhood although this disease can also arise later in life (Naik et al., 2009). Genetic predisposition 
and environmental factors are involved in T1D development, with the incidence increasing 
dramatically over the last twenty years, especially in younger children (Harjutsalo et al., 2008), 
highlighting the influence of environmental factors in disease progression. Some environmental 
factors proposed to influence T1D development include lack of Vitamin D from decreased sun 
exposure (Takiishi et al., 2010), reduced exposure to microbes leading to dysregulation of immune 
responses (D'Angeli et al., 2010), viral infections such as Coxsackievirus-B (Hober et al., 2012) and 
infant nutrition (Knip et al., 2010). In terms of genetic susceptibility, certain loci within the human 
MHC, known as the human leukocyte antigen (HLA), region confer the greatest genetic risk for 
T1D including DRB1 0401 and DQA1 0301 alleles (Erlich et al., 2008). Non-HLA candidate genes 
associated with T1D include INS, PTPN22, CTLA4 [reviewed in (Bluestone et al., 2010; Concannon 
et al., 2009)] and IL2RA (Lowe et al., 2007). The fact that the majority of T1D-associated 
candidate-genes are involved in immune function emphasises the autoimmune nature of T1D. As 
such, autoantibodies against various β-cell antigens, including insulin, glutamic acid decarboxylase 
65 (GAD65), IA-2 (insulinoma antigen 2) and islet-specific glucose-6-phosphatase catalytic 
subunit-related protein (IGRP), are present in the majority of T1D patients and detection of 
autoantibodies is currently the most reliable predictor of high risk of developing T1D (Pihoker et 
al., 2005).  
Since T1D is a disease resulting from immune dysregulation, restoration of immune 
regulation would provide an opportunity to therapeutically intervene in the course of disease. 
Therefore, antigen-specific immunotherapy is an attractive approach for T1D. Due to the early age 
of onset and generally non-fatal nature of T1D, the window for therapeutic manipulation is small 
and for any immunotherapy there is emphasis on inactivating autoreactive T-cell responses in an 
antigen-specific manner, while maintaining robust immunity to foreign antigens. At T1D diagnosis, 
patients have developed a pool of well established effector T cell and Tmem responses as a result of 
ongoing β-cell autoimmunity and for an immunotherapy to provide a curative effect, these Tmem 
responses need to be inactivated. The host laboratory has demonstrated that transfer of antigen-
encoding haematopoietic stem and progenitor cells (HSPC) is an effective tool to instate potentially 
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tolerogenic antigen expression and thus inactivate cognate memory CD8+ T cells (Coleman et al., 
2012).  
 
1.5 T cells in autoimmune diabetes  
Although autoimmune diabetes is a T-cell mediated autoimmune disease, involvement of 
other immune cell types, such as B cells and innate immune cells, are also important for diabetes 
progression (Diana et al., 2013; Serreze et al., 1996). The primary role of both CD8+ and CD4+ T 
cells in autoimmune diabetes of the non-obese diabetic (NOD) mouse is evident in the ability of 
purified CD8+ and CD4+ T cells from NOD mice to transfer diabetes (Christianson et al., 1993; 
Wong et al., 1996) and by inhibition of diabetes by therapies modulating T cells (Chatenoud et al., 
1994). Early histological studies identified both CD4+ and CD8+ T cells within the pancreatic islets 
of diabetic patients (Hanninen et al., 1992; Itoh et al., 1993). Furthermore, IGRP-, GAD65- and 
insulin-specific T cells have been detected in the peripheral blood of patients with T1D (Luce et al., 
2011; Yang et al., 2006; Yang et al., 2012a). 
CD4+ T cells were initially suspected of being the cause of T1D as CD4+ T cells were highly 
abundant in infiltrated islets of NOD mice, CD4+ T cell clones could transfer disease (Haskins et 
al., 1988) and in humans, the most significant genetic risk for T1D mapped to MHC class II (Shiina 
et al., 2004). Although current evidence suggests CD8+ T cells play a key role in β-cell destruction. 
For instance, pancreatic β cells express only MHC class I (Thomas et al., 1998), and not MHC class 
II (McInerney et al., 1991), suggesting only CD8+ T cells can directly recognise antigens presented 
by β cells. However, a recent study suggests MHC class II expression is up-regulated by β cells in 
response to IFN-γ in NOD mice (Zhao et al., 2015). Furthermore, NOD mice deficient in MHC 
class I and CD8+ T cells are protected from insulitis as well as autoimmune diabetes (Katz et al., 
1993a; Serreze et al., 1994). While when only pancreatic β cells were deficient in MHC class I, 
insulitis proceeded unhindered but diabetes development was impaired (Hamilton-Williams et al., 
2003), which may indicate a direct role for CD8+ T-cell interaction in the progression from insulitis 
to overt diabetes . Using a humanised mouse model, it has been demonstrated that CD8+ T cells 
cloned from peripheral blood of a new-onset T1D patient were able to induce destructive insulitis 
(Unger et al., 2012). Also in human T1D, a strong association between the presence of autoreactive 
CD8+ T cells and islet transplantation failure suggests CD8+ T cells are important for β-cell 
destruction (Pinkse et al., 2005). Following lysis of β cells, further autoreactive T cells can be 
primed as a result of antigen release from dead β cells (Turley et al., 2003), perpetuating 
autoimmunity. Diabetogenic CD4+ T cells are primed in pLN (Hoglund et al., 1999), while 
autoreactive CD8+ T cells may develop effector function in islets (Chee et al., 2014), suggesting 
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CD8+ T cells initiate islet autoimmunity through direct interaction with β cells and CD4+ T cells are 
necessary to magnify and sustain this response through to the progression of insulitis.  
NOD TCR transgenic mice in which T cells recognise β-cell antigens have been established 
and have proven to be invaluable tools for dissecting the role of self-reactive T cells in autoimmune 
diabetes. The TCRs utilised to generate these TCR transgenic mice are typically derived from T-cell 
clones isolated from NOD mice at various disease stages. An example of an H2-Ag7-restricted TCR 
transgenic mouse is the BDC2.5 mouse (Katz et al., 1993b), which expresses a transgenic TCR 
derived from a CD4+ T-cell clone isolated from NOD mice (Haskins et al., 1988), recognising 
chromogranin A (ChgA) (Stadinski et al., 2010). An example of an H2-Kd-restricted TCR 
transgenic mouse is the G9 mouse (Wong et al., 2009), generated using the TCR chains from a 
CD8+ T-cell clone isolated from young NOD mice (Wong et al., 1996) and which recognises insulin 
B15-23 peptide (InsB15-23) (Wong et al., 1999). Another is the 8.3 mouse (Verdaguer et al., 1997), in 
which the transgenic TCR was derived from an IGRP206-214-specific (Lieberman et al., 2003) CD8
+ 
T cell clone isolated from NOD mice older than 10 weeks of age (Nagata & Yoon, 1992). Studies 
utilising these T-cell clones and TCR transgenic mice have been instrumental in developing the 
understanding of T-cell pathogenesis in autoimmune diabetes.  
 
1.6 Autoantigen involvement in autoimmune diabetes 
Since the identification of insulin as a target of the autoimmune response in T1D patients 
(Palmer et al., 1983), over thirty β-cell antigens have been identified (DiLorenzo, 2011), including 
insulin, IGRP and GAD65. The process by which immune responses are generated to many 
antigens as a result of an initial response toward a primary antigen is termed epitope spreading. 
Epitope spreading is evident in autoimmune disease models including the NOD mouse, where this 
process is crucial to disease progression (Tian et al., 2006). Also, there is evidence to suggest 
epitope spreading occurs in human T1D also (Ott et al., 2004). Therefore, it is important to 
understand the contribution of β-cell antigens in the pathogenesis of autoimmune diabetes. 
 
1.6.1 Insulin 
Insulin is not only the hormone lacking in patients with T1D, it is also a key autoantigen 
recognised by self-reactive T cells critical to autoimmune diabetes pathogenesis. Insulin was the 
first target for autoantibodies in autoimmune diabetes to be characterised at the molecular level 
(Palmer et al., 1983). However, these autoantibodies are not pathogenic (Bach, 1994), indicating a 
prime role for autoreactive T cells in autoimmune diabetes. Several lines of evidence suggest 
insulin is the primary autoantigen of autoimmune diabetes in the NOD mouse and T-cell responses 
to insulin are required for diabetes development. The G9 T-cell clone, recognising InsB15-23 (Wong 
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et al., 1999), isolated from the islets of young NOD mice rapidly transfer disease (Wong et al., 
1996). Insulin-reactive CD4+ T-cells clones from NOD islets have also been identified, specifically 
for InsB9-23 (Daniel et al., 1995). Moreover, insulin-specific T cells have been identified in human 
T1D, both in the circulation (Luce et al., 2011; Sachdeva et al., 2015) and from pLN (Kent et al., 
2005). While the presence of insulin-reactive T cells in NOD mice and humans has indicated a role 
for insulin-specific T-cell responses in diabetes, manipulation of insulin expression in mice has 
been crucial in dissecting the role of insulin as an autoantigen in autoimmune diabetes. Mice 
possess two insulin genes, Ins1 and Ins2, with greater expression of insulin II protein in the thymus 
(Heath et al., 1998). NOD mice made deficient in the Ins2 gene show accelerated development of 
autoimmune diabetes (Thebault-Baumont et al., 2003), this is in contrast to the protection from 
diabetes observed for Ins1 knockout NOD mice (Moriyama et al., 2003). Proinsulin is the 
prohormone precursor of insulin and transgenic expression of proinsulin in APC of NOD mice 
protects from diabetes (French et al., 1997). Using this model, it has been shown that proinsulin-
specific T-cell responses are required for expansion of T cells specific for other β-cell antigens 
(Krishnamurthy et al., 2006; Krishnamurthy et al., 2008), providing strong evidence that 
(pro)insulin is the primary autoantigen in NOD mice. Furthermore, altering the InsB9-23 sequence, 
which contains overlapping CD8+ T-cell and CD4+ T-cell determinants (Daniel et al., 1995; Wong 
et al., 1999), by a tyrosine to alanine substitution at position 16, protects NOD mice from insulitis 
and diabetes development (Nakayama et al., 2005; Nakayama et al., 2007).  
Genetically, the role of insulin in T1D is emphasised by the contribution of human insulin 
(INS) gene polymorphisms to disease susceptibility (Concannon et al., 2009). Shorter repeat 
polymorphisms in the promoter region of the INS gene confer risk, while longer repeats are 
associated with protection from diabetes (Kockum et al., 1996). The longer repeat polymorphisms, 
known as class III alleles, are thought to provide protection due to higher levels of thymic insulin 
transcription compared to transcription from short class I polymorphisms (Vafiadis et al., 1997). 
The protective effect of higher thymic insulin levels has been attributed to greater IL-10 production 
from proinsulin-specific Tmem (Durinovic-Bello et al., 2005). While there is strong evidence for 
the role of insulin as a prime autoantigen in autoimmune diabetes, there remain roles for other β-cell 
antigens in the pathogenesis of T1D. 
 
1.6.2 IGRP  
IGRP-specific TCR transgenic mice show different diabetes kinetics dependent on whether 
the IGRP-specific T cells are H2-Kd- or H2-Ag7-restricted. While monoclonal IGRP-specific CD4+ 
T cells are sufficient to cause diabetes, the reduced frequency and prolonged disease initiation 
observed for mice with a monoclonal IGRP-specific CD8+ T-cell repertoire (Verdaguer et al., 
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1997), suggests that IGRP-specific CTL require help from autoreactive CD4+ T cells to effectively 
propagate autoimmune diabetes. Building on this, it was shown that proinsulin-specific T-cell 
responses are necessary for IGRP-specific CD8+ T-cell expansion and transgenic expression of 
IGRP in APC resulted in loss of IGRP-specific T cells in islets of transgenic mice but IGRP 
expression had no effect on insulitis or diabetes development (Krishnamurthy et al., 2006). 
Similarly, deletion of the gene encoding IGRP had no effect on diabetes progression in NOD mice, 
despite the absence of IGRP-reactive T cells in islets of IGRP knockout mice (Oeser et al., 2011). 
Altering the T-cell repertoire of NOD mice by specifically depleting IGRP-reactive CD8+ T cells 
using toxin-coupled tetramer delayed the onset of, but did not prevent, autoimmune diabetes 
(Vincent et al., 2010), which may indicate responses to IGRP are not crucial to initiate islet 
autoimmunity, but rather act synergistically with other specificities to mediate diabetes 
development. Furthermore, unlike insulin, IGRP expression is not detectable in thymus of NOD 
mice (Gardener, 2008), suggesting IGRP-specific T cells in the periphery may be of a higher 
affinity than insulin-specific T cells, which may underlie differences in T-cell responses in the 
periphery and how these T-cell specificities mediate diabetes pathogenesis. 
 
1.6.3 GAD65 
GAD65 is an enzyme expressed in pancreatic β cells, as well as in neurons, and its role in 
diabetes initiation and progression is conflicted in the literature. GAD65-specific T-cell responses 
are detected in pre-diabetic NOD mice (Kaufman et al., 1993) and human T1D (Mannering et al., 
2004; Oling et al., 2005; Worsaae et al., 1995). Inducing tolerance to GAD65 in NOD mice has had 
varying effects on diabetes development, in that, passive tolerance induction in young NOD mice 
by i.v. injection of GAD65 prevented insulitis and autoimmune diabetes (Kaufman et al., 1993), 
while oral administration of porcine GAD65 had no effect on disease progression in NOD mice 
(Ramiya et al., 1997). In contrast, feeding transgenic plants expressing the other GAD isoform, 
GAD67, reduced diabetes incidence in NOD mice (Ma et al., 1997). As another example, nasal 
administration of various GAD65 peptides protected over 50% of treated NOD mice from diabetes 
and T cells from treated mice displayed a Th2 phenotype, as opposed to the high Th1-bias present 
in autoimmune diabetes (Tian et al., 1996). The efficacious therapies using GAD, and its peptides, 
in NOD mice have not translated to human T1D. Injection with GAD65 and alum in recent-onset 
T1D patients had no effect on C-peptide levels at four years follow-up (Ludvigsson et al., 2011), 
but increased GAD65-specifc CD4+CD25hi T cells were observed in peripheral blood from GAD65-
treated relative to placebo-treated patients (Hjorth et al., 2011). Manipulation of GAD65 expression 
in NOD mice suggests GAD65 is not required for autoimmune diabetes development. For example, 
GAD65 knockout mice develop diabetes as per their wild type counterparts (Yamamoto et al., 
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2004) and transgenic expression of GAD65 in APC does not protect mice from diabetes (Jaeckel et 
al., 2003). Further analysis of young GAD65 transgenic mice displayed reduced β-cell specific T-
cell responses (Tian et al., 2009), implying the involvement of GAD65 in diabetes development is 
to promote activation and expansion of T cells specific for other β-cell antigens.  
 
1.6.4 Other autoantigens 
ChgA is a protein found in secretory granules of β cells and neuroendocrine tissues. It was 
identified as a T1D autoantigen for its ability to activate the CD4+ BDC2.5 T-cell clone (Stadinski 
et al., 2010). ChgA-specific CD4+ and CD8+ T-cell responses have been identified in T1D patients 
(Gottlieb et al., 2014; Li et al., 2015), indicating ChgA may be an important autoantigen in human 
T1D. Another more recently identified autoantigen is zinc transporter 8 (ZnT8) (Wenzlau et al., 
2007). Zinc is crucial for proper storage, secretion and function of insulin and ZnT8 is specifically 
expressed in pancreatic β cells. The proportion of T1D patients positive for ZnT8 autoantibodies 
ranges between 24%-80%, depending on the study (Kawasaki et al., 2011; Wenzlau et al., 2007). 
The identification of novel T1D autoantigens is beneficial for screening at-risk individuals to 
predict diabetes onset and for diagnostic applications.  
Post-translational modification of protein, such as glycoslyation and methylation, can result 
in the generation of unique self-antigens and post-translationally modified antigens have been 
extensively investigated in autoimmune diseases including rheumatoid arthritis and multiple 
sclerosis (MS) (Doyle & Mamula, 2001). T cells from T1D patients recognise post-translationally 
modified insulin (Mannering et al., 2005) and GAD65 (McGinty et al., 2014) determinants, while a 
post-translationally modified ChgA peptide more effectively activates BDC2.5 T cells than the 
native ChgA peptide (Delong et al., 2012). Examination of post-translationally modified antigens in 
T1D provides insight into the pathogenesis of diabetes and may explain how low-affinity antigens, 
such as insulin, generate strongly diabetogenic responses.  
 
1.7 Failure of immunological tolerance in autoimmune diabetes 
1.7.1 Failure of immunological tolerance in the NOD mouse 
The NOD mouse is the most well-established mouse model of autoimmune diabetes 
(Makino et al., 1980). Diabetes occurs spontaneously in 60-80% of female and 20-30% of male 
NOD mice, depending on housing conditions (Bach, 1994; Kikutani & Makino, 1992). The 
presence of immune cell infiltrates that surround the islet, termed peri-insulitis, is observed by 
approximately 3-4 weeks of age. Invasion of the islets by immune cells is termed insulitis and 
occurs several weeks after the initiation of peri-insulitis in both male and female mice (Anderson & 
Bluestone, 2005). Onset of overt diabetes begins to occur from 12-14 weeks of age in female NOD 
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mice. The presence of insulitis in both male and female NOD mice, but the disparity between 
diabetes incidence, suggests late stage regulatory events are capable of controlling progression to 
overt diabetes. NOD mice exhibit defects in multiple leukocyte subsets. Treg are important in 
controlling autoimmunity and in the NOD mouse dysregulation of Treg has been described. For 
example, the suppressive function of Treg decreases with age in NOD mice (Gregori et al., 2003) 
and, compounding this decrease in Treg suppression, is the increased resistance of effector T cells 
to Treg-mediated suppression in older NOD mice (You et al., 2005). Evidence suggests these 
defects may not be Treg-intrinsic and that APC may be defective in maintaining Treg function. As 
such, APC from autoimmune-resistant C57BL/6 mice were more effective in stimulating 
CD4+CD25+ Treg than APC from NOD mice (Alard et al., 2006). Furthermore, CD11b+CD11c- 
APC from NOD mice expressing C57BL/6 resistant alleles prime more suppressive Treg than APC 
from wild type NOD mice (Anderson et al., 2008). The maturation and function of macrophages has 
been shown to be defective in NOD mice (Lee et al., 2012b; Padgett et al., 2015; Serreze et al., 
1993), as is the function of natural killer (NK) and NKT cells (Poulton et al., 2001). Such defects in 
Treg, APC and other cell types may act in concert to bring about the autoimmune disease phenotype 
observed in NOD mice.  
NOD mice possess the unique H2-Ag7 MHC haplotype which is not only the most high risk 
genetic factor, but is also necessary for diabetes development in NOD mice (Wicker et al., 1995). 
There is a specific substitution on the I-A molecule, an aspartic acid to glutamine at position 57 on 
the β chain (Acha-Orbea & McDevitt, 1987), that alters peptide binding (Kanagawa et al., 1998), 
and this substitution is also present in the human susceptibility HLA DQ β chain (Todd et al., 
1987). Manipulations of MHC in NOD mice can provide protection from diabetes development 
(Nishimoto et al., 1987; Uehira et al., 1989). Other loci, apart from MHC, which contribute to 
diabetes susceptibility in the NOD mouse are termed Idd (insulin-dependent diabetes) loci (Todd & 
Wicker, 2001). Ctla4 is contained in the Idd5 locus and polymorphisms in this gene can confer risk 
of autoimmune diabetes in the NOD mouse and T1D in humans (Ueda et al., 2003). Il2 is the 
strongest candidate-gene in the Idd3 region (Yamanouchi et al., 2007) and congenic NOD mice 
which express diabetes-resistant Idd3 alleles have reduced diabetes incidence, due to an increase in 
suppressive Treg in pLN and islets (Goudy et al., 2011). 
NOD mice have been shown to possess defects in peripheral tolerance pathways, including 
reduced deletion and increased accumulation of islet-specific CD8+ T cells (Hamilton-Williams et 
al., 2012). These tolerance defects could be rescued with the introduction of diabetes-resistant Idd 
alleles from non-autoimmune strains, such as C57BL/6. Expansion of HA-specific CD8+ T cells 
was suppressed by CD25+ Treg in Idd3/5 mice expressing HA in islets (Martinez et al., 2005). This 
is important when the candidate genes of Idd3 and Idd5, Il2 and Ctla4, respectively, are considered 
14 
 
with regard to their known function in Treg survival and suppressive activity (Barron et al., 2010; 
Sojka et al., 2009). The presence of multiple susceptibility loci in the NOD mouse hints at the 
complexity of genetic pathways involved in diabetes development and that numerous tolerance 
pathways are perturbed in the NOD mouse. Since several of the genetic lesions in NOD mice are 
similar to those described in human T1D, it is possible that similar peripheral tolerance defects 
contribute to islet autoimmunity in human T1D. 
 
1.7.2 Failure of immunological tolerance in human T1D 
It has long been suggested that abnormalities within immune cell subsets exist in patients 
with T1D. This includes differences, compared to healthy controls, in the proportion of T cells (al-
Kassab & Raziuddin, 1990; Ilonen et al., 1991; Petersen et al., 1996) and also in their function 
(Hehmke et al., 1995; Spatz et al., 2003). In particular, there has been much conjecture over the 
frequency and function of Treg in T1D (Zhang et al., 2012). CD4+CD25hi, but not CD4+CD25-, T 
cells from recent-onset T1D patients have shown increased propensity toward apoptosis than those 
from healthy controls (Jailwala et al., 2009). This effect was replicated in CD4+CD25hi T cells from 
healthy controls after depleting IL-2, suggesting reduced IL-2 signalling in T1D patients might be 
responsible for an increase in apoptosis-prone Treg. Reduced IL-2 receptor (IL-2R) signalling in 
T1D patients has been associated with impaired maintenance of Foxp3 expression by CD4+CD25+ 
T cells (Long et al., 2010). Also, reduced suppression by Treg from T1D patients compared to 
healthy controls has been demonstrated (Brusko et al., 2005; Lindley et al., 2005). Augmenting 
defects in the Treg population, is the reduced sensitivity of effector T cells and Tmem to Treg-
mediated inhibition in T1D patients (Afzali et al., 2011; Lawson et al., 2008; Schneider et al., 
2008).  
While the majority of studies in humans have investigated immune cell subsets in the 
peripheral blood of T1D patients, it is not known how these data represent what is occurring within 
the target organ, that is, the pancreas, and the draining LN. In peripheral blood, there is no 
difference in Treg number between T1D patients and non-diabetic controls (Brusko et al., 2005; 
Lindley et al., 2005). Although, a significant decrease in Foxp3+ Treg frequency and function has 
been observed in pLN from T1D patients relative to healthy controls (Ferraro et al., 2011). As 
CD25 and Foxp3 expression can be influenced by environmental factors, Ferraro et al. employed a 
Treg-specific demethylation region (TSDR) assay to identify epigenetically imprinted Treg. No 
difference in Treg frequency was observed between T1D patients and healthy controls using this 
method (Ferraro et al., 2011). Although, the suppressive function of CD25bright Treg isolated from 
pLN of T1D patients was impaired, but those from peripheral blood were as suppressive as Treg 
from healthy controls. This study highlights the potential for site-specific defects in immune cell 
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subsets and this may explain discrepancies in the literature regarding the function of regulatory cells 
in peripheral blood of T1D patients.  
With regard to the APC compartment, plasmacytoid DC are less frequent in T1D patients 
than healthy controls (Chen et al., 2008a). Data from Treg suppression assays with cells from T1D 
patients and healthy controls indicate APC dysfunction might be responsible for reduced Treg 
suppression in T1D patients (Jin et al., 2009). Additionally, gene expression profiles of CD14+ 
monocytes from a subset of T1D patients were associated with cellular stress pathways and diabetes 
progression (Irvine et al., 2012). It is the combination of multiple immunological defects that bring 
about β-cell autoimmunity and subsequent progression to autoimmune diabetes in humans and 
NOD mice. While there are differences between diabetes in the NOD mouse and human T1D, it is 
important to investigate inflammatory sites, that is, the pancreas and pLN, from NOD mice which 
can guide analyses of infrequently obtained human pancreatic samples.  
 
1.8 Therapies for autoimmune diabetes 
1.8.1 Exogenous insulin/islet transplantation  
Exogenous insulin therapy is the standard treatment for T1D and while the use of insulin has 
drastically reduced mortality, this treatment is not curative and complications from imperfect blood 
glucose control still occur (Lachin et al., 2014; Steffes et al., 2003). In some cases where glucose 
monitoring and subsequent insulin replacement therapy are inadequate, an alternative approach to 
the management of T1D is islet, or to a lesser extent, whole pancreas transplantation [reviewed in 
(Fotino et al., 2015; Watson, 2015). Inclusion criteria include recurrent, severe hypoglycemia, 
marked hyperglycemia and ketoacidosis (Robertson et al., 2000; Robertson et al., 2006). Islet 
transplantation is beneficial as β-cell replacement might reinstate some level of physiological 
glucose homeostasis thereby helping to control long-term complications. However, there are risks 
involved with islet or pancreas transplantation including chronic immunosuppression, limited 
organ/islet availability and general risks of surgery. It should be noted that the β cell-specific 
effector CD8+ T cells responsible for initial islet destruction and the subsequent pool of β cell-
specific memory CD8+ T cells perpetuate islet autoimmunity and can contribute to the destruction 
of transplanted, allogeneic islets (Okitsu et al., 2001). This highlights the importance of an 
immunotherapy for T1D which terminates these pathogenic CD8+ Tmem responses. 
 
1.8.2 Immune modulators 
Since T1D was identified as an autoimmune disease (Bottazzo et al., 1974; MacCuish et al., 
1974), focus has shifted to immunotherapeutic approaches to address the underlying immune 
dysregulation that results in β-cell destruction. Early studies focused on non-specific immune 
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modulators such as cyclosporine and anti-CD3 monoclonal antibody (mAb) therapy as a means to 
suppress immune responses in autoimmune diabetes. While continuous cyclosporine treatment in 
recent-onset T1D patients was effective in reducing insulin dependence, and in some patients 
abolishing the need for exogenous insulin entirely, there were toxic side effects and eventually the 
beneficial effects diminished leading to the decline in use of this therapy for T1D (Bougneres et al., 
1988; Stiller et al., 1984). Long-term remission of autoimmune diabetes was observed in recent-
onset NOD mice following anti-CD3 mAb treatment (Chatenoud et al., 1994). The presence of 
insulitis and acceptance of syngeneic islet grafts in anti-CD3 mAb-cured mice (Mottram et al., 
2002) suggested restoration of immune regulation, and it was later demonstrated that administration 
of anti-CD3 mAb induced T cells with regulatory properties (Belghith et al., 2003; Bresson et al., 
2006). These and other studies using anti-CD3 mAb in mice (Hayward & Shriber, 1992; Herold et 
al., 1992) did not necessarily translate to human T1D. Single-dose anti-CD3 mAb treatment has 
been shown to maintain insulin production for up to a year in T1D (Herold et al., 2002), however, 
treatment may need to be repeated for long-term clinical outcomes. Dosing was a critical issue, 
high-dose anti-CD3 mAb treatment has been associated with Epstein-Barr virus (EBV) reactivation 
(Keymeulen et al., 2010a) and low-dose anti-CD3 mAb therapy had no effect on T1D progression 
(Sherry et al., 2011). Despite β-cell destruction in T1D being T-cell mediated, anti-CD20 mAb 
therapy, to deplete B cells, can reverse autoimmune diabetes in recent-onset NOD mice (Hu et al., 
2007). In human T1D, anti-CD20 mAb therapy has been shown to partially protect β-cell function 
(Pescovitz et al., 2009), possibly by transient disruption of pathogenic T-cell recruitment (Herold et 
al., 2011). It appears repeated or long-term dosing would be required for increased efficacy of anti-
CD20 mAb therapy, and neither has been tested for safety. It is also currently unknown whether 
anti-CD20 mAb therapy would prevent or delay T1D onset in at-risk individuals.  
Transplantation of bone marrow (BM) or HSPC has been shown to prevent autoimmune 
diabetes in mouse models, possibly by ‘re-setting’ the immune system. Insulitis and diabetes have 
been prevented in NOD mice following transfer of BM from diabetes-resistant mice (Ikehara et al., 
1985). Further study into the use of BM transfer for autoimmune diabetes highlighted the necessity 
for sublethal conditioning for this approach to proceed clinically. Sublethal conditioning was shown 
to be effective in achieving stable, allogeneic chimerism that prevented diabetes in pre-diabetic 
NOD mice (Li et al., 1996). Transplantation of autologous HSC in combination with high-dose 
immune suppression in recent-onset T1D patients has been shown to induce insulin independence, 
however, this was transient (de Oliveira et al., 2012; Voltarelli et al., 2007). Targeting tolerogenic 
antigen expression to HSPC may represent a means to overcome the transient efficacy observed for 
studies employing HSPC transplantation, in that pathogenic T cells might be continually inactivated 
by antigen expression in a long-lived population of APC (Coleman et al., 2012).  
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1.8.3 IL-2 to expand Treg  
The notion of IL-2 and Treg induction as a therapeutic approach in T1D is logical 
considering the genetic lesions of the NOD mouse and in human T1D. CTLA-4 is constitutively 
expressed by Treg and has been shown to be important in Treg suppressive function (Sojka et al., 
2009). The Ctla4 gene is located in the Idd5 locus of the NOD mouse (Araki et al., 2009b) and 
polymorphisms in CTLA4 can confer risk of T1D in humans (Ueda et al., 2003). IL-2 is a 
pleiotropic cytokine important for effector T-cell function and essential for Treg survival [reviewed 
in (Long et al., 2013)]. The Idd3 locus in NOD mice includes the Il2 gene and the IL-2Rα gene has 
been associated with human T1D (Lowe et al., 2007). Furthermore, the candidate-gene PTPN2 has 
been implicated in reduced IL-2R signaling in human T1D in that the risk allele conferred reduced 
Foxp3 expression on activated CD4+ T cells in response to IL-2 (Long et al., 2011). These genetic 
studies suggest therapies to expand Treg number and/or function may be beneficial in regulating the 
inflammatory responses that drive autoimmune diabetes pathogenesis.  
While daily administration of IL-2 did not prevent diabetes development in NOD mice, IL-2 
in combination with rapamycin protected NOD mice from diabetes development (Rabinovitch et al., 
2002). Low-dose IL-2 administered for ten days was shown to reverse hyperglycemia in a 
significant proportion of new-onset diabetic NOD mice when compared to PBS-treated controls 
(Grinberg-Bleyer et al., 2010). Islet-infiltrating Treg in IL-2-treated mice displayed higher 
expression of markers indicative of suppressive activity, including Foxp3, CD25, CTLA-4 and 
GITR, compared to PBS-treated control mice. In this system, these data suggest IL-2 treatment 
increases the number and function of Treg localised within the inflamed site, that is, the pancreas, 
which are capable of reversing established diabetes. Therefore, at least in NOD mice, IL-2 may be 
more beneficial after hyperglycemia onset. 
With regard to human T1D, in a phase I/II clinical trial, low-dose IL-2 was shown to be 
well-tolerated in T1D patients and increased the proportion of CD4+CD25+Foxp3+ Treg in 
peripheral blood, however, no change in exogenous insulin requirement or C-peptide was observed 
(Hartemann et al., 2013). Employing the same patient cohort as Hartemann et al., it was shown that 
the expanded CD4+ Treg also displayed a suppressive phenotype indicated by increased CD25 and 
CTLA-4 expression (Rosenzwajg et al., 2015). Furthermore, a reduction of β cell-specific effector 
T-cell responses, compared to pre-treatment baseline values, was observed following IL-2 
treatment. In addition to expansion of conventional CD4+ Treg, low-dose IL-2 treatment of patients 
with T1D increased the proportion of CD8+CD25+Foxp3+ T cells (Churlaud et al., 2015). In a 
combinatory approach, IL-2 in conjunction with rapamycin increased Treg in T1D patients, 
however, the metabolic indicator, C-peptide, decreased transiently in all patients (Long et al., 2012). 
The IL-2 dose used by Long et al. was higher than that used by Hartemann et al. which might 
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explain the undesired outcome. In NOD mice, IL-2 in combination with rapamycin reduced β-cell 
division and glucose metabolism (Baeyens et al., 2013), despite previously being demonstrated to 
protect NOD mice from diabetes (Rabinovitch et al., 2002),  and in other mouse models rapamycin 
reduced β-cell survival and function (Tanemura et al., 2012; Yang et al., 2012b), also providing a 
possible explanation for the outcome in humans. Translating therapies from mice to humans is 
therefore challenging, particularly with regard to IL-2 therapy in the context of T1D. The 
complexity of translation is emphasised by the pleiotropic nature of IL-2 and the need to ensure the 
dose remains effective in expanding Treg to mediate suppression of diabetogenic immune responses 
but low enough to avoid expansion of potentially pathogenic IL-2-dependent immune cells such as 
effector T cells and NK cells. 
 
1.8.4 Insulin-specific immunotherapy  
Since T1D arises as a result of β-cell destruction by immune cells, particularly T cells, 
recognising β-cell antigens, antigen-specific immunotherapy is an attractive approach for the 
treatment of T1D. Antigen-specific immunotherapy has the potential to restore tolerance to β-cell 
antigens without the concern of general immune suppression. In the NOD mouse, there is strong 
evidence to suggest insulin is the primary antigen involved in autoimmune diabetes, and while in 
humans the evidence is not as clear, it does implicate a crucial role for insulin responses in the 
pathogenesis of T1D. Therefore, there has been considerable focus on insulin-specific 
immunotherapy studies in both mouse models and humans.  
 
1.8.4.1 Insulin immunotherapy in NOD mice 
Early immunotherapy studies in NOD mice found treatment with oral insulin delayed the 
onset of autoimmune diabetes (Zhang et al., 1991). Transfer of T cells from oral insulin-treated 
mice also protected untreated mice from diabetes, suggesting oral insulin promoted immune 
regulation capable of controlling diabetes progression. Similarly, the induction of oral tolerance to 
insulin, or its peptides, was characterised by an increase in IL-10, TGF-β and IL-4 production by 
lymphocytes following in vitro re-stimulation with InsB (Polanski et al., 1997). Coupling oral 
insulin to a non-toxic subunit of cholera toxin increased the efficacy of oral insulin immunotherapy, 
which was thought to be mediated by the induction of insulin-specific Treg (Meng et al., 2011; 
Petersen et al., 2003), but this protection was not absolute as some treated mice developed diabetes. 
Nasal administration of insulin is another delivery route able to induce Treg capable of modulating 
diabetes development in NOD mice (Daniel & Wegmann, 1996; Every et al., 2006). 
The combination of antigen delivery through nasal insulin therapy and the 
immunomodulatory, Treg- boosting capacity of anti-CD3 mAb therapy has been shown to reverse 
19 
 
recent-onset autoimmune diabetes and reduce insulitis in both NOD mice and a mouse model of 
virus-induced diabetes (Bresson et al., 2006). The increased efficacy of combination approaches is 
evident from the reduction of autoimmune diabetes in mice treated with a TNF receptor family 
member (OX40) agonist mAb, OX86, and InsB9-23 peptide (Bresson et al., 2011). The reduction in 
diabetes development was due to insulin-specific Treg induction following combination treatment 
compared to insulin peptide immunotherapy alone. Similarly, reversal of new-onset diabetes in the 
NOD mouse has been achieved through oral dosing of a commensal bacterium, Lactococcus lactis, 
genetically modified to secrete human proinsulin and IL-10 in combination with administration of 
low-dose anti-CD3 mAb (Takiishi et al., 2012).  
As opposed to the induction of mucosal tolerance, 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (EDCI)-fixed splenic APC pulsed with antigen can induce T-cell tolerance through T-
cell unresponsiveness (Jenkins & Schwartz, 1987). Complete diabetes protection was observed in 
young NOD mice injected with fixed APC coupled with whole insulin, while treatment with fixed 
APC coupled with InsB9-23 protected approximately 80% of young NOD mice from diabetes 
development (Prasad et al., 2012). The outcomes of insulin immunotherapy studies in mouse 
models highlight the possible need to induce deletional tolerance or inactivation of β cell-reactive T 
cells as regulation of effector T cells alone may be insufficient for complete protection from 
diabetes.  
Since mice in which proinsulin II is transgenically expressed by MHC class II+ APC are 
protected from autoimmune diabetes (French et al., 1997), studies have subsequently instated this 
tolerogenic antigen expression to non-transgenic NOD mice. Transfer of proinsulin-encoding HSPC 
has been shown to reconstitute the hematopoietic compartment of young, myeloablated NOD mice 
(Steptoe et al., 2003). Engraftment of proinsulin-encoding HSPC was protective as recipients of 
proinsulin-encoding HSPC showed significantly reduced incidence of autoimmune diabetes 
compared to recipients of NOD HSPC. In a potentially more translational manner, young NOD 
mice were protected from insulitis by transfer of retrovirus-transduced HSC expressing proinsulin 
(Chan et al., 2006). This effect was proinsulin-specific, as the incidence of sialitis did not differ 
between recipients of proinsulin-expressing HSC and unmanipulated control mice. All of these 
studies combined suggest (pro)insulin-specific immune responses are an attractive target for 
immunomodulation that may have potential therapeutic implications in T1D treatment.  
 
1.8.4.2 Insulin immunotherapy in human T1D 
Translation of insulin-specific immunotherapy from animal models to human T1D patients 
has been challenging, with routes of administration, dosing and timing of treatment being explored 
in clinical trials. The purpose of the immunotherapy diabetes (IMDIAB) trial was to determine 
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whether oral insulin therapy at time of T1D diagnosis would induce immunological tolerance to 
insulin, and its peptides, and thereby preserve remaining β-cell function (Pozzilli et al., 2000). 
Pozzilli et al. proposed that if oral insulin therapy was effective in recent-onset T1D patients, it 
might then be applied to high-risk individuals to potentially prevent diabetes development. The 
results, however, showed no difference between patients receiving oral insulin or placebo in C-
peptide levels or exogenous insulin requirement at one year follow up. It was concluded that the 
dose of 5mg of oral insulin daily did not alter diabetes progression. Similarly, another trial to 
determine whether oral insulin therapy at T1D diagnosis could protect remaining β-cell function 
found no effect of treatment on the decline of β-cell function (Chaillous et al., 2000). A phase I 
clinical trial in which human InsB was administered in incomplete Freund’s adjuvant (IFA) to 
recently-diagnosed T1D patients showed no effect on residual β-cell function (Orban et al., 2010). 
As this was a pilot study, with the main objective being to test safety, and the number of 
participants was small (n=12), this study was not powered to detect significant changes in residual 
β-cell function. Data from the study by Orban et al., provide some evidence for a Treg response to 
InsB immunisation, in that, peripheral blood cells from InsB-treated patients produced higher levels 
of TGF-β after in vitro re-stimulation with InsB. Also, InsB-reactive CD4+ T cells from peripheral 
blood of InsB-treated patients displayed Foxp3 expression. One study, in patients within five years 
of T1D diagnosis, showed preservation of C-peptide in groups treated with defined doses of a DNA 
plasmid encoding proinsulin (Roep et al., 2013). There was a reduction in the frequency of 
proinsulin-specific CD8+ T cells in the treatment group compared to placebo. This effect was 
antigen-specific, since the frequency of irrelevant islet-antigen or virus-reactive CD8+ T cells was 
not altered. The immunological and metabolic effects observed in this study were transient, 
potentially highlighting the importance of a long-lived source of tolerogenic antigen presentation.   
Insulin immunotherapy has also been trialled in prevention studies, which aim to prevent or 
delay diabetes development in at-risk individuals, and an example is the Diabetes Prevention Trial 
(DPT-1) (Diabetes Prevention Trial--Type 1 Diabetes Study, 2002). DPT-1 involved an intervention 
strategy consisting of twice daily, low-dose subcutaneous insulin injections or no treatment as a 
control. No difference in the overall incidence of T1D was observed between insulin treated- and 
untreated-individuals. Therefore, insulin therapy, as used in the DPT-1 study, did not delay or 
prevent diabetes. A pilot study in patients with islet autoantibodies found nasal insulin therapy to be 
safe, that is, acceleration of β-cell destruction was not observed, and provided evidence of reduced 
T-cell responses to insulin, which is consistent with mucosal tolerance as a result of nasal antigen 
delivery (Harrison et al., 2004). Another prevention trial investigated the effect of nasal insulin 
therapy on children with high susceptibility HLA-DQB1 alleles and positivity for autoantibodies 
(Nanto-Salonen et al., 2008). Despite the initiation of nasal insulin therapy soon after autoantibody 
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detection, there was no effect on diabetes incidence when compared to placebo. The second DPT-1 
study evaluated the effect of oral insulin therapy in relatives at lower risk of developing T1D than 
relatives in the first DPT-1 study, but still with a 10- to 20-fold higher risk than the general 
population (Skyler et al., 2005). Overall, T1D incidence was similar in the oral insulin treated-group 
and placebo group, suggesting there was no effect of oral insulin in delaying or preventing T1D in 
at-risk individuals. There was, however, an indication of the benefit of oral insulin therapy in a 
subgroup of patients with higher levels of insulin autoantibodies and further studies are required to 
explore this effect.  
Further stratification of patients by baseline immunologic, metabolic and genetic factors for 
therapy trials might help to identify patients which may benefit most from the defined treatment. 
The lack of efficacy observed for therapies which rely solely on induction of immune regulation, 
suggest there is the need for an approach to induce robust tolerance of β cell-specific effector T 
cells and Tmem through deletion or inactivation, the benefits of which might be enhanced with 
concurrent expansion of Treg. If such a therapy was demonstrated to be efficacious using insulin as 
the tolerogenic antigen, it might be possible to widen the window for therapeutic intervention by 
targeting multiple β-cell antigens, which may prove capable of reversing established islet 
autoimmunity.   
Table 1.8.1 Summary of immunotherapy in mouse and man 
 NOD mice Human T1D 
αCD3 Diabetes remission, acceptance 
of syngeneic islet grafts 
Maintenance of insulin 
production (≥ 1 year), EBV 
reactivation with high dose, no 
effect with low-dose 
αCD20 Reversal in new-onset NOD 
mice 
Transient protection of β-cell 
function 
BM/HSPC transplantation Diabetes prevention with 
diabetes-resistant and 
allogeneic  BM 
Transient insulin independence 
following autologous HSC 
transplantation 
IL-2 Protection with IL-2/ 
rapamycin, reversal with low-
dose IL-2  
No change with low-dose IL-2, 
decrease in C-peptide with IL-
2/rapamycin 
Oral insulin Delayed onset, transfer of T 
cells from treated mice 
protected untreated mice from 
diabetes 
No change in C-peptide or 
exogenous insulin requirement 
Inducing T cell tolerance to 
proinsulin 
Protection when proinsulin is 
over-expressed in APC, 
protection when proinsulin-
expressing HSC transferred 
C-peptide preservation after 
proinsulin-encoding plasmid 
DNA treatment  
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1.9 Purpose of the study 
For an effective T1D immunotherapy, pathogenic, islet-reactive T-cell responses must be 
inactivated. Targeting antigen to APC using an MHC class II promoter rapidly inactivates cognate 
CD8+ T cells (Kenna et al., 2010). There is strong evidence implicating insulin as the primary 
autoantigen for autoimmune diabetes in the NOD mouse (French et al., 1997; Nakayama et al., 
2005) and studies suggest insulin is also an important autoantigen in human T1D (Kent et al., 2005; 
Luce et al., 2011). Importantly, T1D in humans and autoimmune diabetes in NOD mice develop as 
a consequence of a genetic background associated with failure of peripheral tolerance pathways. 
Therefore, it is pertinent to understand if insulin-specific T-cell responses can be tolerised in a 
diabetes-prone environment, where known genetic tolerance defects exist. This study aims to 
determine whether tolerance induction occurs for naïve and memory CD8+ T cells recognising the 
important β-cell antigen, insulin, in an autoimmune-prone background. Transfer of antigen-
encoding HSPC has been used as a tool to instate tolerogenic antigen expression in non-transgenic 
recipient mice, specifically for the purpose of diabetes prevention (Steptoe et al., 2003). To date, 
this procedure has been performed only under conditions where the host immune system is ablated 
at the time of BM/HSPC transfer, which leads to a full ‘re-set’ of the immune system. Given the 
potential capacity of APC-targeted proinsulin expression to inactivate naïve and memory insulin-
specific CD8+ T cells, I propose immune-ablation may not be required for effective prevention of 
diabetes by proinsulin-encoding BM/HSPC transfer. Due to the young age at diagnosis and non-
fatal nature of T1D, safety afforded from reduced intensity, immune-preserving conditioning would 
be favourable in a clinical setting. Therefore, this study seeks to extend current knowledge by 
determining the effect transfer of proinsulin-encoding BM/HSPC has on diabetes development 
when this procedure is performed under conditions where host immunity is not ablated.  
 
1.10 Hypothesis and aims 
1.10.1 Hypothesis 
‘Transgenic expression of proinsulin in APC induces peripheral tolerance in naïve and memory 
insulin-specific CD8+ T cells and transfer of proinsulin-encoding BM/HSPC will impede diabetes 
development in non-transgenic NOD mice.’ 
1.10.2 Aims 
Aim I Determine whether transgenic proinsulin expression induces peripheral tolerance in 
naïve insulin-specific CD8+ T cells. 
Aim II Determine whether transgenic proinsulin expression induces peripheral tolerance in 
insulin-specific CD8+ memory T cells. 
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Aim III Determine whether, and at what stage of disease, transfer of proinsulin-encoding 
BM/HSPC impedes diabetes development in sublethally irradiated NOD mice. 
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Chapter 2 
Materials and methods 
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2.1 Mice 
Mice were maintained in a specific pathogen-free environment at the Princess Alexandra Hospital 
Biological Resource Facility (PAH-BRF; Brisbane, Australia), the Australian Institute for 
Bioengineering and Nanotechnology Animal Facility (AIBN; Brisbane, Australia), the Pharmacy 
Australia Centre of Excellence Biological Resources (PACE-BR; Brisbane, Australia) and the 
Translational Research Institute Biological Resources Facility (TRI-BRF; Brisbane, Australia). All 
mice were euthanised by CO2 asphyxiation. Mice were sex-matched within individual experiments. 
Animals were used between 6-15 weeks of age unless otherwise indicated and all experiments were 
approved by the University of Queensland Animal Ethics Committee under ARC project 164/12.  
 
2.1.1 Inbred and Congenic strains 
NOD/Lt mice: 
NOD/Lt mice (referred to as NOD) (Makino et al., 1980) are inbred mice in which approximately 
80% of females spontaneously develop autoimmune diabetes. NOD mice carry the H-2d haplotype 
and express the CD45.1 allelic variant of the CD45 pan-leukocyte molecule. All NOD mice were 
purchased from the Animal Resource Centre (Perth, Australia) at 6-8 weeks of age and used at this 
age unless otherwise indicated.  
 
NOD.CD45.2 mice: 
NOD.CD45.2 mice are congenic NOD mice that express the CD45.2 allelic variant of the CD45 
pan-leukocyte molecule (Steptoe et al., 2004). NOD.CD45.2 mice were bred and maintained at 
AIBN (Brisbane, Australia) and the TRI-BRF (Brisbane, Australia). For adoptive transfer 
experiments, male NOD.CD45.2 mice at 8-10 weeks of age were used as recipients unless 
otherwise stated. 
 
NOD.CD45.2 x NOD mice: 
NOD/Lt mice were mated with NOD.CD45.2 mice to generate F1 mice that express both CD45.1 
and CD45.2. NOD.CD45.2 x NOD mice were bred and maintained at the PAH-BRF (Brisbane, 
Australia), the PACE-BR (Brisbane, Australia) and the TRI-BRF (Brisbane, Australia). For 
adoptive transfer experiments, male NOD.CD45.2xNOD mice at 8-10 weeks of age were used as 
recipients unless otherwise stated. 
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2.1.2 Transgenic strains 
Proinsulin transgenic mice: 
Proinsulin transgenic mice are transgenic mice expressing mouse proinsulin II under the control of 
an MHC class II (I-Eα
k) promoter (French et al., 1997).  Proinsulin transgenic mice are protected 
from spontaneous autoimmune diabetes. Proinsulin transgenic mice were bred and maintained at the 
PAH-BRF (Brisbane, Australia) or the TRI-BRF (Brisbane, Australia). Proinsulin transgenic mice 
were a kind gift from Prof Leonard C. Harrison (The Walter and Eliza Hall Institute of Medical 
Research, Parkville, Victoria, Australia).  
 
NOD.CD45.2 x proinsulin transgenic mice: 
Proinsulin transgenic mice were mated with NOD.CD45.2 to generate F1 mice that express both 
CD45.1 and CD45.2. NOD.CD45.2 x proinsulin transgenic mice were bred and maintained the 
PAH-BRF (Brisbane, Australia), the PACE-BR (Brisbane, Australia) or the TRI-BRF (Brisbane, 
Australia).  For adoptive transfer experiments, male NOD.CD45.2 x proinsulin transgenic mice at 
8-12 weeks of age were used as recipients unless otherwise stated. 
 
G9 mice: 
G9 are transgenic mice expressing an H2-Kd-restricted TCR specific for InsB15-23. The G9 mice 
used were offspring of F1 matings between TCRα transgenic Cα-/- (line 22) and TCRβ transgenic 
Cα-/- (line 2) founder lines (Wong et al., 2009). G9 mice were bred and maintained at the PAH-BRF 
(Brisbane, Australia) or the TRI-BRF (Brisbane, Australia). The TCRα and TCRβ founder lines 
used to generate the G9 mice were kind gifts from Prof F. Susan Wong (Institute of Molecular and 
Experimental Medicine, School of Medicine, Cardiff University, Cardiff, UK). 
 
B16A mice: 
B16A mice are double knockout mice lacking both insulin 1 and insulin 2 and expressing a mutated 
preproinsulin (B16:A insulin) (Nakayama et al., 2005). B16A mice are protected from spontaneous 
autoimmune diabetes. B16A mice were bred and maintained at the PAH-BRF (Brisbane, Australia) 
or the TRI-BRF (Brisbane, Australia). 
 
2.2 Reagents 
2.2.1 Peptides 
InsB15-23: 
Insulin B15-23 (LYLVCGERG) is a H2-K
d-restricted determinant of insulin and together with H-2Kd 
forms an MHC class I/peptide complex recognised by CD8+ T cells.  Ins B15-23 (23 Gly) was 
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purchased from Auspep (Melbourne, Australia). Ins B15-23 was dissolved in pyrogen free H2O to a 
concentration of 10mg/ml, aliquoted, and stored at -30oC. 
 
InsB15-23 (23 Val): 
InsB15-23 (23 Val) (LYLVCGERV) is an altered peptide ligand (APL) of native Ins B15-23 with 
valine replacing glycine at p9. Ins B15-23 (23 Val) binds more strongly to H2-K
d than native Ins B15-
23 (Wong et al., 2002). Ins B15-23 (23 Val) was purchased from Auspep (Melbourne, Australia). 
InsB15-23 (23 Val) was dissolved in pyrogen free H2O to a concentration of 10mg/ml, aliquoted, and 
stored at -30oC. 
 
2.2.2 Buffers  
MT-PBS: 
Mouse tonicity phosphate buffered saline (MT-PBS) was composed of Na2HPO4.2H20 (28.5g/L), 
NaH2PO4.1H20 (5.52g/L) and NaCl (87g/L) dissolved in MilliQ water as a 10x stock and diluted for 
use. MT-PBS was prepared in-house and sterilised by autoclaving prior to use.   
 
MT-PBS / 2.5% FCS: 
MT-PBS/2.5% FCS (F2.5) was used for organ collection and cell preparations. MT-PBS was 
supplemented with 2.5% fetal calf serum (FCS) for cells to be adoptively transferred, or 2.5% 
bovine serum for cells used in vitro.  
 
ACK buffer: 
ACK buffer was used to eliminate red blood cells (RBC) from spleens, bone marrow cell 
suspensions and peripheral blood. ACK buffer was made in house and was composed of NH4Cl 
(8.29g/L), KHCO3 (1g/L) add Na2EDTA (0.0372g/L) dissolved in MilliQ water. The pH of ACK 
buffer was adjusted to 7.2-7.4, filter sterilised and stored at 4°C. 
 
FACS wash: 
FACS wash was made in house to 10x concentrations and was composed of 1% bovine serum 
albumin (BSA) and 20mM EDTA in MT-PBS. 1x FACS wash was made by diluting 100mL of 10x 
FACS wash in 1L of MT-PBS. 10x FACS wash was stored at -20°C and 1x FACS wash was stored 
at 4°C. 
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FACS block: 
FACS block was made in house from the supernatant of 2.4G2 hybridoma cells producing anti-
CD16/32 to allow blocking of mouse Fc-receptors, Fc-gamma II (CD32) and Fc-gamma III (CD16).  
1% BSA was added to supernatant and filter-sterilised aliquots were stored at -20°C.  
 
2.2.3 Adjuvants 
Poly I:C: 
Polyinosinic–polycytidylic acid potassium salt (Poly I:C) (Sigma-Aldrich, St. Louis, MA, USA) 
was dissolved in sterile MT-PBS to a concentration of 1mg/ml, aliquoted and stored at -30°C. 
100µg per mouse administered intraperitoneally (i.p.) was used for routine immunisations.  
 
QuilA: 
Quillaja saponaria A (QuilA) (Soperfos Biosector DK-Vedback, Denmark) was diluted in sterile 
MT-PBS, aliquoted and stored at -30°C. 20µg per mouse administered subcutaneously was used for 
routine immunisations. 
 
CpG: 
CpG 1663 oligonucleotide (Invitrogen, Carlsbad, CA, USA) was diluted in H2O, aliquoted and 
stored at -30°C. 15.5nmol per mouse administered subcutaneously was used for routine 
immunisations.  
 
CASAC: 
Combined Adjuvant for Synergistic Activation of Cellular Immunity (CASAC) (Wells et al., 2008) 
is a combination adjuvant that induces a high level of CD8+ T cell activation in response to peptide 
immunisation. CASAC comprises anti-mouse CD40 (clone: FGK4.5, isotype: Rat IgG2a. 25µg per 
mouse, BioXCell, New Hampshire, USA), CpG 1826 oligonucleotides (50µg per mouse, Integrated 
DNA Technologies, Iowa, USA), recombinant mouse IFN-γ (100ng per mouse, R&D Systems, 
New South Wales, Australia) and adjuvant (Sigma Adjuvant System: 100µl per mouse, Sigma-
Aldrich, Missouri, USA). CASAC was prepared immediately prior to injection. 200µl per mouse 
administered intradermally was used for routine immunisations. CASAC was a kind gift from Dr 
James W. Wells (The University of Queensland Diamantina Institute, Brisbane, Queensland, 
Australia). 
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IL-2/αIL-2 complex: 
Complexing recombinant mouse IL-2 with an anti-IL-2 mAb, JES6-1, has been shown to 
specifically expand Treg in vivo (Webster et al., 2009). IL-2/αIL-2 complex was made fresh for 
each use by diluting 2.5µl of JES6-1 (at 2mg/ml) in 195 µL of MT-PBS. 2.5µl of recombinant 
mouse IL-2 (at 400µg/ml) was added and the solution mixed by gentle pipetting. The solution was 
incubated at 37°C for 30 minutes, then stored on ice until use. The final complex (5µg of JES6-1; 
1µg of IL-2) was administered to mice by injecting 200µl i.p. per day for 3 consecutive days.  
 
2.2.4 Tissue culture media 
Complete Roswell Park Memorial Institute (RPMI-1640) Media: 
Complete RPMI-1640 consists of sterile RPMI-1640 (Gibco-Invitrogen, Carlsbad, CA, USA) 
supplemented with 1mM sodium pyruvate (Gibco-Invitrogen, Carlsbad, CA, USA), 5x10-5M 2-
Mercaptoethanol (Sigma-Aldrich, St. Louis, MA, USA), 1x10-4M non-essential Amino Acids 
(Gibco-Invitrogen, Carlsbad, CA, USA), 100units/ml Penicillin, 100units/ml Streptomycin and 
2mM L-glutamine (Gibco-Invitrogen, Carlsbad, CA, USA).  
 
2.2.5 Monoclonal antibodies, streptavidin conjugates and H2-Kd tetramers  
Table 2.2.5.1- List of monoclonal antibodies for flow cytometry 
Antigen Conj. Isotype Diln (FACS) Clone Supplier/Cat# 
CD3ε FITC hamster IgG 1/100 145-2C11 Biolegend/100306 
CD3ε PE hamster IgG 1/400 145-2C11 Biolegend/100308 
CD4 FITC rat IgG2b k 1/200 GK1.5 Biolegend/100406 
CD4 PE/Cy7 rat IgG2b k 1/100 GK1.5 Biolegend/100422 
CD5 PE rat IgG2a k 1/400 53-7.3 Biolegend/100608 
CD8α PerCP/Cy5.5 rat IgG2b k 1/200 53-6.7 Biolegend/100734 
CD8α APC/Cy7 rat IgG2b k 1/100 53-6.7 Biolegend/100414 
CD8β PE rat IgG2a k 1/400 YTS156.7.7 Biolegend/126608 
CD11b FITC rat IgG2bk 1/800 M1/70 Grown in house 
CD11b PerCP/Cy5.5 rat IgG2bk 1/400 M1/70 Biolegend/101228 
CD11c FITC hamster IgG 1/200 N418 Biolegend/117306 
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CD25 PE rat IgG1 1/400 PC61 Biolegend/102007 
CD25 APC rat IgG1 1/200 PC61 Biolegend/102012 
CD44 PE rat IgG2bk 1/400 IM7 Biolegend/103008 
CD45R 
(B220) 
FITC rat IgG2a k 1/800 
RA3-6B2 
Biolegend/103206  
CD45R 
(B220) 
PE rat IgG2a k 1/200 
RA3-6B2 
Biolegend/103208 
CD45.1 PE/Cy7 mouse IgG2aκ 1/100 A20 Biolegend/110730 
CD45.1 APC mouse IgG2aκ 1/100 A20 Biolegend/110714 
CD45.2 FITC mouse IgG2aκ 1/200 104 Biolegend/109806 
CD45.2 PE/Cy7 mouse IgG2aκ 1/100 104 Biolegend/109830 
CD49b FITC rat IgM 1/100 DX5 Biolegend/108906 
CD62L PerCP/Cy5.5 rat IgG2a k 1/200 MEL-14 Biolegend/104432 
CD62L APC rat IgG2a k 1/200 MEL-14 Biolegend/104412 
CD69 PE hamster IgG 1/200 H1.2F3 Biolegend/104507 
CD103 PerCP/Cy5.5 hamster IgG 1/100 2E7 Biolegend/121416 
CD117 
(c-kit) 
PE rat IgG2b k 1/800 2B8 Biolegend/105808 
CD120b 
(TNFRII) 
PE hamster IgG 1/100 TR75-89 Biolegend/113406 
CD127 
(IL-7Rα) 
PE rat IgG2a k 1/150 A7R34 eBioscience/ 
12-1271-82 
CD152 
(CTLA-4) 
biotinylated hamster IgG 1/100 
VCIO-4B9 
Biolegend/106304 
CD223 
(LAG-3) 
biotinylated 
rat IgG1 κ 
1/100 
C9B7W 
Biolegend/125206 
CD279 
(PD-1) 
PerCP/Cy5.5 rat IgG2a k 1/100 
29F.1A12 
Biolegend/135208 
Foxp3 FITC rat IgG2a k 1/200 FJK-16s eBioscience/ 
11-5773-82 
Granzyme B PE rat IgG2b k 1/200 16G6 eBioscience/ 
12-8822 
GITR PE hamster IgG 1/100 YGITR 765 Biolegend/120207 
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HELIOS PE hamster IgG 1/100 22F6 Biolegend/157216 
I-Ak,g7,r,f,s 
FITC mouse IgG2aκ 1/200 10.2.16 Grown in house 
I-Ak,g7,r,f,s 
biotinylated mouse IgG2aκ 1/400 10.2.16 Grown in house 
KLRG1 APC rat IgG2a k 1/100 2F1 eBioscience/ 
17-5893-82 
Ly6-A/E 
(Sca-1) 
PerCP/Cy5.5 rat IgG2a 1/100 D7 Biolegend/108124 
Ly-6G/C (Gr-
1) 
FITC rat IgG2b k 1/800 RB6-8C5 Grown in house 
Pan-TCRβ APC hamster IgG 1/200 H57-597 Biolegend/109212 
Perforin FITC rat IgG2a k 1/100 MAK-D eBioscience/ 
11-9392-82 
TER-119 
(Ly-76) 
FITC rat IgG2b k 1/400 TER-119 Grown in house 
Vβ6 APC rat IgG2bk 1/400 RR4-7 eBioscience/ 
17-5795 
Rat IgG2a 
(isotype 
control) 
FITC rat IgG2ak 1/200 RTK2758 Biolegend/400506 
Rat IgG2b 
(isotype 
control) 
FITC rat IgG2bk 1/200 RTK4530 Biolegend/400606 
Hamster IgG 
(isotype 
control) 
PE hamster IgG 1/200 HTK888 Biolegend/400907 
 
Table 2.2.5.2 - List of streptavidin conjugates for flow cytometry 
Antigen Conj. Diln (FACS) Supplier/Cat# 
Streptavidin FITC 1/400 CALTAG/ SA1001 
Streptavidin PE 1/200 CALTAG/ SA1004-4 
Streptavidin PerCP/Cy5.5 1/200 eBioscience/45431782 
Streptavidin APC 1/200 CALTAG/ SA1005 
Streptavidin Brilliant Violet 421 1/400 Biolegend/405225 
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2.2.6 H2-Kd tetramers  
InsB15-23- and IGRP206-214- loaded, H2-K
d tetramers were used to identify insulin- and IGRP-
specific CD8+ T cells, respectively, in recipient mice. Listeriolysin O (LLO) is derived from 
Listeria monocytogenes and a tetrameric complex of H2-Kd loaded with LLO91-99 was used as an 
irrelevant peptide control in analyses using InsB15-23- and IGRP206-214- loaded, H2-K
d tetramers as 
an indicator of the level of non-specific tetramer staining. 
 
Table 2.2.6.1 - List of H2-Kd tetramers for flow cytometry 
MHC class I allele Peptide  Conj.  Diln (FACS) Supplier/Cat#  
H2-Kd InsB15-23 (23 Val) 
(LYLVCGERV) 
PE 1/1000 NIH Tetramer 
Facility 
H2-Kd IGRP206-214 
(VYLKTNVFL) 
PE 1/1000 NIH Tetramer 
Facility 
H2-Kd LLO91-99 
(GYKDGNEYI) 
PE 1/1000 NIH Tetramer 
Facility 
 
2.3 Cell preparations 
2.3.1 Lymph nodes and spleens 
Using aseptic technique, axial, brachial, inguinal, mesenteric or pancreatic LN were removed and 
pooled in a 15ml Falcon tube (BD Biosciences, San Jose, CA, USA) filled with cold F2.5. 
Likewise, spleens were removed and placed in a 15ml Falcon tube with 5ml of cold F2.5. To 
prepare single cell suspensions, LN or spleens were placed into separate 70µm nylon mesh cell 
strainers (BD Biosciences, San Jose, CA, USA) placed on top of 50ml Falcon tubes (BD 
Biosciences, San Jose, CA, USA) in a biological safety cabinet. The rubber end of a plunger from a 
5ml syringe (BD Biosciences, San Jose, CA, USA) was used to manually disrupt the organ and the 
cell strainer was regularly flushed with F2.5. Cells were then collected by centrifugation at 350g for 
5 minutes at 4°C. Spleen cells underwent a RBC lysis step using ACK buffer, while LN cells were 
washed a further time. LN and spleen cells were then re-suspended separately in F2.5 or culture 
medium as required. Cells were counted using trypan blue exclusion and a haemocytometer. For 
adoptive transfers, cell suspensions were further washed in 1x MT-PBS and transferred via 
intravenous (i.v.) tail injection in 200µl of MT-PBS to each mouse. All adoptive transfers 
performed within this thesis were between syngeneic NOD mice.  
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2.3.2 Bone marrow 
Using aseptic technique, femurs and tibiae were harvested from donor mice by severing the femur 
at the hip and the tibia above the ankle. Bulk tissue was removed from bones before being placed 
into a 50ml Falcon tube with 25ml of cold F2.5. In a biological safety cabinet, BM was flushed 
from individual bones. Forceps and scissors were used to cut the epiphyseal plate from the proximal 
end of the tibia and a 23g needle (BD Biosciences, San Jose, CA, USA) inserted into the marrow 
cavity. F2.5 was used to flush BM from individual bones. The distal end of the femur was cut and 
marrow flushed. BM cell clumps were re-suspended by passaging several times through the syringe. 
The cell suspension was then transferred to a sterile 50ml Falcon tube and centrifuged at 350g for 5 
minutes at 4°C. The pellet was RBC lysed with ACK buffer for 2 minutes and washed with F2.5. 
Cells were counted and re-suspended to the appropriate concentration for further use. 
Recipient mice were gamma-irradiated (137Cs source) with a single dose of 300cGy. Following 
irradiation, mice were reconstituted with 2x107 BM cells via i.v. injection, unless otherwise 
indicated.  
 
2.3.3 Liver 
Mice were perfused with MT-PBS. Livers were removed by grasping the hilus with forceps and 
severing the cruciate ligament attached to the diaphragm and then the portal vein. Livers were 
placed in 50ml Falcon tubes (BD Biosciences, San Jose, CA, USA) with 10ml of MT-PBS. In a 
biological safety cabinet, livers were gently disrupted using a cell scraper (Greiner Bio-One, 
Frickenhausen, Germany). Liver cell suspensions were then passed through a 70µm nylon mesh cell 
strainer and centrifuged at 75g for 1 minute at 4oC to sediment parenchymal cells. Supernatants 
were transferred to a fresh 50ml Falcon tube and centrifuged at 350g for 5 minutes at 4oC. Cells 
were re-suspended in 30-35% isotonic Percoll (Sigma-Aldrich, St. Louis, MA, USA) solution with 
Lympholyte-M (CedarLane, Ontario, Canada) underlay. Cells were centrifuged at 750g for 20 
minutes at R.T. and collected at the Percoll/Lympholyte-M interface. Cells were washed twice with 
F2.5 and RBC lysed using ACK buffer as described above. Cells were re-suspended in F2.5 for 
staining steps.  
 
2.3.4 Pancreas 
Digest medium was made fresh for each use and comprised collagenase type III (Worthington, 
Lakewood, NJ, USA) at 1mg/ml and DNase I (Roche Diagnostics, Basel, Switzerland) at 0.1mg/ml 
in RPMI 1640 supplemented with 2% FCS. Using aseptic technique, pancreata were excised from 
recipient mice and placed in a 15ml Falcon tube with 5ml of cold F2.5. To obtain single cell 
suspensions, pancreas tissue was gently disrupted using the end of a plunger from a 5ml syringe. 
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The pancreas tissue was then transferred using a transfer pipette to a 15mL Falcon tube filled with 
4.5ml of digest medium and incubated at 37°C in water bath for 15 minutes. During this incubation 
period, pancreas tissue was gently disrupted by pipetting every 5 minutes. 0.5ml of room 
temperature 100mM EDTA was added per tube and pancreas tissue was continually disrupted by 
pipetting for a further 5 minutes. The little remaining undigested material was placed on a 70µm 
nylon mesh cell strainer positioned on a 50ml Falcon tube and further disrupted gently with a 5ml 
syringe plunger. The strainer was washed through with 10ml ice-cold 
RPMI/10%FCS/10mMEDTA. Cells were then collected by centrifugation 350g for 5 minutes at 
4°C. Cells were washed further with 20ml ice-cold RPMI/10%FCS/10mMEDTA and collected by 
centrifugation. Cells were re-suspended in RPMI/10%FCS/10mMEDTA as required for staining 
steps.  
 
2.3.5 CFSE-labelling  
Pooled LN single cell suspensions were re-suspended in warm MT-PBS to approximately 107 
cells/ml in a clean 50ml Falcon tube. 0.5µl/ml of carboxyfluorescein diacetate succinimidyl ester 
(CFSE; 2.5µM final; Molecular Probes, Invitrogen, Carlsbad, CA, USA) was added to the side of 
the tube and the cell suspension rapidly vortexed to ensure even labelling. The cell suspension was 
incubated at 37°C in the dark for 10 minutes. 30ml of cold F2.5 was added to stop labelling. Cells 
were then counted and re-suspended to appropriate volume in MT-PBS for adoptive transfer. 5x106 
CFSE-labelled naïve G9 T cells or 2x106 CFSE-labelled G9 Tmem were transferred to recipients 
unless otherwise stated.  
 
2.3.6 Purification of CD8+ T cells 
Following preparation of LN single cell suspension, cells were re-suspended in F2.5/20mM EDTA 
at a concentration of 108 cells/ml and stained with an anti-CD8β mAb using standard FACS staining 
procedures. Cells were washed and re-suspended to 5x107 cells/ml in F2.5/20mM EDTA and then 
transferred to a polypropylene FACS tube (BD Biosciences, San Jose, CA, USA) by filtering 
through a 35µm cell strainer (BD Biosciences, San Jose, CA, USA). Cells were maintained on ice, 
with all centrifugation steps at 4°C. Sterile propidium iodide (PI) (Sigma-Aldrich, St. Louis, MA, 
USA) was added to a working concentration of approximately 10µg/ml immediately prior to sorting 
to identify and exclude dead cells. CD8β-positive cells were sorted to a purity of > 90% on a MoFlo 
Astrios (Beckman Coutler, Fort Collins, USA). Sorted cells were collected into 10% FCS-coated 
tubes containing 5ml of cold F2.5. After sorting, cells were counted and re-suspended in MT-PBS 
for adoptive transfer. Aliquots of cells were kept for independent pre- and post-sort flow cytometry 
analyses to determine purity and sort efficiency. 
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2.3.7 Generation of G9 memory T cells 
LN and spleen single cell suspensions from G9 mice were prepared as described above. Both LN 
and spleen cells were then resuspended in complete RPMI/10% FCS at 2x106 cells/ml. InsB15-23 (23 
Gly) and recombinant human IL-2 (PeproTech, Rocky Hill, NJ) were added to cultures at 10µg/ml 
and 10ng/ml, respectively. Cells were plated in 6 well plates (Greiner Bio-one, Frickenhausen, 
Germany) at 3ml/well. Cells were incubated at 37°C, 5% CO2 for 3 days.  On day 3, cells were 
harvested and washed 3 times in warm RPMI. Cells were counted and re-suspended in complete 
RPMI/10% FCS to 2x106/ml. Recombinant mouse IL-15 (PeproTech, Rocky Hill, NJ) was added at 
10ng/ml and cells were plated and cultured at 37°C, 5% CO2 for 2 days. Tmem were washed 3 
times in F2.5, counted and transferred via i.v. injection. 2x106 cells per mouse were transferred in 
200µl of MT-PBS, unless indicated otherwise.  
 
2.3.8 Purification of hematopoietic stem and progenitor cells 
HSPC were isolated from BM by sorting on a MoFlo Astrios (Beckman Coutler, Fort Collins, USA) 
or FACSAria II (BD Biosciences, San Jose, CA, USA). After RBC lysis, cells were re-suspended in 
F2.5/20mM EDTA at 108 cells/ml and stained with anti-c-kit and anti-lineage (lin) mix (CD4, CD8, 
CD45R (B220), CD11b, Gr-1 (Ly-6G), TER-119 (Ly-76)) mAb using standard FACS staining 
procedures. Cells were washed and re-suspended to 5x107 cells/ml in F2.5/20mM EDTA. Cells 
were passed through a 35µm cell strainer (BD Biosciences, San Jose, CA, USA) before being 
transferred to a polypropylene FACS tube (BD Biosciences, San Jose, CA, USA). Cells were 
maintained on ice with all centrifugation steps at 4°C. Sterile PI was added to cells immediately 
prior to sorting to identify and exclude dead cells. c-kit-positive, lin-negative cells were sorted to a 
purity of > 90%.  Sorted cells were collected into 10% FCS-coated tubes with 5ml of cold F2.5. 
After sorting, cells were counted and re-suspended in MT-PBS for adoptive transfer. Aliquots of 
cells were kept for independent pre- and post-sort flow cytometry analyses to determine purity and 
sort efficiency.  
Recipient mice were γ-irradiated (137Cs source) with a single dose of 300cGy. Following irradiation, 
mice were reconstituted with purified HSPC via i.v. injection or intrahepatic injection (for neonates; 
(Pearson et al., 2008)). 2x105 HSPC were injected in 200µl MT-PBS for recipient mice at 6 weeks 
of age or older (approximately 1x107 HSPC/kg). 1x105 HSPC were injected in 100µl MT-PBS for 
recipient mice at 3 weeks of age. 2x104 HSPC were injected in 50µl MT-PBS for recipient mice at 3 
days of age. 
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2.4 Flow cytometry 
2.4.1 Surface staining 
All staining procedures were performed on ice. For flow count analyses to determine total organ 
cellularity, 1ml of spleen or LN samples were added to FACS tubes, centrifuged at 750g for 2 
minutes at 4oC and supernatant was discarded to leave ~100µl. Samples were briefly vortexed to 
resuspend cells. For all other flow analyses, 100µl of sample was added straight to each FACS tube. 
All samples were treated with 10µl FACS block (anti CD16/32 [2.4G2]) for 5mins. Next, 10µl of 
required antibodies (at 10x final working concentrations; Table 2.2.5.1) were added to each sample 
and tubes were incubated in the dark for 30 minutes. Following staining, cells were washed with 
cold FACS wash and cells collected. Supernatant was ‘tipped off’ to leave ~100µl and briefly 
vortexed to resuspend cells. If required for flow count analysis, Flow-CountTM Fluorospheres 
(Beckman Coulter, Miami Lakes, FL, USA) were added at 20µl per tube. Where appropriate, PI 
was added to samples immediately prior to analysis to distinguish and exclude dead cells. Samples 
were collected on a BD FACSCanto (BD Biosciences, San Jose, CA, USA). Diva (BD Biosciences, 
San Jose, CA, USA) or FlowJo (TreeStar Inc, Ashland, OR, USA) software was used to analyze 
data. 
 
2.4.2 Intracellular staining  
Cells were stained for surface markers as described above and kept on ice. Cells were fixed with 
0.5ml of Fixation/Permeabilization solution (eBioscience, San Diego, CA, USA) and briefly 
vortexed. Cells were incubated in the dark for 3 hours (for Foxp3) or 30 minutes (for other 
intracellular markers) prior to 2 washes with Permeabilization buffer (eBioscience, San Diego, CA, 
USA). Cells were blocked (10µl FACS-block and 10% normal rat serum), relevant antibodies added 
and incubated in the dark for 30 minutes. Cells were washed twice with Permeabilization buffer and 
re-suspended in an appropriate volume for flow cytometric analysis.  
 
2.4.3 Tetramer staining  
Cells were prepared as per ‘Surface staining’ method, however, the tetramer staining step was 
performed at room temperature (R.T.). 10µl of required tetramer (at 10x final working 
concentration; Table 2.2.6.1) was added to each sample and tubes were incubated at R.T. in the dark 
for 15 minutes. Without washing, 10µl of required antibodies (at 10x final working concentrations; 
Table 2.2.5.1) were added to each sample and tubes were incubated on ice in the dark for a further 
15 minutes. Following staining, cells were washed with cold FACS wash and cells collected. 
Supernatant was ‘tipped off’ to leave ~100µl and briefly vortexed to resuspend cells prior to flow 
cytometric analysis.  
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2.5 Ex vivo assays 
2.5.1 ELISPOT 
Polyvinylidene difluoride enzyme-linked immunospot (ELISPOT) plates (Millipore) were pre-
treated with ethanol and washed with MT-PBS. The required capture antibody (Table 2.5.1.1) was 
added and plates incubated overnight at 4°C wrapped in foil. The next day, plates were washed and 
blocked with RPMI/5% FCS for 1-2 hours. Spleen cells were plated at 5x105 cells/well in 200µl 
RPMI/5% FCS in triplicate. Necessary wells were left untreated or stimulated with InsB15-23 (23 
Gly) (10µg/ml), InsB15-23 (23 Val) (0.5µg/ml), or anti-CD3 mAb (0.1µg/ml). Plates were incubated 
for 2 days at 37°C, 5% CO2 in a damp chamber. After 2 days, plates were washed and required 
detection antibody (Table 2.5.1.1) was added. Plates were then incubated overnight at 4°C wrapped 
in foil. Avidin-HRP detection enzyme (Sigma-Aldrich, St. Louis, MA, USA) was added and plates 
were incubated at R.T. for 1 hour. Plates were washed and AEC substrate (Calibochem, San Diego, 
CA, USA) added. Development of colour change from the substrate reaction was observed under a 
dissecting microscope for 5-15 minutes and plates washed with tap water as soon as background 
development was observed. Plates were stored at R.T. in the dark until dry and then read using an 
immuno-spot plate reader (AID GmbH, Strassburg, Germany). 
Table 2.5.1.1- Monoclonal antibodies for IFN-γ ELISPOT 
Cytokine Capture antibody 
clone 
Supplier/Cat# 
(working conc.) 
Detection antibody 
clone 
Supplier/Cat# 
(working conc.) 
IFN-γ AN-18 eBioscience/ 
14-7313-85 
(5µg/ml) 
R4-6A2 eBioscience/ 
13-7312-85 
(2µg/ml) 
 
2.6 Assessment of diabetes 
Mice screened for glycosuria weekly using Diastix Reagent Strip (Bayer, Leverkusen, Germany). 
Blood glucose was determined for glycosuric mice using an Accu-Chek Go meter (Roche, Basel, 
Switzerland). Mice were deemed diabetic following two consecutive blood glucose readings 
>12mM. Mice deemed diabetic were subsequently euthanised.  
 
2.7 Statistical analysis 
Graphpad Prism 6 was used to generate all graphs and statistical analyses. Means were compared by 
student’s t-test for pairwise comparison, or one-way analysis of variance (ANOVA) with Tukey’s 
multiple comparison post-test for multiple comparisons. Significance was assigned for the 
following p-values: < 0.05 (*), < 0.01 (**), < 0.001 (***), < 0.0001 (****).  
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Chapter 3 
Transgenic expression of proinsulin induces peripheral tolerance 
in insulin-specific CD8+ T cells 
 
  
39 
 
3.1 Introduction  
β cell-specific CD8+ T cells are important contributors to T1D pathogenesis, capable of 
directly lysing β cells by the Fas/FasL pathway and by release of perforin/granzymes (Bulek et al., 
2012; Unger et al., 2012). As well as direct lysis, β cell-specific CD8+ T cells drive islet 
inflammation through production of proinflammatory cytokines such as IFN-γ and TNF-α (Varanasi 
et al., 2012; Yi et al., 2012). Peripheral tolerance induction in antigen-specific CD8+ T cells by 
targeting antigen expression to APC has been well established using foreign model antigens in both 
adoptive transfer (Kenna et al., 2010; Kurts et al., 1997; Steptoe et al., 2007) and inducible 
Cre/LoxP systems (Probst et al., 2003). T-cell responses in islet autoimmunity are directed toward 
β-cell antigens and robust evidence from the NOD mouse suggests insulin is the initiating antigen 
from which islet autoimmunity arises. This is evidenced by firstly, B16A mice in which insulin 1 
and insulin 2 are knocked out and replaced with a mutated, non-antigenic preproinsulin under 
control of the rat insulin promoter (RIP) and B16A mice do not develop insulitis nor diabetes 
(Nakayama et al., 2005). This indicates CD8+ and CD4+ T cells must recognize the 
immunodominant region of insulin B chain, that is, InsB9-23, for diabetes development in NOD 
mice. Secondly, transgenic expression of proinsulin under control of an MHC class II promoter 
protects NOD mice from insulitis and autoimmune diabetes (French et al., 1997). Furthermore, 
transfer of HSPC from proinsulin transgenic mice abrogates diabetes development in NOD 
recipients (Steptoe et al., 2003). It was determined that transgenic expression of proinsulin targeted 
to APC prevented development and expansion of diabetogenic T-cell responses to other β-cell 
antigen specificities such as IGRP (Krishnamurthy et al., 2006). Krishnamurthy et al. also 
demonstrated that while transgenic expression of IGRP resulted in deletion of IGRP-specific CD8+ 
T cells, this alone was not sufficient to prevent diabetes development. Such studies emphasise not 
only the precedence of (pro)insulin in islet autoimmunity, but also, the potential of transgenic 
antigen, particularly insulin, expression to alter diabetes development. As the studies described 
demonstrate ‘developmental’ induction of antigen-specific tolerance, it remains unclear as to 
whether transgenic proinsulin expression might induce peripheral tolerance in mature insulin-
specific CD8+ T cells.  
G9 TCR transgenic mice (Wong et al., 2009) express a H2-Kd-restricted InsB15-23-specific 
TCR derived from a CD8+ T cell clone isolated from the islet infiltrate of young RIP.B7-1 NOD 
mice (Wong et al., 1999; Wong et al., 1996). The original G9 T cell is highly diabetogenic and 
effectively transfers diabetes to irradiated NOD and immunodeficient NOD.SCID recipients, even 
in the absence of endogenous CD4+ T cells. Since the G9 T cell clone was isolated from young 
NOD mice, prior to diabetes onset, it is possible that the InsB15-23 specificity is involved in early 
islet autoimmunity. In keeping with this suggestion, InsB15-23-loaded, H2-K
d-tetramer binding (G9-
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like) T cells comprise a large proportion of islet-infiltrating T cells in 4-week old NOD mice and 
the frequency of these G9-like T cells diminishes over time (Wong et al., 1999). G9 TCR transgenic 
T cells (herein referred to as G9 T cells) may, therefore, be a good model of early CD8+ T-cell 
responses in autoimmune diabetes development and they can be employed to examine the responses 
of insulin-specific CD8+ T cells in an adoptive transfer setting and an example would be using G9 T 
cells to investigate peripheral tolerance induction. Notably, unlike many model systems using 
foreign model antigens to test tolerance induction, G9 T cells have undergone thymic selection in 
the presence of their cognate antigen. This is an important consideration as autoreactive, β cell-
specific T cells in T1D in human may have undergone thymic selection in the presence of their 
cognate antigen. If different tolerance outcomes were observed in a study using G9 T cells 
compared to studies using foreign model antigens, this may have implications in understanding 
peripheral tolerance induction in T cells that have been subjected to thymic selection pressure. This 
might impact the development of, for example, immunotherapies for T1D that induce T-cell 
peripheral tolerance. Here, with these considerations in mind, I will test whether G9 T cells undergo 
peripheral tolerance after transfer to proinsulin transgenic mice.   
Transgenic mouse models have been used to understand the effect of the autoimmune-prone 
NOD background on antigen-specific T cell tolerance. When HA is expressed transgenically in 
autoimmune-resistant BALB/c or B10.D2 background mice, only low-avidity HA-specific T cells 
are recovered from HA transgenic mice, indicating high-avidity HA-specific T cells have been 
deleted (Lo et al., 1992). In addition, these mice did not develop diabetes after influenza 
immunization. In contrast, in autoimmune-prone NOD HA-expressing mice, islets contained high-
avidity HA-specific CD8+ T cells, capable of transferring diabetes, suggesting that the NOD 
background permits the survival and effector function of these cells (Kreuwel et al., 2001). The 
different tolerance outcomes observed underlines the importance of peripheral tolerance in 
controlling CD8+ T cell responses to prevent autoimmunity and suggests NOD mice are inherently 
defective in pathway(s) associated with peripheral tolerance induction. Furthermore, transgenic 
expression of protective Idd alleles restores peripheral tolerance in clone 4 T cells on the NOD 
background (Martinez et al., 2005). Peripheral CD8+ T cell tolerance to the important β-cell antigen, 
IGRP, is also restored upon introduction of protective Idd3/5 alleles to NOD mice (Hamilton-
Williams et al., 2012). These studies using Idd congenic mice suggest genetic loci crucial to 
autoimmune diabetes development in NOD mice have a direct influence on CD8+ T-cell peripheral 
tolerance pathways. 
In this chapter, I investigate whether targeting proinsulin expression to MHC class II+ APC 
induces peripheral tolerance in insulin-specific CD8+ T cells. In an adoptive-transfer setting, the 
response of G9 T cells to transgenic proinsulin expression and islet-derived insulin expression was 
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compared. G9 T cell proliferation and population dynamics in secondary lymphoid sites were 
assessed in recipients, as well as G9 T cell TCR expression, phenotype and binding of InsB15-23-
loaded tetramer. The response of transferred G9 T cells to InsB15-23 immunisation and the 
contribution of G9 T-cell transfer to diabetes development were assessed.  
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3.2 Results 
3.2.1 G9 T cells display a naïve T-cell phenotype despite expression of cognate antigen in G9 mice 
G9 TCR transgenic T cells have developed, undergone thymic selection and been 
maintained peripherally in the presence of their cognate antigen, InsB15-23. It is possible that this 
antigen exposure has activated G9 T cells in vivo. To investigate this, the phenotype of CD8+ T cells 
expressing the transgenic TCR chain Vβ6+ from LN of G9 mice was compared to CD8+Vβ6+ T 
cells from LN of non-transgenic NOD mice. As expected, CD8+Vβ6+ T cells from LN of TCR 
transgenic G9 mice were consistently more frequent than from non-transgenic NOD mice (Fig. 
3.1A, B). The level of Vβ6 expression was high on transgenic G9 T cells (MFI: 7529±2704, 
mean±S.D., n=3) and was not significantly different to that of T cells from non-transgenic NOD 
mice (MFI: 6815±3312, mean±S.D., n=3, p=0.8) (Fig. 3.1A). CD69 expression was low and similar 
between G9 and NOD T cells (Fig. 3.1A). The proportion of CD8+Vβ6+ T cells expressing CD44 
was slightly higher from NOD (% CD44+: 54.7±19.6, mean±S.D.) than G9 (% CD44+: 33.9±15.4, 
mean±S.D.) (Fig. 3.1A). This difference might be due to the polyclonal nature of the T-cell 
repertoire in non-transgenic NOD mice compared to that of the specificity-restricted TCR 
transgenic G9. Finally, the majority of CD8+Vβ6+ T cells from both G9 and non-transgenic NOD 
mice expressed high levels of CD62L (Fig. 3.1A). Since G9 TCR transgenic mice express insulin in 
pancreatic β cells, it is possible that G9 T cells would be activated in pLN, the site of islet-derived 
insulin presentation. To test this, the phenotype of CD8+Vβ6+ T cells from pLN of G9 mice was 
also analysed. A small proportion of CD8+Vβ6+ T cells from pLN expressed CD69 (% CD69+: 
0.4±0.2, mean±S.D.) (Fig. 3.1C). Similarly to CD8+Vβ6+ T cells from non-pancreatic LN of G9 
mice (Fig. 3.1A), most CD8+Vβ6+ T cells expressed CD62L (% CD62L+: 85.8±3.3, mean±S.D.) 
and low levels of CD44 (Fig. 3.1C). Some CD8+Vβ6+ T cells expressed CD44 (% CD44+: 20.5±9.1, 
mean±S.D.), which may indicate activation (Fig. 3.1C). Despite some evidence of activation, the 
majority of G9 T cells from pLN displayed a typically naïve T-cell phenotype. Despite expression 
of insulin in pancreatic islets and thymus of G9 mice, these data confirm G9 T cells exhibit a 
phenotype typical of naïve CD8+ T cells with similar expression patterns of CD69, CD44 and 
CD62L to that of analogous, non-transgenic T cells.  
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Strain  CD8+Vβ6+ of live cells (%) 
[mean±S.D.] 
NOD (non-transgenic) 2.50±0.26 
G9 (TCR transgenic) 36.83±8.16 
A 
B 
Figure 3.1- G9 T cells display a typically naïve phenotype in the presence of cognate antigen 
expression in G9 mice. 
(A) Axillary, brachial, inguinal and mesenteric LN cells were harvested and pooled from G9 and NOD 
mice. Surface expression of Vβ6, CD69, CD44 and CD62L on CD8+Vβ6+ T cells was determined 
using flow cytometry. Histograms are representative of five G9 and three NOD mice. (B) The 
proportion of CD8+Vβ6+ T cells from live cells was determined using flow cytometry. Proportions are 
mean±S.D. of pooled male G9 LN cells from 11 independent experiments and pooled male NOD LN 
cells from three independent experiments. (C) pLN were harvested from G9 mice. Surface expression 
of CD69, Vβ6, CD44 and CD62L on CD8+Vβ6+ T cells was determined using flow cytometry. n=2. 
The percentages in each quadrant refer to the mAb-stained population (blue) for each histogram. Dot 
plots are representative of two independent experiments.  
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3.2.2 G9 T cells divide extensively after transfer to proinsulin transgenic mice 
Since G9 T cells represent a population of naïve, insulin-specific CD8+ T cells, the next step 
was to determine whether G9 T cells respond to presentation of InsB15-23 derived from transgenic 
proinsulin. To test this, CFSE-labelled G9 LN cells were transferred to B16A, NOD and proinsulin 
transgenic mice and G9 T cell CFSE dilution was determined three days later. As expected, due to 
B16A mice lacking the G9 T-cell determinant, there was no CFSE dilution observed in G9 T cells 
recovered from spleen, skin-draining LN (sdLN) or pLN of B16A recipients (Fig. 3.2A). A low 
proportion of G9 T cells from pLN, but not spleen or sdLN, of NOD recipients showed evidence of 
1-2 divisions, as indicated by CFSE dilution (Fig. 3.2A). In contrast, in proinsulin transgenic 
recipients, widespread G9 T cell proliferation was observed in that the majority of G9 T cells from 
spleen, sdLN and pLN had diluted CFSE (Fig. 3.2A). The proportion of CFSElo G9 T cells 
recovered from proinsulin transgenic recipients was significantly higher than from B16A and NOD 
recipients (Fig. 3.2B). In NOD recipients, the proportion of CFSElo G9 T cells was significantly 
higher for pLN than for spleen or sdLN (Fig. 3.2B). When the proliferation index was calculated, 
the extent of G9 T-cell division in pLN of NOD recipients was identical to that in spleen and sdLN 
(Fig. 3.2C). However, the proliferation index of G9 T cells was significantly higher in spleen, sdLN 
and pLN from proinsulin transgenic recipients than from B16A and NOD recipients (Fig. 3.2C).  
Despite a low number of replicates analysed, the proportion of CFSElo G9 T cells recovered 
from proinsulin transgenic recipients was similar at both two (Fig. 3.2D) and three days after 
transfer (91.7% vs. 90.4%±6.9). The proportion of CFSElo G9 T cells in pLN of NOD recipients 
appeared to be lower at two compared to three days after transfer (Fig. 3.2D). As early as two days 
after transfer, there was a trend toward a much higher proportion of CFSElo G9 T cells in proinsulin 
transgenic recipients compared to B16A and NOD recipients (Fig. 3.2D). The proliferation index of 
G9 T cells from proinsulin transgenic recipients was lower at two than three days after transfer (2.5 
vs 5.0±1.40; Fig. 3.2E), indicating ongoing division of G9 T cells between days 2 and 3 after 
transfer to proinsulin transgenic recipients. The proliferation index of G9 T cells from proinsulin 
transgenic recipients appeared to be higher than B16A and NOD recipients (Fig. 3.2E). These data 
suggest functional presentation of Ins B15-23 from transgenic proinsulin occurs in proinsulin 
transgenic mice and that G9 T cells are responsive to this presentation in vivo. Additionally, the 
CFSE-based analyses suggest a difference in the proliferative response of G9 T cells to transgene-
derived antigen presentation compared to presentation of islet-derived insulin, in that, most G9 T 
cells proliferate early after transfer to proinsulin transgenic recipients, whereas only a low 
proportion of G9 T cells in pLN of NOD recipients proliferated and more slowly. A difference in 
proliferative response to antigen presentation might indicate different T-cell tolerance outcomes 
between recipient strains. 
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CFSE 
pLN 
sdLN 
Spleen 
B16A NOD proIns Tg 
2% 
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Figure 3.2 – G9 T cells proliferate extensively after transfer to proinsulin transgenic mice. 
(A-E) CFSE-labelled G9 LN cells (5x106) were transferred to B16A, NOD and proinsulin transgenic 
recipients. Three (A-C) or two (D, E) days later, CFSE dilution and proliferation index was 
determined in spleen, sdLN (axillary, brachial and inguinal) and pLN using flow cytometry. FACS 
plots (A) display CFSE dilution of CFSE+ G9 T cells and are representative of at least six individual 
mice. Data are pooled from four independent experiments (A-C) or from a single experiment (D, E). 
Each point represents a single mouse. Error bars show S.D. One-way ANOVA followed by Tukey 
post-test. (****p<0.0001).  
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3.2.3 G9 T cells are rapidly deleted after transfer to mice transgenically expressing proinsulin 
Since transferred G9 T cells undergo several divisions in proinsulin transgenic recipients 
within two to three days after transfer, it might be expected that transferred G9 T cells would 
accumulate in secondary lymphoid organs. To determine the population dynamics of G9 T cells 
after transfer, a congenic system was established to identify G9 T cells in recipients. NOD.CD45.2 
mice (CD45.2+CD45.1-) were mated to proinsulin transgenic (CD45.1+CD45.2-) and NOD 
(CD45.1+CD45.2-) mice. F1 offspring (CD45.1+CD45.2+) were used as recipients for G9 LN cells 
(CD45.1+CD45.2-) and, at defined time points, G9 T cells (CD45.1+CD45.2-CD8+Vβ6+) were 
enumerated (Fig. 3.3A). To control for background mAb staining, mice of each strain that were not 
injected with G9 T cells were analysed alongside test mice in each experiment. Mice that were not 
injected with G9 T cells consistently displayed negligible CD45.1+CD45.2-Vβ6+CD8+-gated events. 
Also, since similar trends were observed at the day 3 time point when bulk G9 LN cells or purified 
CD8+ G9 T cells were transferred, the results obtained from when both bulk G9 LN cells and 
purified CD8+ G9 T cells were used as donor cells were pooled for the day 3 time point represented 
in the time course analyses. Despite extensive proliferation of G9 T cells after transfer to proinsulin 
transgenic recipients (Fig. 3.2A), the total number of G9 T cells was similar between NOD and 
proinsulin transgenic recipients in spleen, sdLN or pLN at one, two or three days after transfer (Fig. 
3.3B). At both five and seven days after transfer, fewer G9 T cells were detected in spleens of 
proinsulin transgenic recipients than NOD recipients (Fig.3.3B). The total number of G9 T cells 
present in spleen of proinsulin transgenic recipients decreased over time (day 2 vs day 5, p<0.05), 
whereas the total number of G9 T cells in spleen of NOD recipients remained unchanged over this 
period (Fig. 3.3B). When the proportion of G9 T cells in the total CD8+ T cell population was 
analysed, there was a decrease in the proportion of G9 T cells in spleen of proinsulin transgenic 
recipients over time (day 2 vs day 5, p<0.05; day 3 vs day 5, p<0.05) (Fig. 3.3C). Likewise, there 
was a decrease in the proportion of G9 T cells across time in sdLN of proinsulin transgenic 
recipients (day 1 vs day 3, p<0.05; day 3 vs day 5, p<0.05) (Fig. 3.3C). In contrast, the proportion 
of G9 T cells of total CD8+ T cells in spleen and sdLN of NOD recipients did not differ over time 
(Fig. 3.3C). At five and seven days after transfer, the proportion of G9 T cells was significantly 
lower in proinsulin transgenic recipients than in NOD recipients for spleen, sdLN and pLN (Fig. 
3.3C).  
Since bulk LN cells from G9 mice comprise CD8+Vβ6+ G9 T cells and a population of 
uninvolved CD8-Vβ6- cells (referred to herein as non-G9 cells), analysis of the non-G9 cell 
population might be an indicator of the antigen-specificity of G9 T-cell population dynamics 
observed after transfer to NOD and proinsulin transgenic recipients. When the ratio of G9 T cells 
(CD45.1+CD45.2-CD8+Vβ6+) to non-G9 cells (CD45.1+CD45.2-CD8-) was analysed, the ratio 
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remained similar in NOD and proinsulin transgenic recipients (Fig.3.3D). An increased ratio was 
observed in pLN of NOD recipients (Fig. 3.3D), suggesting expansion of G9 T cells in response to 
islet-derived proinsulin was specific to transferred G9 T cells. Data derived from timecourse studies 
demonstrate a decrease in the total number and proportion of G9 T cells over time after transfer to 
proinsulin transgenic recipients. In contrast, the number of G9 T cells was relatively stable after 
transfer to NOD recipients. Therefore, G9 T cells appear to be deleted after transfer to proinsulin 
transgenic recipients. 
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Figure 3.3- G9 T cells are deleted after transfer to proinsulin transgenic mice.  
G9 LN cells (5x106; day 1, 2, 3, 5, 7; n=4-5 day 3) or purified CD8+ G9 T cells (2x106; day 3, n=3-4) 
were transferred to NOD and proinsulin transgenic recipients. (A) Gating strategy for analysis of G9 T 
cells transferred to congenic (CD45.1+CD45.2+) recipients. At times shown, the total number (B) and 
proportion of G9 T cells (CD45.1+CD8+Vβ6+) of total CD8+ T cells (C) in spleen, sdLN and pLN was 
determined using flow cytometry. (D) Ratio of G9 (CD45.1+CD8+Vβ6+) to non-G9 cells 
(CD45.1+CD8-). Data are pooled from two (day 1, 2, 5) or four (day 3) independent experiments. n=4 
(day 1, 2, 5 and 7); n= 7-9 (day 3). Error bars show S.D. One-way ANOVA followed by Tukey post-
test. (B) (****p<0.0001: NOD spl vs proIns Tg spl) (C) (**** p<0.0001: NOD pLN vs proIns Tg 
pLN) (D) (**** p<0.0001: NOD pLN vs NOD spl).  
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3.2.4 Transferred G9 T cells do not infiltrate the pancreas of NOD or proinsulin transgenic 
recipients 
Since low numbers of G9 T cells were recovered from secondary lymphoid organs of 
proinsulin transgenic recipients, it is possible that G9 T cells might traffic to the pancreas after 
transfer thereby reducing the G9 T cell number observed in spleen and LN. To test this, G9 LN cells 
were transferred to NOD and proinsulin transgenic mice and pancreas-infiltrating lymphocytes were 
enumerated three days later. Few host (CD45.1+CD45.2+) leukocytes were observed in pancreas of 
NOD and proinsulin transgenic recipients (Fig. 3.4A). Transferred leukocytes (CD45.1+CD45.2-) as 
a proportion of host leukocytes (CD45.1+CD45.2+) did not differ between NOD and proinsulin 
transgenic recipients (Fig. 3.4B). Despite a low number of biological replicates analysed, there 
appeared to be no difference in the proportion of transferred leukocytes in NOD and proinsulin 
transgenic mice that were not injected with G9 T cells compared to either NOD or proinsulin 
transgenic recipients of G9 T cells (Fig. 3.4B). Similarly, there was no significant difference in the 
proportion of transferred G9 T cells (CD45.1+CD45.2-CD8+) of host CD8+ T cells between NOD 
and proinsulin transgenic recipients (Fig. 3.4C). With the caveat that a low number of untransferred 
control mice were analysed, there appeared to be no difference in the proportion of G9 T cells of 
host CD8+ T cells between untransferred mice and recipients of G9 T cells (Fig. 3.4C). It should be 
noted that it is possible that transferred G9 T cells may adhere to the collagen matrix within the 
pancreas, precluding their identification using flow cytometry. Therefore, histology on pancreas 
samples from recipients of G9 T cells could be examined to validate these data. From the available 
data, G9 T cells do not appear to preferentially traffic to pancreas in NOD or proinsulin transgenic 
recipients.  
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Figure 3.4- Low recovery of transferred G9 T cells in pancreas of NOD and proinsulin 
transgenic recipients. 
(A-C) G9 LN cells (5x106) or purified CD8+ G9 T cells (2x106) were transferred to NOD and 
proinsulin transgenic recipients (males, at 8-10 weeks of age). Three days later, the proportion of 
pancreas-infiltrating transferred leukocytes (CD45.1+/CD45.2-) of total leukocytes (B) and the 
proportion of G9 T cells (CD45.1+/CD45.2-/CD8+) of total CD8+ T cells (C) were determined using 
flow cytometry. Representative gating strategy to analyse infiltrating leukocytes in pancreas samples 
(A). Data are pooled from three independent experiments. Each point represents a single mouse. Error 
bars show S.D. One-way ANOVA followed by Tukey post-test.  
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3.2.5 G9 T cells are not preferentially activated and retained in the liver of proinsulin transgenic 
recipients 
Since the liver is a site of CD8+ T cell activation and retention or clearance (Benseler et al., 
2011; Bertolino et al., 2001; Huang et al., 1994), it is possible that G9 T cells may become activated 
and retained in liver after transfer to proinsulin transgenic mice. This could account for the reduced 
number of G9 T cells recovered from secondary lymphoid organs in proinsulin transgenic 
recipients. To test this, G9 LN cells were transferred to NOD and proinsulin transgenic recipients 
and the frequency and CD69 expression by G9 T cells in liver were assessed three hours later. 
Although only two mice were analysed, the percentage of G9 T cells was higher in spleen compared 
to liver for both strains, while in liver the percentage of G9 T cells was similar between strains (Fig. 
3.5A). In proinsulin transgenic recipients, the proportion of CD69+ G9 T cells was higher in spleen 
than in liver but in NOD recipients the inverse was observed (Fig. 3.5B). These data suggest G9 T 
cells are not preferentially activated and retained in liver after transfer to proinsulin transgenic 
recipients. 
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Figure 3.5- Low recovery of transferred G9 T cells in liver of NOD and proinsulin transgenic 
recipients. 
G9 LN cells (5x106) were transferred to NOD and proinsulin transgenic recipients. Three hours later, 
the proportion of G9 T cells (CD45.1+CD45.2-CD8+Vβ6+) of total CD8+ T cells (A) and the proportion 
of CD69+ G9 T cells (B) in liver and spleen were determined using flow cytometry. Data are from a 
single experiment. Each point represents a single mouse.  
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3.2.6 Reduced recovery of G9 T cells from proinsulin transgenic recipients is not due to allotype-
mediated rejection 
Overall, the number of G9 T cells recovered from lymphoid tissues of proinsulin transgenic 
recipients was lower than that typically recovered in other adoptive transfer studies either in 
C57BL/6 (Nasreen et al., 2010; Steptoe et al., 2007) or NOD mice (Krishnamurthy et al., 2012). 
While the data considered to this point are consistent with deletion of G9 T cells in proinsulin 
transgenic recipients, it is possible that the low number of G9 T cells recovered was due to a 
suboptimal number of cells being transferred. Therefore, a pilot experiment was performed where 
graded doses of G9 LN, up to 20x106, cells were transferred. The total number of G9 T cells 
recovered from both NOD and proinsulin transgenic recipients remained relatively low three days 
after transfer, particularly in proinsulin transgenic recipients, even at the highest G9 T cell number 
transferred (Fig. 3.6A). Importantly, the frequency of G9 T cells was similar relative to the number 
of G9 T cells transferred for both strains (Fig. 3.6B). These data suggest that increasing the number 
of G9 LN cells transferred does not alter the pattern of G9 T-cell recovery from proinsulin 
transgenic recipients and this remains low relative other models (Nasreen et al., 2010; Steptoe et al., 
2007). Furthermore, the data indicate that the number of G9 T cells transferred in experiments 
shown to date (that is, 5x106 G9 LN cells, representing approximately 2x106 CD8+Vβ6+ G9 T cells) 
provides a valid insight into G9 T-cell dynamics. 
The lower than expected recovery of G9 T cells from NOD and proinsulin transgenic 
recipients prompted the question of whether unexpected immune-mediated rejection of transferred 
G9 T cells due to genetic differences between donor and recipient strains might be occurring. 
Therefore a pilot experiment was performed where CFSE-labelled G9 LN cells were transferred to 
syngeneic G9 and non-transgenic NOD mice. When analysed three days after transfer, the 
proportion of G9 T cells within the total CD8+ T cell pool was only slightly higher in syngeneic G9 
compared to NOD recipients (Fig. 3.6C). However, T cell-mediated rejection of transferred G9 T 
cells is unlikely to be ruled out by these data as three days is insufficient time for T cell-mediated 
rejection to occur, although NK cell-mediated rejection can occur within this timeframe (Liu et al., 
2012). To examine the possibility of immune rejection further, CFSE-labelled G9 LN cells were 
transferred to proinsulin transgenic (CD45.1+CD45.2-), F1 proinsulin transgenic 
(CD45.1+CD45.2+), NOD (CD45.1+CD45.2-), F1 NOD (CD45.1+CD45.2+), NOD.CD45.2 (CD45.1-
CD45.2+), B16A (CD45.1+CD45.2-) and G9 (CD45.1+CD45.2-) mice and G9 T cells analysed 
twenty one days later. These combinations of recipient mice allowed not only the interaction 
between recipient strains, but also CD45 congenic status, to be examined. The percentage of G9 T 
cells was low in spleen, sdLN and pLN of proinsulin transgenic recipients, regardless of the 
congenic background (Fig. 3.6D-F). G9 T cells were somewhat increased in NOD recipients than 
A 
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proinsulin transgenic recipients, but remained similar between the groups of NOD recipients, 
regardless of CD45 congenic status (Fig. 3.6D-F). The frequency of G9 T cells was similar between 
B16A and G9 recipients but was higher than NOD and proinsulin transgenic recipients (Fig. 3.6D-
F). From this it can be concluded that G9-T cell recovery from proinsulin transgenic or NOD 
recipients is not influenced by CD45 congenic status. Similarly, reduced recovery of G9 T cells 
from proinsulin transgenic relative to NOD is likewise not influenced by CD45 congenic status. If, 
to account for reduced G9 T cell recovery in proinsulin transgenic recipients, immune-mediated 
rejection of G9 T cells was occurring in this strain and not NOD recipients, then it might be 
expected that the non-G9 cell population described in Figure 3.3 would, in addition to G9 T cells, 
decrease at a faster rate than in NOD recipients. When analysed across all time points, non-G9 cells 
displayed similar dynamics in both NOD and proinsulin transgenic recipients for spleen, sdLN and 
pLN (Fig. 3.6G-I). This suggests the rapid reduction of G9 T cells in proinsulin transgenic 
recipients is not due to non-specific immune rejection but most likely due to antigen-specific effects 
of transgenic proinsulin expression. 
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Figure 3.6 - G9 T cells are not rejected due to an allotypic difference between NOD and proinsulin 
transgenic recipients. 
(A, B) G9 LN cells (5x106, 10x106 or 20x106) were transferred to NOD and proinsulin transgenic 
recipients. Three days later, the total number of G9 T cells (CD45.1+CD45.2-CD8+Vβ6+) and G9 T cells as 
proportion of total CD8+ T cells was determined in spleen, sdLN and pLN using flow cytometry. (C) 
CFSE-labelled G9 LN cells (5x106) were transferred to G9 and NOD recipients. Three days later, G9 T 
cells (CFSE+CD8+Vβ6+) as a proportion of total CD8+ T cells was determined using flow cytometry. (D-F) 
CFSE-labelled G9 LN cells (5x106) were transferred to G9 (CD45.1+CD45.2-), B16A (CD45.1+CD45.2-), 
NOD.CD45.2 (CD45.1-CD45.2+), F1 NOD (CD45.1+CD45.2+), NOD (CD45.1+CD45.2-), F1 proinsulin 
transgenic (CD45.1+CD45.2+) and proinsulin transgenic (CD45.1+CD45.2-) mice. Twenty one days later, 
G9 T cells (CFSE+CD8+Vβ6+) as a proportion of total CD8+ T cells was determined in spleen (D), sdLN, 
(E) and pLN (F) using flow cytometry. (G-I) G9 LN cells (5x106) were transferred to NOD 
(CD45.1+CD45.2+) and proinsulin transgenic (CD45.1+CD45.2+) mice. At times shown, the ratio of G9 T 
cells (CD45.1+CD8+Vβ6+) to non-G9 cells (CD45.1+CD8-) was determined using flow cytometry. Data are 
from one (A-F) or pooled from at least two (G-I) independent experiments. n=3-4 at each time point (G-I). 
Each point represents a single mouse. Error bars show S.D. 
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3.2.7 Transferred G9 T cells persist in the absence of cognate antigen  
Using a congenic marker-based adoptive transfer setting, it was demonstrated that the 
number of G9 T cells decreased rapidly after transfer to proinsulin transgenic recipients, while the 
number of G9 T cells remained relatively stable after transfer to NOD recipients (Fig. 3.3). 
Inclusion of B16A mice, which do not express the G9 T-cell determinant would be informative, but 
these timecourse studies were not conducive to this as B16A mice express the same CD45 allotype 
as G9 mice. If the assumption is made that G9 T cells are not expected to proliferate after transfer to 
B16A recipients, CFSE-labelling might be useful to visualise transferred G9 T cells in B16A 
recipients. To explore this, CFSE-labelled G9 LN cells were transferred to B16A, NOD and 
proinsulin transgenic mice, and G9 T cells were enumerated at both three and twenty one days after 
transfer. Three days after transfer, G9 T-cell recovery was similar between B16A, NOD and 
proinsulin transgenic recipients in spleen and sdLN (Fig. 3.7A, B). The proportion of G9 T cells of 
total CD8+ T cells was significantly lower in pLN from proinsulin transgenic compared to NOD 
recipients (Fig. 3.7B). At twenty one days after transfer, despite a low number of replicates, G9 T-
cell number appeared to be higher in spleen and sdLN of B16A recipients compared to NOD and 
proinsulin transgenic recipients (Fig. 3.7C). When the proportion of G9 T cells was analysed, this 
was significantly lower from both NOD and proinsulin transgenic recipients compared to B16A 
recipients in spleen, sdLN and pLN (Fig. 3.7D). There is the possibility that this reduced G9 T-cell 
frequency observed for NOD and proinsulin transgenic recipients may be due to loss of CFSE-
labelled G9 T cells as a result of proliferation. Although, G9 T cells were enumerated using a 
congenic marker twenty one days after transfer to NOD and proinsulin transgenic recipients and 
low recovery of G9 T cells was observed in both strains also (data not shown). A small population 
of G9 T cells was detected in spleen, sdLN and pLN of NOD recipients, which was not present in 
proinsulin transgenic recipients (Fig. 3.7D). Taken together, these data indicate G9 T cells persist in 
B16A recipients, in the absence of their cognate antigen. On the other hand, expression of islet-
derived insulin in NOD mice appears to lead to the gradual deletion of transferred G9 T cells. 
Notably, there were no G9 T cells detected in proinsulin transgenic recipients, indicating the rapid 
deletion observed in timecourse studies (Fig. 3.3) is maintained.  
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Figure 3.7- High recovery of transferred G9 T cells in B16A recipients. 
CFSE-labelled G9 LN cells (5x106) were transferred to B16A, NOD and proinsulin transgenic 
recipients. Three (A, B) or twenty one (C, D) days later, the total number (A, C) of G9 T cells 
(CFSE+CD8+Vβ6+) and G9 T cells as a proportion of total CD8+ T cells (B, D) in spleen, sdLN and 
pLN were determined using flow cytometry. Data are pooled from four (B) or two (A, D) independent 
or a single (C) experiment(s). Each point represents a single mouse. Error bars show S.D. One-way 
ANOVA followed by Tukey post-test. (*p<0.05, ***p<0.001). 
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3.2.8 Down-regulation of TCR on G9 T cells after transfer to proinsulin transgenic recipients 
It has been previously shown that rapid inactivation of OT-I T cells after transfer to mice in 
which OVA expression is driven by an MHC class II promoter (MII.OVA) was due to TCR down-
regulation (Kenna et al., 2010). Since, in proinsulin transgenic mice, proinsulin expression is under 
control of an MHC class II promoter, it is possible that TCR expression by G9 T cells is reduced 
after transfer to proinsulin transgenic recipients. Initially, a pan-TCRβ mAb, recognising all 
rearranged TCRβ chains, was used to determine TCR expression on G9 T cells. However, the 
relative level of anti-TCRβ mAb staining was higher on G9 CD8+TCRβ+ T cells compared to non-
transgenic NOD CD8+TCRβ+ T cells (Fig. 3.8A). When an anti-Vβ6 mAb was used, the level of 
staining was not significantly different for G9 CD8+Vβ6+ T cells (MFI: 7529±2704 mean ±SD, 
n=3) compared to non-transgenic NOD CD8+Vβ6+ T cells (MFI: 6815±3312, mean ±SD; n=3, 
p=0.8) (Fig. 3.8A). The difference in mAb staining intensity might indicate the pan-TCRβ mAb had 
an increased specificity for Vβ6 arrangements and the higher frequency of Vβ6-expressing CD8+ T 
cells in G9 mice resulted in an overall increased staining intensity compared to non-transgenic NOD 
T cells (Fig. 3.8B). To determine TCR expression by G9 T cells after transfer, CFSE-labelled G9 
LN cells were transferred to B16A, NOD and proinsulin transgenic recipients and TCR expression 
analysed three days later. G9 T cell TCR expression was determined relative to TCR expression of 
host CD8+Vβ6+ T cells as an internal control for the staining technique. Three days after transfer, 
there appeared to be an increase in TCRβ expression on G9 T cells relative to host CD8+Vβ6+ T 
cells from B16A and NOD recipients (Fig. 3.8C), however, this is probably due to the higher 
staining intensity of transferred G9 T cells relative to the analogous host population (Fig. 3.8A, B). 
Considering this, in proinsulin transgenic recipients, G9 T cells expressed significantly lower TCRβ 
compared to B16A and NOD recipients (Fig. 3.8C). There was no significant difference in G9 T 
cell TCR expression between B16A and NOD recipients (Fig. 3.8C).  
Having accounted for the different levels of staining between anti-TCRβ and anti-Vβ6 mAb, 
the anti-Vβ6 mAb was used in future experiments to determine TCR expression of transferred G9 T 
cells. To determine the dynamics of TCR expression by G9 T cells, G9 LN cells were transferred to 
congenic NOD and proinsulin transgenic recipients and TCR expression analysed at defined time 
points. In proinsulin transgenic recipients, transferred G9 T cells displayed significantly lower Vβ6 
expression than those from NOD recipients as early as one day after transfer and Vβ6 expression 
continued to decrease over time on G9 T cells in proinsulin transgenic recipients (Fig. 3.8D, E). 
Despite proliferation of G9 T cells in pLN of NOD recipients (Fig. 3.2), the level of Vβ6 expression 
on G9 T cells from pLN of NOD recipients remained similar to that of the host CD8+Vβ6+ T-cell 
population and was also similar to G9 T cells from spleen and sdLN of NOD recipients (Fig. 3.8E).  
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Since only minimal G9 T cell proliferation was observed in pLN of NOD recipients, it might 
be possible that TCR down-regulation is occurring for proliferating G9 T cells but that this would 
not be evident when non-proliferating G9 T cells were included in the analysis. To test this, TCRβ 
expression of proliferating (CFSElo) G9 T cells was analysed relative to both the non-proliferating 
(CFSEhi) G9 T cells and host CD8+ T cells. There was no significant difference between TCRβ 
expression on proliferating and non-proliferating G9 T cells, or when this expression was compared 
to host CD8+ T cells (Fig. 3.8F). This suggests rapid TCR down-regulation occurs only for G9 T 
cells in response to transgenic proinsulin expression. 
These data indicate TCR down-regulation occurs on G9 T cells after transfer to proinsulin 
transgenic recipients. In contrast, TCR down-regulation was not observed for G9 T cells in response 
to islet-derived insulin presentation in pLN of NOD recipients, suggesting rapid TCR down-
regulation is not merely a consequence of G9 T-cell activation.  
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mAb Relative MFI 
(G9/NOD) 
Pan-TCRβ  
(clone: H57-957) 
1.51±0.01 
Anti-Vβ6  
(clone:RR4-7) 
1.15±0.13 
Divided G9 T cells 
relative to non-divided 
G9 
Divided G9 T cells 
relative to host CD8+ T 
cells 
Non-divided G9 T cells 
relative to host CD8+ T 
cells 
1.08±0.29 1.36±0.24 1.30±0.30 
A 
B 
D 
Figure 3.8 – G9 T cell TCR down-regulation after transfer to proinsulin transgenic recipients. 
(A) Vβ6 and pan-TCRβ expression on G9 or NOD LN cells was analysed using flow cytometry. Gating 
strategy and relative histograms of CD8+Vβ6+ T cells. (B) Ratio of MFI of TCRβ staining on CD8+Vβ6+ T cells 
or Vβ6 staining CD8+TCRβ+ T cells from G9 relative to NOD (mean±S.D.; n=3). (C) CFSE-labelled G9 LN 
cells (5x106) were transferred to B16A, NOD and proinsulin transgenic mice. Three days later, TCRβ 
expression on G9 T cells (CFSE+CD8+Vβ6+) relative to host CD8+Vβ6+ T cells in spleen, sdLN and pLN was 
determined using flow cytometry. (D-E) G9 LN cells (5x106) or purified CD8+ G9 T cells (2x106) were 
transferred to NOD and proinsulin transgenic mice. (D) Representative histogram of Vβ6 expression on G9 T 
cells seven days after transfer. (E) At times shown, Vβ6 expression on G9 T cells (CD45.1+CD8+Vβ6+) relative 
to host CD8+Vβ6+ T cells in spleen, sdLN and pLN was determined using flow cytometry. Data are pooled 
from two (E), three (B) and four (C) independent experiments. Histograms are representative of at least two 
independent experiments. Each point represents a single mouse. (E) n=4 (day 1, 2, 5, 7); n= 7-9 (day 3). (F) 
Ratio of TCRβ expression by dividing (CFSElo), non-dividing (CFSEhi) G9 T cells and host CD8+ T cells 
(CD8+CFSE-), n=6.  Error bars show S.D. One-way ANOVA followed by Tukey post-test. (**p<0.01, 
***p<0.001, ****p<0.0001: NOD pLN vs proIns Tg pLN).  
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3.2.9 InsB15-23-loaded tetramer binding of G9 T cells is impaired after transfer to proinsulin 
transgenic recipients  
Since the remaining, non-deleted G9 T cells in proinsulin transgenic recipients display 
evidence of TCR down-regulation, it is plausible that these G9 T cells are functionally inactivated. 
A reduction in binding of cognate peptide/MHC tetrameric complex (tetramer) by CD8+ T cells has 
been associated with reduced effector function (Drake et al., 2005). To investigate this, InsB15-23-
loaded, H2-Kd-tetramer binding to transferred G9 T cells was analysed in B16A, NOD and 
proinsulin transgenic recipients three days after transfer. Tetramer-binding G9 T cells as a 
proportion of total CD8+ T cells were generally more frequent in B16A recipients (Fig. 3.9A). 
Tetramer-binding G9 T cells were also relatively abundant in pLN of NOD recipients (Fig. 3.9A), 
and this was similar to the proportion of CFSE-labelled G9 T cells of total CD8+ T cells in the same 
site (Fig. 3.7B). Strikingly, few tetramer-binding G9 T cells were detected at any lymphoid site of 
proinsulin transgenic recipients (Fig. 3.9A). In fact, this frequency was lower than the mean 
proportion of control peptide (LLO91-99)-loaded tetramer-binding CD8
+ T cells of total CD8+ T 
cells, as indicated in Figure 3.9 by the dashed line. When the proportion of G9 T cells binding 
tetramer was analysed, approximately 40-75% (depending on the site of collection) of G9 T cells 
from B16A recipients bound tetramer (Fig. 3.9B). The proportion of G9 T cells that bound tetramer 
from NOD recipients was slightly lower, but this was not statistically significant (Fig. 3.9B). 
Interestingly, the proportion of tetramer-binding G9 T cells was higher in pLN than that of spleen or 
sdLN in NOD recipients (Fig. 3.9B). In contrast, in proinsulin transgenic recipients, the proportion 
of tetramer-binding G9 T cells was low and in some cases, below the level of control tetramer 
binding (Fig. 3.9B). This indicates substantial loss of tetramer-binding capacity by G9 T cells after 
transfer to proinsulin transgenic recipients, and when considered in relation to the TCR down-
regulation reported above (Fig. 3.8), this explains the low recovery of tetramer-binding G9 T cells 
in proinsulin transgenic recipients.  
The relationship between reduced tetramer binding and TCR expression was particularly 
evident when the level of G9 T cell tetramer binding was shown relative to the level of G9 T cell 
TCR expression. As such, G9 T cells in any lymphoid site from proinsulin transgenic recipients 
generally clustered together, co-expressing low levels of Vβ6 and tetramer (Fig. 3.9C), although 
one sample from pLN displayed a high level of tetramer expression despite low Vβ6 expression. In 
contrast, G9 T cells from spleen, sdLN and pLN of B16A and NOD recipients clustered with high 
expression of Vβ6 and tetramer (Fig. 3.9C) and were not distinguishable from each other. 
Interestingly, some G9 T cells from pLN of B16A and NOD recipients displayed higher levels of 
tetramer binding, despite similar Vβ6 expression compared to G9 T cells from spleen and sdLN of 
B16A and NOD recipients (Fig. 3.9C). Overall, these data suggest G9 T cells transferred to 
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proinsulin transgenic mice are less able to recognise their cognate antigen in the context of H2-Kd, 
which is probably due to TCR down-regulation, and may be indicative of functional inactivation.  
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  Figure 3.9 – Transferred G9 T cells bind less InsB15-23-loaded, H2-Kd-tetramer in proinsulin 
transgenic compared to B16A and NOD recipients.  
CFSE-labelled G9 LN cells (5x106) were transferred to B16A, NOD and proinsulin transgenic 
recipients. Three days later, the proportion of CFSE+Kd:Ins+CD8+Vβ6+ T cells of total CD8+ T cells 
(A), the proportion of Kd:Ins-binding CFSE+CD8+Vβ6+ T cells (B) and the MFI of Vβ6 relative to the 
MFI of Kd:Ins on CFSE+CD8+Vβ6+ T cells was determined using flow cytometry. Data are pooled 
from two independent experiments. Each point represents a single mouse. Error bars show S.D. The 
dashed line represents the limit of detection for the Kd:Ins tetramer and shows the mean of the 
proportion of control (LLO91-99) tetramer-binding CD8
+ T cells of total CD8+ T cells (A) or the 
proportion of control tetramer-binding CFSE+CD8+Vβ6+ T cells (B). One-way ANOVA followed by 
Tukey post-test. (*p<0.05, **p<0.01, ***p<0.001).  
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3.2.10 Transferred G9 T cells are predominantly CD44hiCD62L+ in proinsulin transgenic recipients 
Since G9 T cells appear to undergo peripheral tolerance induction after transfer to proinsulin 
transgenic mice, it is possible that these G9 T cells will have a different phenotype than G9 T cells 
transferred to NOD recipients. To test this, G9 LN cells were transferred to NOD and proinsulin 
transgenic recipients and the phenotype of G9 T cells analysed at defined time points. The 
proportion of G9 T cells expressing the early activation marker, CD69, was higher in proinsulin 
transgenic recipients than NOD recipients for spleen and sdLN as early as one day after transfer 
(Fig. 3.10A). In NOD recipients, the proportion of CD69-expressing G9 T cells was higher in pLN 
than spleen and sdLN (Fig. 3.10A). The proportion of G9 T cells expressing high levels of CD44 
was significantly higher from proinsulin transgenic recipients than NOD recipients at one day after 
transfer (Fig. 3.10B). In NOD recipients, G9 T cells expressed high levels of CD44 by three days 
after transfer in pLN, while G9 T cells from spleen and sdLN remained consistently CD44lo (Fig. 
3.10B). The proportion of G9 T cells expressing CD44 and low levels of CD62L was relatively low 
from both proinsulin transgenic and NOD recipients (Fig. 3.10C). At five and seven days after 
transfer, the proportion of CD44hiCD62L- G9 T cells was higher in pLN compared to spleen of 
NOD recipients (Fig. 3.10C). Most G9 T cells from proinsulin transgenic recipients were 
CD44hiCD62L+ (Fig. 3.10D) The proportion of host CD8+Vβ6+ T cells expressing CD69 and CD44 
remained low, while CD62L expression remained high over time in proinsulin transgenic and NOD 
recipients (data not shown). At seven days after transfer, the total number of CD44hiCD62L- G9 T 
cells in pLN of NOD recipients was significantly higher than in proinsulin transgenic recipients 
(Fig. 3.10E). An increase in the number of CD44hiCD62L- G9 T cells was not observed in spleen of 
NOD recipients (Fig. 3.10E). These data suggest G9 T cells are rapidly activated after transfer to 
proinsulin transgenic recipients, and are predominantly CD44hiCD62L+ seven days after transfer. In 
contrast, G9 T cells in spleen and sdLN from NOD recipients did not display an activated 
phenotype. In pLN from NOD recipients, there was an accumulation of CD44hiCD62L- G9 T cells, 
which might indicate development of effector function in response to islet-derived insulin 
presentation.  
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Figure 3.10 – G9 T cells are predominantly CD44hiCD62L+ after transfer to proinsulin 
transgenic recipients.   
G9 LN cells (5x106) were transferred to NOD and proinsulin transgenic mice. At times shown, the 
proportion of CD69+ (A), CD44+ (B), CD44hiCD62L- (C) and CD44hiCD62L+ (D) G9 T cells 
(CD45.1+CD45.2-CD8+Vβ6+) in spleen, sdLN and pLN were determined using flow cytometry. (E) 
Total number of CD44hiCD62L- and CD44hiCD62L+ G9 T cells in pLN (left) and spleen (right) seven 
days after transfer, n=4. Data are pooled from two (day 1, 2, 5, 7 (A); (E)) or four (day 3 (A)) 
independent experiments. n=4 (day 1, 2, 5 and 7); n= 6-8 (day 3). Error bars show S.D. One-way 
ANOVA followed by Tukey post-test. (A) (**p<0.01, ***p<0.001, ****p<0.0001: NOD spl vs proIns 
Tg spl) (B) (**p<0.01, ***p<0.001, ****p<0.0001: NOD spl vs proIns Tg spl) (C) (*p<0.05, 
**p<0.01: NOD spl vs NOD pLN) (D) (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001: NOD spl vs 
proIns Tg spl) (E) (*p<0.05: CD44hiCD62L- NOD vs proIns Tg). 
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3.2.11 Optimisation of InsB15-23 peptide immunisation  
As the data above are consistent with deletion of a portion of transferred G9 T cells in 
proinsulin transgenic recipients and the retention of a small population of, possibly inactivated, G9 
T cells, I next wanted to test the functional response of G9 T cells. To do so, it was first necessary 
to develop an appropriate peptide immunisation regimen. To determine the optimal 
antigen/adjuvant combination to induce an IFN-γ response from transferred G9 T cells, a pilot 
experiment was performed. G9 LN cells were transferred to NOD mice and one day later, recipients 
were immunised with defined InsB15-23/adjuvant combinations and IFN-γ production assessed five 
days later using an ELISPOT assay. The highest number of IFN-γ spots was observed for NOD 
recipients immunised with poly I:C/InsB15-23, with the least variability between replicates  (Fig. 
3.11A). Poly I:C was therefore employed for future peptide immunisations. Native InsB15-23 binds 
poorly to H2-Kd (Wong et al., 2002) and it is possible that poor binding limits presentation to G9 T 
cells. Increasing peptide/H2-Kd binding affinity might result in an increased G9 T cell response to 
immunisation. An APL of InsB15-23, where glycine is replaced by valine at p9, InsB15-23 (23 Val), 
has been shown to increase the cytotoxicity of the G9 T cell clone (Wong et al., 2002). To test 
whether InsB15-23 (23 Val) immunisation increases the G9 T cell recall response, G9 LN cells were 
transferred to NOD mice. One day later, recipients were immunised with defined doses of InsB15-23 
(23 Val) or InsB15-23 (23 Gly) in combination with poly I:C and five days later, G9 T cells were 
enumerated by flow cytometry and IFN-γ production was determined by ELISPOT. A trend toward 
an increase in the number of IFN-γ spots was observed following InsB15-23 (23 Val) immunisation 
compared to InsB15-23 (23 Gly) immunisation, however, more variability between replicates was 
observed in NOD recipients immunised with InsB15-23 (23 Val) (Fig. 3.11B, left). The total number 
of G9 T cells was increased only marginally after immunisation with 10µg InsB15-23 (23 Val) 
compared to InsB15-23 (23 Gly) and 50µg InsB15-23 (23 Val), (Fig. 3.11B, middle). The proportion of 
G9 T cells of total CD8+ T cells in recipients immunised with InsB15-23 (23 Gly) was similar 
compared to 10 µg InsB15-23 (23 Val) (Fig. 3.11B, right). Given the reduced variability of the G9 T-
cell recall response elicited by immunisation with 50µg InsB15-23 (23 Gly), future peptide 
immunisations contained 50µg InsB15-23 (23 Gly).  
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A 
Figure 3.11 – G9 T-cell expansion and IFN-γ production following InsB15-23 peptide 
immunisation. 
(A) G9 LN cells (5x106, CD45.1+CD45.2-) were transferred to NOD (CD45.1-CD45.2+) mice. One day 
later, recipients were immunised with InsB15-23 (50µg) combined with CpG (15.5nM, s.c.), QuilA 
(20µg, s.c.), poly I:C (100µg, i.p.), CASAC (200µl, s.c. flank), poly I:C+CpG (100µg+15.5nM, s.c.) or 
left unimmunised. Five days later, IFN-γ production was determined in spleen using ELISPOT. (B) G9 
LN cells (20x106, CD45.1+CD45.2-) were transferred to NOD (CD45.1-CD45.2+) mice. One day later, 
recipients were immunised with 50µg InsB15-23 (23 Gly), 10µg InsB15-23 (23 Val) or 50µg InsB15-23 (23 
Val) combined with 100µg poly I:C i.p. or left unimmunised. Five days later, IFN-γ production was 
determined in spleen using ELISPOT (left panel), and the total number of G9 T cells 
(CD45.1+CD45.2-CD8+Vβ6+) (middle) and G9 T cells as a proportion (right) of total CD8+ T cells 
were determined in spleen using flow cytometry. Mean number of IFN-γ+ spots determined by 
subtracting unstimulated wells from peptide-stimulated wells (B, left panel). Data are from one 
individual experiment. Each point represents a single mouse. Error bars show S.D. 
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3.2.12 G9 T cells are unresponsive to InsB15-23 immunisation after transfer to proinsulin transgenic 
mice 
Since immunisation with InsB15-23 (23 Gly)/poly I:C expanded and induced IFN-γ 
production by transferred G9 T cells in NOD recipients, I wanted to use this immunisation regimen 
to investigate whether G9 T cells in proinsulin transgenic recipients were functionally inactive. To 
do so, G9 LN cells were transferred to B16A, NOD and proinsulin transgenic mice and seven days 
later recipients were immunised. Five days later, G9 T cells were enumerated using flow cytometry 
and IFN-γ production analysed by ELISPOT. Since B16A mice express the same CD45.1 allotype 
as transferred G9 T cells, InsB15-23-loaded, H2-K
d-tetramer was employed to visualise G9 T cells 
after transfer to B16A mice. In B16A recipients, the total number of tetramer-binding G9 T cells 
and their proportion of total CD8+ T cells remained unchanged following immunisation (Fig. 3.12A, 
B). The total number of G9 T cells detected with a congenic marker was increased following 
immunisation in NOD recipients (Fig. 3.12A). In contrast, the total number of G9 T cells and their 
proportion of total CD8+ T cells was low in proinsulin transgenic recipients and this was not altered 
by immunisation when detected with a congenic marker (Fig. 3.12A, B). To allow for direct 
comparison between the three strains, tetramer-binding G9 T cells were also enumerated in 
congenic NOD and proinsulin transgenic recipients. The pattern of the response was similar when 
transferred G9 T cells were identified using tetramer (Fig. 3.12C, D) or a congenic marker (Fig. 
3.12A, B). By ELISPOT, there was no significant difference in the number of IFN-γ-producing 
cells following immunisation in neither B16A nor NOD recipients, however, a significant level of 
IFN-γ production was observed in both B16A and NOD recipients (Fig. 3.12E, F). In contrast, IFN-
γ production was low in proinsulin transgenic recipients regardless of immunisation (Fig. 3.12F). 
There were minimal IFN-γ-producing cells detected from mice which were not injected with G9 T 
cells, despite immunisation (Fig. 3.12F), which indicates that in recipients of G9 T cells,  IFN-γ 
production can be attributed to the transferred G9 T cells. These data indicate G9 T cells are 
frequent and produce IFN-γ in B16A and NOD recipients. This response, however, is subverted 
after transfer to proinsulin transgenic mice, suggesting transferred G9 T cells are functionally 
inactivate in proinsulin transgenic recipients. 
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Figure 3.12 - G9 T cells do not expand or produce IFN-γ following InsB15-23 immunisation in 
proinsulin transgenic recipients.  
G9 LN cells (5x106, CD45.1+CD45.2-) were transferred to B16A (CD45.1+CD45.2-), NOD 
(CD45.1+CD45.2+) and proinsulin transgenic (CD45.1+CD45.2+) mice. Seven days later, recipients 
were immunised with 50µg InsB15-23 and 100µg poly I:C i.p. or left unimmunised. Five days later, the 
total number (A) or proportion (B) of Kd:Ins+CD8+Vβ6+ (for B16A recipients, left) or 
CD45.1+CD45.2-CD8+Vβ6+ (for NOD and proinsulin transgenic recipients, right) G9 T cells and the 
total number (C) or proportion (D) of Kd:Ins+CD8+Vβ6+ G9 T cells in spleen was determined using 
flow cytometry. IFN-γ production in spleen was determined using ELISPOT. Representative well 
images of InsB15-23-stimulated wells from immunised B16A (left), NOD (middle) and proinsulin 
transgenic (right) recipients (E). Mean number of IFN-γ+ spots determined by subtracting unstimulated 
wells from InsB15-23-stimulated wells (F). Data are pooled from three independent experiments. Each 
point represents a single mouse. Error bars show S.D. The dashed line represents the detection limit for 
Kd:Ins tetramer binding and shows the mean frequency of Kd:LLO (control) tetramer-binding CD8+ T 
cells. One-way ANOVA followed by Tukey post-test. (*p<0.05, **p<0.01, ****p<0.0001).  
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3.2.13 Unresponsiveness of transferred G9 T cells in proinsulin transgenic recipients is maintained  
G9 T cells did not respond to InsB15-23 peptide immunisation seven days after transfer to 
proinsulin transgenic recipients. It is possible that G9 T-cell inactivation observed in proinsulin 
transgenic recipients is transient and may not be maintained. To test the longevity of G9 T-cell 
inactivation, G9 LN cells were transferred to B16A, NOD and proinsulin transgenic mice and 
twenty one days later recipients were immunised. Five days after immunisation, G9 T cells were 
enumerated using flow cytometry and IFN-γ production analysed by ELISPOT. In B16A recipients, 
the total number of tetramer-binding G9 T cells and their proportion of total CD8+ T cells were not 
significantly altered following immunisation (Fig. 3.13A, B). The total number of G9 T cells and 
their proportion of total CD8+ T cells were low and unchanged by immunisation when detected by a 
congenic marker in NOD and proinsulin transgenic recipients (Fig. 3.13A, B). When transferred G9 
T cells were detected using tetramer in all three strains, the pattern of the G9 T cell response was 
similar as to when G9 T cells were detected with a congenic marker (Fig. 3.13A, B), in that the total 
number and proportion of G9 T cells was significantly higher in B16A recipients than NOD and 
proinsulin transgenic recipients (Fig. 3.13C, D). Although the total number of tetramer-binding G9 
T cells (Fig. 3.13C) appeared marginally higher than CD45.1-gated G9 T cells (Fig. 3.13A), most 
tetramer-binding G9 T cells in NOD and proinsulin transgenic recipients fell below the limit of 
detection, which represents the level of control tetramer binding.  
Systemic immunisation might increase the cellularity of spleens and since the total G9 T cell 
number is based on the calculated spleen cellularity, a non-specific increase could skew the G9 T 
cell total number. There was no significant difference in the cellularity of spleens from B16A, NOD 
and proinsulin transgenic recipients following immunisation (Fig. 3.13E). Next, production of IFN-
γ was assessed as an indicator of effector function of transferred G9 T cells following 
immunisation. There were a higher number of IFN-γ-producing spots in InsB15-23 peptide-stimulated 
wells from immunised B16A recipients compared to immunised NOD and immunised proinsulin 
transgenic recipients (Fig. 3.13F). IFN-γ production was higher in immunised B16A recipients 
compared to both immunised NOD and immunised proinsulin transgenic recipients (Fig. 3.13G). 
IFN-γ production was not significantly different when unimmunised and immunised mice were 
compared within each recipient strain (Fig. 3.13G). These data confirm inactivation of G9 T cells 
after transfer to proinsulin transgenic recipients is maintained. Interestingly, in NOD recipients, G9 
T cells were unresponsive to InsB15-23 immunisation at this late time point despite IFN-γ production 
observed when InsB15-23/poly I:C was administered seven days after transfer, suggesting G9 T cells 
become unresponsive slowly over time in response to islet-derived insulin.   
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Figure 3.13 - G9 T cells are unresponsive to InsB15-23 immunisation in proinsulin transgenic 
recipients.  
G9 LN cells (5x106, CD45.1+CD45.2-) were transferred to B16A (CD45.1+CD45.2-), NOD 
(CD45.1+CD45.2+) and proinsulin transgenic (CD45.1+CD45.2+) mice. Twenty one days later, 
recipients were immunised with 50µg InsB15-23 and 100µg poly I:C i.p. or left unimmunised. Five days 
later, the total number (A) and proportion (B) of Kd:Ins+CD8+Vβ6+ (B16A, left) or CD45.1+CD45.2-
CD8+Vβ6+ (NOD and proinsulin transgenic, right) G9 T cells of total CD8+ T cells, the total number 
(C) and proportion (D) of Kd:Ins+CD8+Vβ6+ G9 T cells of total CD8+ T cells and the total number of 
spleen cells (E) in spleen were determined using flow cytometry. IFN-γ production was determined 
using ELISPOT. Representative well images of InsB15-23-stimulated wells from immunised B16A 
(left), NOD (middle) and proinsulin transgenic (right) recipients (F). Mean number of IFN-γ+ spots 
determined by subtracting unstimulated wells from InsB15-23-stimulated wells (G). Data are pooled 
from two independent experiments. Each point represents a single mouse. Error bars show S.D. The 
dashed line shows the mean frequency of Kd:LLO (control) tetramer-binding CD8+ T cells. One-way 
ANOVA followed by Tukey post-test. (** p<0.01, *** p<0.001, **** p<0.0001).  
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3.2.14 Transferred G9 T cells do not contribute to diabetes development  
Male mice have been used as recipients for the adoptive transfer studies described so far. As 
males exhibit reduced islet inflammation and diabetes incidence compared to female NOD mice, 
this should minimise the effects of islet inflammation on tolerance outcomes in this adoptive 
transfer setting. Therefore, transferring G9 T cells to male and female recipients may provide 
insight into the effect of islet inflammation on this setting by directly comparing the population 
dynamics of transferred G9 T cells in both male and female NOD and proinsulin transgenic 
recipients. Considering the population dynamics of G9 T cells after transfer to NOD and proinsulin 
transgenic recipients, the previous analyses have focused on early time points after transfer. To 
investigate the influence of islet inflammation and to determine the involvement of transferred G9 T 
cells in islet autoimmunity, G9 LN cells were transferred to both male and female congenic NOD 
and proinsulin transgenic mice and analysis was performed eight weeks later, at the stage of severe 
insulitis in NOD mice. G9 T cells were enumerated based on CD45 expression while host CD8+ T 
cells recognising insulin and IGRP were analysed, as indicators of islet autoimmunity, using InsB15-
23- and IGRP206-214- loaded , H2-K
d-tetramers, respectively,  in pancreas and secondary lymphoid 
organs of recipients by flow cytometry.  
There was a trend toward a lower total number of pancreas-infiltrating leukocytes in 
proinsulin transgenic compared to NOD recipients (Fig. 3.14A), as expected (French et al., 1997) 
and this pattern was similar for the number of pancreas-infltrating CD8+ T cells, in that, this was 
significantly higher in male NOD recipients than in male proinsulin transgenic recipients (Fig. 
3.14B). The proportion of pancreas-infiltrating leukocytes of live-gated cells was higher in female 
NOD compared to female proinsulin transgenic recipients, while this appeared to be higher in male 
NOD compared to male proinsulin transgenic recipients, it was not significant (Fig. 3.14C). The 
proportion of pancreas-infiltrating CD8+ T cells of total leukocytes was higher in female NOD 
recipients than from female proinsulin transgenic recipients (Fig. 3.14D). The number of pancreas-
infiltrating insulin-specific CD8+ T cells was low in all recipients (Fig. 3.14E, F), as indicated by 
the level of control tetramer binding, represented here by the dashed line. This is consistent with the 
insulin response waning with age (Wong et al., 1999), given the recipients were approximately 16-
weeks old at the time of analysis. More pancreas-infiltrating IGRP-specific CD8+ T cells were 
observed in recipients than insulin-specific CD8+ T cells, but there were no significant differences 
observed between male and female NOD or proinsulin transgenic recipients (Fig. 3.14G, H). It 
should be noted that all recipients were negative for glycosuria at the time of cull for these analyses. 
Next, the lymphoid site draining the pancreas was assessed to determine the involvement of 
G9 T cell transfer on islet autoimmunity. The total number and proportion of G9 T cells of total 
CD8+ T cells in pLN was low and there were no differences between male and female recipients of 
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either strain (Fig. 3.15A, B). The total number of insulin specific CD8+ T cells was lower from pLN 
of male compared to female counterparts (Fig. 3.15C). The number of IGRP-specific CD8+ T cells 
was significantly higher in female NOD recipients compared to male proinsulin transgenic 
recipients (Fig. 3.15D). When tetramer-binding CD8+ T cells were expressed as a proportion of 
total CD8+ T cells, there were no significant differences in insulin- or IGRP-specific CD8+ T cells 
observed between groups (Fig. 3.15E, F). There were no significant differences in the proportion of 
Vβ6+ insulin- or IGRP-specific CD8+ T cells in pLN from female or male proinsulin transgenic and 
NOD recipients (Fig. 3.15G, H). In spleen, the number and proportion of G9 T cells was low and 
similar from proinsulin transgenic and NOD recipients, for both male and female (Fig. 3.16A, B). 
The total number and proportion of insulin-specific CD8+ T cells was similar between groups (Fig. 
3.16C, E). The number of IGRP-specific CD8+ T cells was significantly higher in female NOD 
recipients compared to male NOD and proinsulin transgenic recipients (Fig. 3.16D). The proportion 
of IGRP-specific CD8+ T cells was significantly higher from female NOD recipients compared to 
male proinsulin transgenic recipients (Fig. 3.16F). No significant differences were observed in the 
proportion of Vβ6+ insulin- or IGRP-specific CD8+ T cells between groups (Fig. 3.16G, H). Finally, 
sdLN were analysed in order to ascertain cell population dynamics in non-pancreatic draining LN 
tissue following G9 T cell transfer. The total number and proportion of G9 T cells was low and 
remained similar in proinsulin transgenic and NOD recipients, between both males and females 
(Fig. 3.17A, B). The number and proportion of insulin- and IGRP-specific CD8+ T cells was similar 
between groups (Fig. 3.17C-F). In peripheral LN, no significant differences were observed in the 
proportion of Vβ6+ insulin- or IGRP-specific CD8+ T cells between proinsulin transgenic and NOD 
recipients (Fig. 3.17G, H).  
These data indicate that the rapid inactivation of G9 T cells after transfer to proinsulin 
transgenic recipients is maintained over time and are in support of the finding of reduced G9 T-cell 
frequency twenty one days after transfer to NOD recipients. From these findings, transferred G9 T 
cells do not contribute to diabetes development by accumulating in recipients. It might be expected 
that naïve G9 T cells would not contribute to diabetes development in an adoptive transfer setting as 
G9 T cells require activation to become diabetogenic (Wong et al., 2009). Also, the full 
diabetogenic potential of G9 T cells may not be observed where G9 T cells are transferred to 
immune-replete NOD recipients, in which competition from host β cell-reactive T cells may 
influence the diabetogenicity of transferred G9 T cells. To more accurately determine G9 T-cell 
involvement in diabetes development, it would be important to include age-matched NOD mice not 
injected with G9 T cells to attribute the observed outcomes directly to transferred G9 T cells rather 
than predisposed autoimmune events which occur in wild type NOD mice.  
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  Figure 3.14 – Transfer of G9 T cells does not contribute to diabetes development.  
G9 LN cells (5x106, CD45.1+CD45.2-) were transferred to male and female NOD and proinsulin 
transgenic (CD45.1+CD45.2+) mice. Eight weeks after transfer, pancreata were collected and the total 
number of infiltrating leukocytes (A), total number of infiltrating CD8+ T cells (B), leukocytes as a 
proportion of live cells (C), CD8+ T cells as a proportion of total leukocytes (D), total number of 
Kd:Ins+CD8+ T cells (E), total number of Kd:IGRP+CD8+ T cells (F), Kd:Ins+CD8+ T cells as a 
proportion of total CD8+ T cells (G) and Kd:IGRP+CD8+ T cells as a proportion of total CD8+ T cells 
(H) were analysed using flow cytometry. Data are pooled from two independent experiments. Each 
point represents a single mouse. Error bars show S.D. The dashed line represents the detection limit for 
Kd:Ins and Kd:IGRP tetramer binding and shows the mean frequency of Kd:LLO (control) tetramer-
binding CD8+ T cells. One-way ANOVA followed by Tukey post-test. (*p<0.05). 
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Figure 3.15 – Transferred G9 T cells do not accumulate in pLN of recipients. 
G9 LN cells (5x106, CD45.1+CD45.2-) were transferred to male and female NOD and proinsulin 
transgenic (CD45.1+CD45.2+) mice. Eight weeks later, the total number of G9 T cells 
(CD45.1+CD45.2-CD8+Vβ6+) (A), G9 T cells as a proportion of total CD8+ T cells (B), total number of 
Kd:Ins+CD8+ T cells (C), total number of Kd:IGRP+CD8+ T cells (D), Kd:Ins+CD8+ T cells as a 
proportion of total CD8+ T cells (E), Kd:IGRP+CD8+ T cells as a proportion of total CD8+ T cells (F), 
Vβ6+ Kd:Ins+CD8+ T cells as a proportion of total Kd:Ins+CD8+ T cells (G) and Vβ6+Kd:IGRP+CD8+ T 
cells as a proportion of total Kd:IGRP+CD8+ T cells (H) in pLN were analysed using flow cytometry. 
Data are pooled from two independent experiments. Each point represents a single mouse. Error bars 
show S.D. The dashed line represents the detection limit for Kd:Ins and Kd:IGRP tetramer binding and 
shows the mean frequency of Kd:LLO (control) tetramer-binding CD8+ T cells. One-way ANOVA 
followed by Tukey post-test. (* p<0.05, ** p<0.01). 
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Figure 3.16 – Transferred G9 T cells do not accumulate in spleen of recipients. 
G9 LN cells (5x106, CD45.1+CD45.2-) were transferred to male and female NOD and proinsulin 
transgenic (CD45.1+CD45.2+) mice. Eight weeks later, the total number of G9 T cells 
(CD45.1+CD45.2-CD8+Vβ6+) (A), G9 T cells as a proportion of total CD8+ T cells (B), total number of 
Kd:Ins+CD8+ T cells (C), total number of Kd:IGRP+CD8+ T cells (D), Kd:Ins+CD8+ T cells as a 
proportion of total CD8+ T cells (E), Kd:IGRP+CD8+ T cells as a proportion of total CD8+ T cells (F), 
Vβ6+ Kd:Ins+CD8+ T cells as a proportion of total Kd:Ins+CD8+ T cells (G) and Vβ6+ Kd:IGRP+CD8+ 
T cells as a proportion of total Kd:IGRP+CD8+ T cells (H) in spleen were analysed using flow 
cytometry. Data are pooled from two independent experiments. Each point represents a single mouse. 
Error bars show S.D. The dashed line represents the detection limit for Kd:Ins and Kd:IGRP tetramer 
binding and shows the mean frequency of Kd:LLO (control) tetramer-binding CD8+ T cells. One-way 
ANOVA followed by Tukey post-test. (* p<0.05).  
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Figure 3.17 – Transferred G9 T cells do not accumulate in sdLN of recipients. 
G9 LN cells (5x106, CD45.1+CD45.2-) were transferred to male and female NOD and proinsulin 
transgenic mice (CD45.1+CD45.2+). Eight weeks later, the total number of G9 T cells 
(CD45.1+CD45.2-CD8+Vβ6+) (A), G9 T cells as a proportion of total CD8+ T cells (B), total number of 
Kd:Ins+CD8+ T cells (C), total number of Kd:IGRP+CD8+ T cells (D), Kd:Ins+CD8+ T cells as a 
proportion of total CD8+ T cells (E), Kd:IGRP+CD8+ T cells as a proportion of total CD8+ T cells (F), 
Vβ6+ Kd:Ins+CD8+ T cells as a proportion of total Kd:Ins+CD8+ T cells (G) and Vβ6+ Kd:IGRP+CD8+ 
T cells as a proportion of total Kd:IGRP+CD8+ T cells (H) in sdLN were analysed using flow 
cytometry. Data are pooled from two independent experiments. Each point represents a single mouse. 
Error bars show S.D. The dashed line represents the detection limit for Kd:Ins tetramer binding and 
shows the mean frequency of Kd:LLO (control) tetramer-binding CD8+ T cells. One-way ANOVA 
followed by Tukey post-test.  
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Table 3.1 Summary of Chapter 3  
 B16A NOD Proinsulin 
transgenic 
Proliferation No pLN only Yes, in all sites 
analysed 
Absolute number n/a Slow decrease (by 21 
days after transfer) 
Rapid decrease (by 7 
days after transfer) 
Proportion (of total 
CD8+ cells) 
Unchanged Accumulation in pLN 
(at day 3) followed by 
slow decrease in all 
sites analysed (by day 
21) 
Rapid decrease (by day 
7) 
TCR down-
regulation  
No No Yes 
Tetramer binding High High Low 
IFN-γ production Yes Yes (at day 7 
following transfer) 
No 
Figure 3.18 – Summary of main findings from Chapter 3. 
This table represents summarised data from Chapter 3. ‘Proliferation’ refers to Figure 3.2, ‘Absolute 
number’ and ‘proportion’ refer to Figure 3.3 and Figure 3.7, ‘TCR down-regulation’ refers to Figure 
3.8, ‘Tetramer binding’ refers to Figure 3.9 and ‘IFN-γ production’ refers to Figure 3.12 and Figure 
3.13.   
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3.3 Discussion  
Targeted, transgenic antigen expression inactivates antigen-specific CD8+ T cells. Here, the 
ability of transgenic proinsulin expression to inactivate insulin-specific CD8+ T cells on the 
autoimmune-prone NOD background has been tested. The data suggest G9 T cells are deleted after 
transfer to mice transgenically expressing proinsulin. Remaining, non-deleted G9 T cells were 
infrequent, displayed both reduced TCR expression and InsB15-23-loaded tetramer binding, and 
finally, were no longer able to respond to InsB15-23 immunisation, consistent with peripheral 
tolerance. The typically naïve resting phenotype of TCR transgenic G9 T cells, even in pLN, is 
consistent with a previous report showing CD8+ T cells from spleen of unimmunised G9 mice 
display  low CD44 and high CD62L expression (Wong et al., 2009). This might indicate low-
avidity G9 T cells are ignorant of cognate antigen presentation in the periphery. Transgenic mice 
expressing lymphocytic choriomeningitis virus (LCMV) glycoprotein under control of the RIP 
develop autoimmune diabetes only after infection with LCMV (Ohashi et al., 1991; Oldstone et al., 
1991). Likewise, G9 mice rapidly develop autoimmune diabetes in an insulin-specific manner 
following immunisation with InsB15-23 and CpG (Wong et al., 2009). When crossed to RIP.B7-1 
mice, G9 mice also develop diabetes (Thomas et al., 2007), indicating a role of co-stimulation in G9 
T cell activation. This is distinct from some other β cell-specific H2-Kd-restricted TCR transgenic 
NOD mice. For instance, 8.3 TCR transgenic NOD mice, in which CD8+ T cells recognise IGRP206-
214, spontaneously develop diabetes (Verdaguer et al., 1997) and AI4 TCR transgenic NOD mice, in 
which CD8+ T cells recognise InsA14-20, demonstrate accelerated diabetes incidence (Graser et al., 
2000; Lamont et al., 2014). The low-affinity binding of InsB15-23/MHC class I might allow for 
escape of G9-like T cells from thymic tolerance mechanisms into the periphery where activation 
might occur. Due to their apparent primacy in islet autoimmune responses, it might be possible that 
insulin-specific T cells are primed by non-self ligands (Bulek et al., 2012), and subsequent 
specificities are primed directly as a result of insulin-specific T cell-mediated events such as β-cell 
lysis and proinflammatory cytokine production. Therefore, G9 T cells might participate in early 
diabetogenic responses in autoimmune diabetes. CD8+ T cells directed towards low-affinity MHC 
class I-binding preproinsulin peptides are not only identifiable in human T1D (Abreu et al., 2012) 
but are capable of lysing β cells with basal MHC class I expression (Bulek et al., 2012). 
Proliferation of G9 T cells exclusively in pancreatic LN from NOD recipients observed here 
is consistent with a previous study (Wong et al., 2009). Since B16A mice do not express the G9 
determinant, incorporation of B16A recipients in adoptive transfer experiments in the present study 
allows for the involvement of islet-derived antigen presentation to be dissected. Islet-derived insulin 
presentation appeared to be localised to pLN of non-transgenic NOD mice as indicated by CFSE 
dilution by G9 T cells only in that site (Fig. 3.2). It is important to establish the effect of islet-
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derived insulin presentation in an adoptive transfer setting as this will be a confounding factor in 
developing a T1D immunotherapy since varying levels of insulin presentation will occur in patients 
depending on diabetes duration. Despite the fact that the majority of G9 T cells proliferated 
extensively after transfer to proinsulin transgenic mice, the number of G9 T cells decreased over 
time. Extensive proliferation preceding deletional tolerance has been demonstrated for 8.3 T cells in 
response to IGRP expression by extrathymic Aire-expressing cells (Gardner et al., 2008) and for 
OT-I T cells in MII.OVA mice (Kenna et al., 2010). In contrast, G9 T cells accumulated in pLN of 
NOD recipients, even though the level of proliferation was not as substantial as observed in 
proinsulin transgenic recipients. These different proliferative responses suggests G9 T cells become 
activated and accumulate in response to islet-derived insulin presentation, however, in response to 
transgenic proinsulin presentation, G9 T cells become activated but are rapidly deleted, emphasising 
the tolerogenic nature of transgenic antigen expression.  
The liver has been shown to be a reservoir for apoptotic T cells (Bertolino et al., 2001; 
Huang et al., 1994). Kenna et al. did not observe a difference in the rate of apoptosis between OT-I 
T cells transferred to mice expressing OVA in MHC class II+ APC or CD11chi DC, despite 
significantly reduced OT-I T cell expansion in MII.OVA mice (Kenna et al., 2010). These data are 
in agreeance with those from a pilot experiment in the present study suggesting transferred G9 T 
cells did not accumulate to a greater extent in the liver of proinsulin transgenic recipients compared 
to non-transgenic NOD recipients (Fig. 3.5). It is possible that the robustly tolerogenic signals 
provided by antigen expression under control of an MHC class II promoter instruct the cognate 
CD8+ T cell to undergo highly efficient apoptosis, precluding their identification in the liver. 
Another possibility is that examining the liver of recipients of G9 T cells at a later time point may 
show evidence of apoptotic G9 T cells. Further mechanistic studies in which known apoptotic 
pathways are blocked in transferred G9 T cells are required to elucidate how G9 T cells are deleted 
following transfer to proinsulin transgenic recipients.    
OVA expression under control of an MHC class II promoter protected OVA expressing 
islets from OT-I T cell-induced insulitis and autoimmune destruction (Kenna et al., 2010). In 
contrast, in mice in which OVA expression is driven from a CD11c promoter, transferred OT-I T 
cells were present in the islets and β-cell destruction was evident. Targeting tolerogenic antigen 
expression to diverse MHC class II-expressing APC might be preferred in an immunotherapeutic 
setting in order to prevent damage to antigen-expressing tissue by cognate T cells undergoing 
tolerance induction. In the context of T1D, increased β-cell function is associated with a reduced 
risk of complication development, therefore, bystander damage to β cells during T-cell tolerance 
induction would be undesirable. Despite different antigens in each setting, deletion and induction of 
unresponsiveness in G9 T cells after transfer to proinsulin transgenic recipients was similar to that 
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reported for OT-I T cells transferred to MII.OVA mice. Most G9 T cells from proinsulin transgenic 
recipients were CD62Lhi, despite displaying an otherwise activated phenotype indicated by high 
CD69 and CD44 expression. In contrast, in other studies, G9 T cells activated by InsB15-23/CpG 
immunisation develop diabetogenicity and down-regulate CD62L expression (Wong et al., 2009). 
In the present study, a higher proportion of CD62Llo G9 T cells were observed from pLN of NOD 
recipients, suggesting islet-derived insulin presentation might elicit G9 T cell effector function. 
Therefore, the tolerogenic nature of targeting transgenic antigen expression with an MHC class II 
promoter is not restricted to high-affinity T cells recognising foreign antigens such as OVA but 
translates to self-antigens such as insulin.  
With regard to an alternative β-cell antigen, IGRP, expression under control of an MHC 
class II promoter protects TCR transgenic 8.3 mice from autoimmune diabetes (Krishnamurthy et 
al., 2012). Despite 8.3 T cells in the periphery becoming activated and proliferating in response to 
transgenic IGRP expression, these 8.3 T cells produced less IFN-γ and TNF-α after IGRP206-214 
stimulation in vitro. Significantly fewer 8.3 T cells were recovered from IGRP transgenic recipients 
compared to NOD recipients, providing evidence for the ability of transgenic antigen expression to 
delete diabetogenic CD8+ T cells. However, transgenic expression of IGRP in NOD mice does not 
protect from autoimmune diabetes (Krishnamurthy et al., 2006), whereas transgenic expression of 
proinsulin does protect NOD mice from diabetes development (French et al., 1997). Transgenic 
IGRP expression is capable of protecting from diabetes development by peripheral T-cell deletion 
when the diabetogenic CD8+ T cell population is comprised solely of 8.3-like T cells. Nevertheless, 
deletion of 8.3-like T cells is insufficient to protect from diabetes development when insulin or 
other specificities are present, such as in wild type NOD mice. Furthermore, where 8.3 T cells are 
intermediate-avidity T cells, G9 T cells are a population of lower avidity T cells and low-avidity 
autoreactive T cells escape peripheral tolerance mechanisms (Kawamura et al., 2008; Zehn & 
Bevan, 2006), representing a population potentially diabetogenic T cells circulating in the periphery 
which will inevitably encounter cognate antigen. Demonstration of tolerance induction in low-
avidity autoreactive T cells is important physiologically as it might be expected that diabetogenic T 
cells in the periphery would be low-avidity and tolerance outcomes may differ for low-avidity 
compared to higher avidity T cells. Data from the present study suggest low-avidity β cell-specific 
CD8+ T cells undergo peripheral tolerance induction after transfer to recipients expressing antigen 
under the control of an MHC class II promoter.  
Deletion of autoreactive AI4 T cells has been demonstrated using a superagonist mimotope, 
MimA2, coupled to DC via the DEC-205 endocytic receptor (Mukhopadhaya et al., 2008). In 
addition to a reduction in the proportion of AI4 T cells, the remaining AI4 T cells were unable to 
produce IFN-γ after transfer of MimA2-coupled DC. Unresponsiveness was reversed when DC 
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maturation stimuli, poly I:C and an anti-CD40 mAb, were administered. Therefore, robust, 
infallible antigen expression in which inflammatory stimuli would not alter tolerogenicity, would be 
clinically beneficial in terms of T1D immunotherapies where islet-related and unrelated 
inflammation would occur. In addition, the superagonist mimotope, MimA2, used in the DEC-205 
model might impact the tolerance outcome of AI4 T cells by skewing toward higher affinity MHC 
class I binding. Similarly, deletion of endogenous IGRP-specific CD8+ T cells was observed in 
NOD mice treated with an IGRP mimotope, NRP-V7, coupled to DC (Mukherjee et al., 2013) . 
These studies indicate tolerance induction is possible using mimotopes to target diabetogenic CD8+ 
T cells, although it would be pertinent to ensure mimotope presentation could not become 
immunostimulatory, as this might increase the risk of autoimmune damage to antigen-expressing 
tissue by activated T cells. Targeting antigen expression using cell-specific promoters, such as an 
MHC class II promoter, may represent a means to ensure strictly tolerogenic antigen presentation, 
and this could be tested by administration of inflammatory stimulus such as poly I:C and an anti-
CD40 mAb to determine whether this influenced G9 T-cell responses in proinsulin transgenic and 
NOD recipients. 
Persistent antigen exposure leads to deletion of antigen-specific CD8+ T cells (Redmond et 
al., 2003) and transgenically expressed antigen is a robust method to ensure constant presentation of 
potentially tolerogenic antigen. Deletion of autoreactive CD8+ T cells by cell-intrinsic mechanisms 
involving the proapoptotic molecule, Bim, has been demonstrated in transgenic models with 
expression of experimental antigens (Davey et al., 2002; Kenna et al., 2008). Clone 4 T cells 
accumulate in pLN of mice expressing HA in islets equally in the presence or absence of cell-
extrinsic death molecules CD95 and TNF receptor (TNFR) 1 or TNFR2 (Redmond et al., 2008). 
The absence of Bim, or the presence of Bcl-2, resulted in accumulation of clone 4 T cells. 
Although, over-expression of Bcl-2 in clone 4 T cells led to more substantial insulitis in recipients, 
suggesting different outcomes of CD8+ T-cell peripheral tolerance depending on whether a driver of 
apoptosis (Bim) was absent or an apoptosis inhibitor (Bcl-2) was present. The different tolerance 
outcome, in that the clone 4 T cells had increased effector function when Bcl-2 was over-expressed, 
may provide insight into the rapid inactivation of antigen-specific CD8+ T cells in mice expressing 
antigen driven by an MHC class II promoter. Since the absence of Bim had little effect on the 
contraction of OT-I cells in MII.OVA recipients (Kenna et al., 2010), it is possible that Bcl-2-
sensitive pathways may be involved in the similar inactivation of G9 T cells after transfer to 
proinsulin transgenic mice.  
The present study and others have investigated T-cell tolerance using constitutive expression 
transgenic systems targeting antigen expression to self tissue or APC and transfer of monoclonal 
TCR transgenic CD8+ T cell repertoires. It is possible that the effect of transgenic antigen 
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expression might be different for endogenous self-reactive CD8+ T-cell populations compared to 
transferred, monoclonal T cells. Peripheral tolerance induction has been investigated in a 
polyclonal, endogenous CD8+ T-cell population using a tetracycline inducible and reversible 
antigen expression system in which OVA expression is restricted to DC using a CD11c promoter 
(Jellison et al., 2012). Naïve OVA-specific CD8+ T cells expanded following antigen induction and 
finally became unresponsive, with high PD-1 expression. Cognate T-cell expansion preceding 
tolerance induction is similar to the response of OT-I T cells transferred to mice expressing OVA 
under control of a CD11c promoter (Kenna et al., 2008). These studies emphasise differing 
population dynamics of antigen-specific CD8+ T cells depending on whether antigen is targeted to 
DC or MHC class II+ APC. Deletion of OVA-specific CD8+ T cells was not evident in the inducible 
antigen system used by Jellison et al., but this might have been due to recent thymus emigrants 
becoming involved in the process thereby concealing a reduced number of OVA-specific CD8+ T 
cells in the periphery.  
Down-regulation of surface TCR acts to prevent hyper-responsiveness of activated T cells 
by reducing receptor available to respond to antigen stimulation (Naramura et al., 2002; Shamim et 
al., 2007). TCR down-regulation observed on G9 T cells after transfer to proinsulin transgenic mice 
is less substantial than observed for OT-I T cells transferred to MII.OVA mice (Kenna et al., 2010). 
TCR down-regulation observed in the present study might be associated with peripheral tolerance 
or merely the result of recent activation of G9 T cells. In support of the former, G9 T cells from 
pLN of NOD recipients expressed equivalent TCR relative to an analogous host T-cell population, 
despite an activated phenotype of the transferred G9 T cells. Therefore, G9 T-cell TCR down-
regulation was observed only after encounter with the determinant derived from transgenic 
proinsulin rather than from islet-derived insulin, suggesting G9 T-cell TCR down-regulation is 
consistent with peripheral tolerance induction. A study of peptide-mediated tolerance involving 
clone 4 T cells and HA peptide showed slight surface TCR down-regulation on clone 4 T cells after 
administration of high-dose HA peptide (Redmond et al., 2005). Using a tumour antigen-specific 
TCR transgenic model, it has been demonstrated that high-affinity MHC binding peptides induced 
more substantial surface TCR down-regulation than lower affinity peptides (Cai et al., 1997). As G9 
T cells recognise the low-affinity H-2Kd-binding InsB15-23, the level of TCR down-regulation 
observed in the present study may be expected. In the absence of G9 determinant, in B16A 
recipients, TCR expression on transferred G9 T cells remained high and similar to an analogous 
host population (Fig. 3.8). This validates TCR expression observed for G9 T cells transferred to 
NOD mice and suggests islet-derived insulin expression is contained within pLN as G9 T cells from 
non-pancreatic draining sites of NOD recipients expressed a similar and high level of TCR 
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compared to G9 T cells from B16A recipients. Finally, these data indicate TCR down-regulation by 
G9 T cells is a unique response to transgenically expressed proinsulin.  
The mechanism of inactivation of autoreactive CD8+ T cells in the periphery may involve 
inhibitory receptors such as PD-1. OT-I T cells lacking PD-1 are not tolerised, as indicated by OT-I 
T cell accumulation and enhanced IFN-γ production, after transfer to recipients in which pancreatic 
islets express high levels of OVA (Keir et al., 2007). Furthermore, PD-1 knockout OT-I T cells 
effectively transfer autoimmune diabetes to recipients expressing OVA in islets, whereas, wild type 
OT-I T cells do not under the experimental conditions used. This suggests, in this OT-I/RIP-OVA 
tolerance system, PD-1 plays an important role in maintaining peripheral T-cell tolerance to tissue-
targeted antigen expression. Likewise, accelerated onset and complete penetrance of diabetes by 15 
weeks of age was observed for PD-1-deficient NOD mice, and islet-infiltrating CD8+ T cells 
displayed a strong IFN-γ bias (Wang et al., 2005). The PD-1/PD-L1 inhibitory pathway has also 
been implicated in a model of induced autoimmune diabetes in which RIP.B7-1 mice were 
administered preproinsulin-encoding plasmid DNA to induce preproinsulin-specific CD8+ T cells 
(Schuster et al., 2013). The relative affinity of epitopes derived from the preproinsulin-encoding 
DNA influenced co-stimulation dependence in that, CD8+ T cells specific for the lower affinity 
MHC-binding epitope, preproinsulin A12-21, became diabetogenic in the absence of transgenic B7-1 
and PD-1 expression. This suggests differential maintenance of autoreactive T cells in response to 
peptides of varying MHC-binding affinities. In the present study, G9 T cell expansion after transfer 
to proinsulin transgenic mice is limited, which might indicate the PD-1 pathway is involved. 
Although, targeting antigen expression using an MHC class II promoter leads to rapid inactivation 
of cognate CD8+ T cells and this differs compared to tolerance in mice expressing antigen in islets 
as in the study by Schuster et al. Blocking PD-1 or PD-L1 in proinsulin transgenic mice would 
allow the involvement of this pathway in peripheral tolerance of G9 T cells to be elucidated, 
however, unpublished data from the host laboratory using a blocking approach suggests this 
inhibitory pathway is not involved in rapid inactivation of OT-I T cells in MII.OVA mice. 
Taken together, the data in this chapter suggest transgenic expression of proinsulin induces 
peripheral tolerance in insulin-specific CD8+ T cells in autoimmune-prone NOD mice. G9 T cells 
underwent extensive proliferation prior to deletion after transfer to proinsulin transgenic recipients. 
The remaining, non-deleted G9 T cells displayed TCR down-regulation and no longer effectively 
recognised cognate peptide presented by H2-Kd. Finally, residual G9 T cells were unresponsive to 
InsB15-23 immunisation. The response of insulin-specific CD8
+ T cells to transgenic proinsulin 
expression was consistent with other studies investigating CD8+ T cell responses to antigen 
expressed under an MHC class II promoter, suggesting the robust mechanism of peripheral 
tolerance in this setting is translatable from foreign, model antigens to self-antigens. While the 
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mechanism by which rapid inactivation of antigen-specific CD8+ T cells occurs is still unclear, 
these findings suggest an immunotherapeutic approach based on such an antigen targeting strategy 
may be feasible. 
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3.4. Future directions 
An interesting observation in this chapter was the reduced frequency of G9 T cells from NOD 
recipients twenty one days after transfer. Determining G9 T cell population dynamics at time points 
in line with this finding may help elucidate whether this slow deletion occurs solely through G9 T 
cell traffic to pLN in response to islet-derived insulin presentation or whether the insulin 
determinant is presented elsewhere. Further dissection of the mechanism of this response to islet-
derived insulin compared to that which occurs in response to transgenic proinsulin expression will 
provide novel insight into different tolerance pathways of insulin-specific CD8+ T cells. The 
relative contributions of molecules shown to be important for T-cell tolerance in other models, 
including Bim/Bcl-2, PD-1/PD-L1 and CD95, could be tested in G9 T-cell tolerance using knockout 
mice and blocking antibodies.  
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Chapter 4 
Transgenic expression of proinsulin rapidly inactivates  
insulin-specific CD8+ memory T cells 
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4.1 Introduction 
The previous chapter demonstrated peripheral tolerance induction in naïve insulin-specific 
CD8+ T cells. It is important to demonstrate the inactivation of naïve CD8+ T cells in the context of 
autoimmune diabetes as defects in central tolerance mechanisms allow for continual escape of naïve 
islet-reactive T cells from the thymus. Antigen-experienced CD8+ effector T cells and Tmem in the 
periphery must also be inactivated for a T1D immunotherapy to be effective. β-cell antigen-specific 
CD8+ Tmem perpetuate islet autoimmunity and in the case of islet transplantation, can mediate graft 
rejection (Alkemade et al., 2013; Mottram et al., 2002). Since G9 T cells are diabetogenic only after 
activation, it is therefore pertinent to address tolerance induction in activated G9 T cells, which is 
the focus of this chapter.  
It had long been thought Tmem were impervious to cell-intrinsic peripheral tolerance 
mechanisms due to their terminally differentiated nature and reduced requirement for co-stimulation 
(Croft et al., 1994; Dengler & Pober, 2000; London et al., 2000). The resistance of Tmem to co-
stimulation blockade in the context of transplantation tolerance has been widely explored (Chen et 
al., 2004; Valujskikh et al., 2002). In humans, CD8+ T cells can display reduced expression of the 
co-stimulatory molecule, CD28, after differentiation to a memory phenotype (Wills et al., 2002). 
CD28- CD8+ Tmem proliferated more extensively in the presence of IL-15 and an anti-CTLA-4 
mAb, compared to CD28+ CD8+ Tmem (Traitanon et al., 2014). Also, autoreactive Tmem in 
experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, were less susceptible to 
apoptosis possibly due to expression of the anti-apoptotic molecule, Bcl-2, and as a result of 
increased IFN-γ production these Tmem were more pathogenic that their effector counterparts 
(Elyaman et al., 2008). These points lend credence to the argument that CD8+ Tmem may less 
readily undergo peripheral tolerance compared to naïve CD8+ T cells. Additionally, naïve and 
effector T cells are dependent on IL-2, and IL-2 production is modulated by immunosuppressants 
such as rapamycin (Feuerstein et al., 1995; Gonzalez et al., 2001b). In contrast, CD8+ Tmem are 
less dependent on IL-2 for homeostasis and survival (Araki et al., 2009a). Moreover, CD8+ Tmem 
proliferation is less effectively controlled by CD4+Foxp3+ Treg compared to that for naïve and 
effector T cells (Afzali et al., 2011; Yang et al., 2007). Defective IL-2 signalling has been 
associated with reduced maintenance of Foxp3 expression by Treg in T1D patients (Long et al., 
2010) and in mice, Foxp3 instability for CD4+ T cells resulted in their development to diabetogenic 
memory T cells (Zhou et al., 2009). It is possible that genetic defects associated with predisposition 
to autoimmune diabetes in humans and NOD mice may result in otherwise suppressive Treg 
developing pathogenicity in the context of islet inflammation. β cell-specific Tmem, therefore, 
represent a barrier to effective T1D immunotherapy. To overcome this barrier, transgenic 
expression of antigen represents a means to potentially inactivate Tmem responses.  
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In transgenic mice expressing HA under control of the RIP , transferred clone 4 Tmem underwent 
deletional tolerance (Kreuwel et al., 2002). It was suggested that the observed tolerance occurred in 
response to cross-presented HA determinants in the pLN of HA transgenic mice. Using a cell 
subset-specific promoter, that is, a CD11c promoter, it has been shown that targeting OVA 
expression to CD11chi DC resulted in peripheral tolerance induction in transferred OT-I Tmem 
(Kenna et al., 2008). In this setting, a transient phase of effector function was exhibited by the OT-I 
Tmem prior to tolerance induction. However, when OVA expression was enforced under an MHC 
class II promoter, OT-I Tmem were rapidly inactivated (Kenna et al., 2010). Similarly, tolerogenic 
DC have been shown to delete CD8+ Tmem. Expansion of CD8+ Tmem was observed after a single 
stimulation with tolerogenic DC and further stimulation was required for subsequent deletion of the 
CD8+ Tmem (Kleijwegt et al., 2013). In light of the tolerance outcomes achieved in previous 
studies, promoter (or APC) choice will therefore require consideration for effective termination of β 
cell-specific CD8+ Tmem responses. Since naïve and memory CD8+ T cells differ in their response 
to antigen, it is important to address how G9 Tmem respond to islet-derived insulin expression as 
well as transgenically-expressed proinsulin. It is possible that G9 Tmem might undergo more robust 
expansion and develop effector function in the pancreatic LN of NOD recipients compared to naïve 
G9 T cells.  
While most studies have focused on model antigens such as OVA and HA, here CD8+ T-cell 
responses to the important β-cell antigen, insulin, are investigated. In the NOD mouse, immune 
responses directed toward insulin are required for diabetes development (French et al., 1997; 
Nakayama et al., 2005). Insulin-reactive Tmem have been identified in the periphery of patients 
with T1D (Luce et al., 2011) and in the NOD mouse (Chee et al., 2014; Diz et al., 2012). More 
importantly, insulin-specific CD8+ T cells have been detected in the pLN and islets in human T1D 
(Coppieters et al., 2012). Considering the patients’ disease duration and the site of analysis in the 
study by Coppieters et al., it would be expected that the islet-infiltrating CD8+ T cells were of an 
effector/memory phenotype. Homeostatic proliferation following immunosuppressive conditioning 
and islet transplantation has been demonstrated in T1D patients to increase the frequency of 
GAD65-specific CD8+ Tmem (Monti et al., 2008). While T1D patients and healthy controls alike 
where shown to possess GAD- and insulin-reactive naïve T cells, only in T1D patients were GAD- 
and insulin- memory T cell responses observed (Monti et al., 2007).Tolerogenic DC have been 
shown to induce tolerance in insulin-specific effector/memory CD4+ T cells from patients with 
T1D, and the tolerised T cells were characterised by high IL-10 and low IFN-γ expression (Torres-
Aguilar et al., 2010).  
In this chapter, I examine whether transgenic expression of proinsulin induces peripheral tolerance 
in antigen-experienced, insulin-specific memory CD8+ T cells. The response of G9 Tmem to 
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transgenic proinsulin and islet-derived insulin presentation was explored in an adoptive transfer 
setting. G9 T cells were cultured to generate a mixed population of insulin-specific TCM-like and 
TEM-like CD8
+ T cells. In recipient mice presenting transgene-derived, islet-derived or no antigen, 
the proliferation and population dynamics of G9 Tmem were assessed as well as the level of TCR 
expression. G9 Tmem expansion and IFN-γ production were determined following InsB15-23 
immunisation at an early and a late time point after transfer. 
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4.2 Results 
4.2.1 G9 T cells are activated in vitro by InsB15-23  
To determine the optimal InsB15-23 (23 Gly) concentration for in vitro activation of G9 T cells 
and to explore the affinity of G9 T cells relative to another TCR transgenic CD8+ T cell, G9 and 
OT-I LN cells were stimulated overnight with titrated concentrations of InsB15-23 (23 Gly), InsB15-23 
(23 Val) or OVA257-264  peptide. CD69 and TCR expression on G9 and OT-I T cells were 
determined using flow cytometry. CD69 is a marker of T cell activation and is up-regulated within 
hours of activation (Sancho et al., 2005), while TCR down-regulation is a consequence of antigen 
stimulation of T cells (Luton et al., 1994; Minami et al., 1987; Valitutti et al., 1995). Unstimulated 
G9 T cells (CD8+Vβ6+) did not express CD69 (Fig. 4.1A). Upon addition of 1x10-5M InsB15-23 (23 
Gly) and overnight culture, the majority of G9 T cells expressed CD69 (Fig. 4.1A). When titrated, 
there was a dose-dependent response to peptide stimulation, with the highest proportion of CD69-
expressing G9 T cells after stimulation with 1x10-5M InsB15-23 (23 Gly) (Fig. 4.1B). Stimulation 
with a two-log-fold lower concentration of InsB15-23 (23 Val) resulted in the maximum proportion of 
CD69-expressing G9 T cells (Fig. 4.1B). Most OT-I T cells expressed CD69 with a five-log-fold 
lower OVA257-264 concentration compared to InsB15-23 (23 Gly) (Fig. 4.1B). The proportion of 
CD69-expressing OT-I T cells remained low after stimulation with InsB15-23 (23 Gly) or InsB15-23 
(23 Val) (Fig. 4.1B). Down-regulation of Vβ6 was observed on G9 T cells at a log-fold higher 
concentration of InsB15-23 (23 Gly) than was required for maximal CD69 up-regulation (Fig. 4.1C). 
Reduced Vα2 expression observed on OT-I T cells after stimulation with 1x10-9M or higher 
OVA257-264 (Fig. 4.1C). The concentration of OVA257-264 at which reduced TCR expression on OT-I 
T cells was observed was five log-fold lower than the concentration of InsB15-23 (23 Gly) required 
for G9 T cell TCR down-regulation (Fig. 4.1C). In this in vitro model of T-cell activation, a higher 
concentration of cognate peptide is required to maximally activate G9 T cells compared to OT-I T 
cells. Stimulation with an InsB15-23 APL, which is known to bind more strongly to MHC class I, 
resulted in maximal G9-T cell activation at a lower peptide concentration than the native InsB15-23. 
The lower InsB15-23 APL concentration requirement was not due to non-specific T-cell stimulation, 
as OT-I T cells were not activated upon stimulation with InsB15-23 (23 Val). For TCR down-
regulation, this occurred at a peptide concentration approximately one-log-fold higher than required 
for maximal CD69 up-regulation, suggesting a threshold of T-cell activation must be reached prior 
to TCR down-regulation. 
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Figure 4.1 –In vitro stimulation with InsB15-23 (23 Gly) activates G9 T cells in a dose-dependent 
manner. 
LN cells from G9 or OT-I mice (2.5x105) were cultured with titrated concentrations of InsB15-23 (23 
Gly), InsB15-23 (23 Val) or OVA257-264 peptide. The following day, cells were harvested and CD69 and 
TCR expression on G9 (CD8+Vβ6+) or OT-I (CD8+Vα2+) T cells was determined using flow 
cytometry. (A) Representative FACS plots of unstimulated G9 T cells (upper) and InsB15-23 (23 Gly) at 
1x10-5M stimulated G9 T cells (lower). (B) Proportion of CD69+ T cells (from total CD8+Vβ6+ or 
CD8+Vα2+ cells) and (C) relative TCR expression. Data are pooled from three independent 
experiments, n=3. Error bars show S. D. 
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4.2.2 In vitro-cultured G9 Tmem display a phenotype resembling TCM and TEM 
When OT-I T cells are cultured in vitro in the presence of OVA257-264 peptide, a mixed 
population of cells phenotypically resembling TCM and TEM are generated (Kenna et al., 2008; 
Kenna et al., 2010). To determine the phenotype of cultured G9 T cells, G9 LN and spleen cells 
were cultured with InsB15-23 (23 Gly) and IL-2 for 3 days. On day 3, cells were washed and cultured 
in IL-15 for a further 2 days as performed for OT-I T cell in the cited studies. The optimal 
conditions required for G9 Tmem generation were found to be 10µg/ml of InsB15-23 (23 Gly) with 
10% FCS (data not shown). Prior to culture, G9 T cells did not express CD69 and were 
predominantly CD44lo and CD62Lhi (Fig. 4.2A), consistent with a naïve T-cell phenotype. One day 
after culture, G9 T cells were predominantly CD69hi and CD44hi  and a proportion of G9 T cells 
were CD62Llo (Fig. 4.2A). At day 3, G9 T cells were predominantly CD69loCD44hi and there were 
two populations of CD62Lhi and CD62Llo G9 T cells (Fig. 4.2A). On the final day of culture, after 2 
days exposure to IL-15 and absence of InsB15-23, G9 T cells were predominantly CD69
-CD44hi with 
two populations of CD62Lhi and CD62Llo G9 T cells (Fig. 4.2A). Over the culture period, G9 T 
cells enriched to comprise approximately 90% of live cells (Fig. 4.2B). At day 5, there was a higher 
proportion of TCM-like G9 T cells (approximately 60%) compared to TEM-like G9 T cells 
(approximately 30%, Fig. 4.2B). The forward scatter (FSC) profile of InsB15-23-stimulated G9 T 
cells at day 3 was higher than naïve G9 T cells at day 0 (Fig. 4.2C). At day 5 of culture, G9 T cells 
display an intermediate FSC profile (Fig 4.2C), indicative of T-cell activation. At day 3, a small 
proportion of G9 T cells displayed increased granzyme B and perforin expression compared to 
naïve G9 T cells (Fig. 4.3A). By day 5, only a small proportion of G9 T cells expressed granzyme B 
(Fig. 4.3A) A small proportion of G9 T cells expressed IL-7Rα and/or killer-cell lectin like receptor 
G1 (KLRG1) at day 3 compared to naïve G9 T cells (Fig. 4.3B). By day 5, a small proportion of G9 
T cells expressed of IL-7Rα but there were almost no KLRG1-expressing G9 T cells (Fig. 4.3B).  
The majority of G9 T cells expressed lymphocyte activation gene 3 (LAG-3) at day 3 and a 
proportion of LAG-3+ G9 T cells also expressed CTLA-4 (Fig. 4.3C). By day 5, the proportion of 
G9 T cells expressing CTLA-4 was similar to that observed for naïve G9 T cells, although a 
proportion of G9 T cells expressing LAG-3 remained (Fig. 4.3C). CD5 expression was observed for 
naïve G9 T cells relative to isotype control staining and at day 3 a small proportion of G9 T cells 
appeared to further up-regulate CD5 (Fig. 4.3D), however, this might be an artifact of increased T-
cell size as a result of activation. By day 5, CD5 expression was similar to naïve G9 T cells (Fig. 
3D). Unlike CD5, naïve G9 T cells did not express PD-1, yet, the majority of G9 T cells expressed 
PD-1 by day 3 and even at day 5, a proportion of G9 T cells displayed PD-1 expression (Fig. 4.3D).  
Taken together, these data suggest G9 T cells undergo activation and effector differentiation 
during the first 3 days of culture, as indicated by up-regulation of T-cell activation and co-inhibitory 
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markers including CD69, CD44, PD-1 and LAG-3 as well as an increase in FSC profile. An 
additional 2 days of culture in the absence of InsB15-23 and in the presence of IL-15, resulted in a 
mixed population of G9 TEM and TCM. Therefore, in vitro-culture is a valid method for generating a 
mixed population of insulin-specific CD8+ T cells that phenotypically represent TEM and TCM. 
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Enrichment 
(%) 
CD69+ 
(%) 
CD44+CD62Llo 
(%) 
CD44+CD62Lhi 
(%) 
89.95±5.17 3.67±2.43 33.5±14.45 61.67±14.97 
A 
C 
Figure 4.2 – In vitro-culture of G9 T cells results in a mixed population of TEM and TCM. 
Pooled LN and spleen cells from G9 mice were cultured for 3 days with 10µg/ml InsB15-23 and IL-2. 
On day 3, cells were washed and re-cultured with IL-15 for a further 2 days. A sample of cells was 
taken each day throughout the culture period and expression of surface markers was determined using 
flow cytometry. (A) CD69, CD44 and CD62L expression (dashed line) on CD8+Vβ6+ T cells 
compared to isotype controls (solid line). (B) Gating strategy of G9 Tmem at day 5 of culture. 
Enrichment (CD8+Vβ6+ T cells as a proportion of total leukocytes) of and expression of CD69, CD44 
and CD62L on G9 T cells at day 5 of culture. Table shows mean±S.D. Data are pooled from six 
independent experiments. (C) Histogram shows FSC profile of lymphocyte gate. FACS plots are 
representative of at least two independent experiments. 
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Figure 4.3 – G9 T cells up-regulate PD-1, CTLA-4 and LAG-3 following in vitro-culture with 
InsB15-23 and IL-2.  
Pooled LN and spleen cells from G9 mice were cultured for 3 days with 10µg/ml InsB15-23 and IL-2. 
On day 3, cells were washed and re-cultured with IL-15 for a further 2 days. A sample of cells was 
taken at defined time points throughout the culture period and expression of surface and intracellular 
markers were determined using flow cytometry. Expression of indicated markers and relevant isotype 
controls for fixed and permeabilised (A, C) or unfixed (B, D) G9 T cells. FACS plots are 
representative of two independent experiments.  
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4.2.3 G9 Tmem produce IFN-γ  
In vitro-cultured G9 Tmem display a phenotype typical of TCM and TEM and it might be 
expected that G9 Tmem exert effector function. To test this, G9 Tmem were transferred to B16A 
recipients and IFN-γ production was analysed five days later. The concentration of InsB15-23 (23 
Gly) and InsB15-23 (23 Val) used to re-stimulate recipient splenoctyes in these ELISPOT assays was 
titrated to determine the optimal concentration for detection of IFN-γ in future assays. As expected, 
there were no IFN-γ-producing cells in spleen of B16A mice that were not injected with G9 Tmem 
(Fig. 4.4A), indicating IFN-γ production is attributable to transferred G9 Tmem. In the absence of 
in vitro InsB15-23 (23 Gly) re-stimulation, few IFN-γ-producing cells were observed in ELISPOT 
cultures established from B16A recipients of G9 Tmem and IFN-γ production was increased 
following re-stimulation with InsB15-23 (23 Gly) (Fig. 4.4A). In B16A recipients of G9 Tmem, the 
number of IFN-γ-producing cells from spleen was significantly increased by re-stimulation with 
1µg/ml and 10µg/ml of InsB15-23 (23 Gly) (Fig. 4.4B). Re-stimulation with any defined 
concentration of InsB15-23 (23 Val) resulted in similar numbers of IFN-γ-producing cells in B16A 
recipients of G9 Tmem (Fig. 4.4B). Re-stimulation of splenocytes from B16A G9 Tmem recipients 
with 10µg/ml of InsB15-23 (23 Gly) resulted in a high number of IFN-γ-producing cells, with less 
variability observed between replicates than for other groups (Fig. 4.4B). Therefore, 10µg/ml of 
InsB15-23 (23 Gly) was used to re-stimulate splenocytes in future ELISPSOT assays. The high 
number of G9 Tmem transferred in these experiments ensured adequate resolution of the G9 Tmem 
IFN-γ response. In later experiments, the number of G9 Tmem transferred was reduced to 2x106 G9 
Tmem, in line with the total number of naïve G9 T cells transferred in adoptive transfer studies in 
Chapter 3. Overall, these data demonstrate G9 Tmem produce IFN-γ after transfer to B16A mice, 
indicating effector function and considering transferred G9 Tmem were not primed in vivo by 
immunisation, G9 Tmem have been primed during culture and, at this time point, produce basal 
levels of IFN-γ. 
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Figure 4.4 - G9 Tmem produce IFN-γ after transfer to B16A recipients. 
G9 Tmem (10x106) were transferred to B16A mice and five days later, IFN-γ production in spleen was 
determined using ELISPOT. (A) Representative well images showing IFN-γ+ spots from a mouse not 
injected with G9 Tmem (left), a mouse injected with G9 Tmem without re-stimulation (middle) and 
the same recipient with re-stimulation (10µg/ml InsB15-23 (23 Gly); right). (B) The mean number of 
spots in peptide-stimulated wells minus the mean number of spots in unstimulated wells (delta value) 
per 5x105 spleen cells. The concentration of peptide used for re-stimulation is shown on the x-axis. 
Data are pooled from two independent experiments. Each point represents a single mouse. Error bars 
show S.D. One-way ANOVA followed by Tukey post-test. (**p<0.01).  
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4.2.4 G9 Tmem proliferate extensively after transfer to proinsulin transgenic recipients 
When transferred to proinsulin transgenic mice, naïve G9 T cells proliferated in response to 
transgenic proinsulin expression and this proliferation preceded tolerance induction. To determine 
whether G9 Tmem also proliferate in response to transgenic proinsulin expression, CFSE-labelled 
G9 Tmem were transferred to B16A, NOD and proinsulin transgenic and G9 Tmem CFSE dilution 
was assessed three days later. As expected, there was no CFSE dilution observed for G9 Tmem 
from spleen, sdLN or pLN of B16A recipients (Fig. 4.5A). Similarly, CFSE dilution was not 
observed for G9 Tmem from spleen or sdLN of NOD recipients (Fig. 4.5A). A small proportion of 
G9 Tmem from pLN of NOD recipients showed evidence of proliferation (Fig. 4.5A). In contrast, 
the majority of G9 Tmem transferred to proinsulin transgenic recipients exhibited extensive CFSE 
dilution in spleen, sdLN and pLN samples (Fig. 4.5A). The proportion of CFSElo G9 T cells was 
significantly higher from proinsulin transgenic compared to B16A and NOD recipients for spleen, 
sdLN and pLN (Fig. 4.5B). The proportion of CFSElo G9 T cells from pLN was not significantly 
different to spleen or sdLN in NOD recipients (Fig. 4.5B). The proportion of proliferating naïve G9 
T cells observed in pLN from NOD recipients was higher than that observed for G9 Tmem. When 
proliferation index was calculated, the extent of G9 Tmem division from proinsulin transgenic 
recipients was significantly higher than from NOD recipients in sdLN and pLN (Fig. 4.5C). Taken 
together, these data indicate G9 Tmem, similarly to naïve G9 T cells, proliferate extensively after 
transfer to proinsulin transgenic recipients. Interestingly, G9 Tmem proliferated to a lesser extent 
compared to naïve G9 T cells in response to islet-derived insulin presentation in NOD recipients. 
Despite differences in the response of naïve and memory G9 T cells to islet-derived insulin, 
extensive proliferation of G9 Tmem in response to transgenic proinsulin expression might precede 
tolerance induction. 
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Figure 4.5 - G9 Tmem proliferate extensively in response to presentation of transgene-derived, 
but not islet-derived, (pro)insulin. 
CFSE-labelled G9 Tmem (2x106) were transferred to B16A, NOD and proinsulin transgenic mice. 
Three days later, G9 Tmem (CFSE+CD8+Vβ6+) CFSE dilution was determined using flow cytometry. 
(A) FACS plots are representative of at least five individual mice. (B) CFSElo G9 Tmem as a 
proportion of total G9 Tmem. (C) Proliferation index of G9 Tmem. Data are pooled from two 
independent experiments. Each point represents a single mouse. Error bars show S. D. One-way 
ANOVA followed by Tukey post-test. (*p<0.05, ****p<0.0001). 
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4.2.5 G9 Tmem are rapidly deleted after transfer to proinsulin transgenic recipients 
Since G9 Tmem proliferate extensively in proinsulin transgenic recipients, it was next 
important to investigate the population dynamics of transferred G9 Tmem. Firstly, CFSE-labelled 
G9 Tmem were transferred to B16A, NOD and proinsulin transgenic recipients and G9 Tmem were 
enumerated three days later. The proportion of G9 Tmem (CFSE+Vβ6+CD8+) of total CD8+ T cells 
was significantly higher from B16A compared to proinsulin transgenic recipients in spleen and pLN 
(Fig. 4.6A). No difference in G9 Tmem as a proportion of total CD8+ T cells was observed from 
proinsulin transgenic and NOD recipients in pLN (Fig. 4.6A), this lack of G9 Tmem accumulation 
is consistent with minimal G9 Tmem proliferation observed in pLN from NOD recipients (Fig. 4.5). 
The proportion of G9 Tmem was higher from B16A compared to NOD recipients in spleen (Fig. 
4.6A).  
Secondly, to track the population dynamics of transferred G9 Tmem over time, G9 Tmem 
(CD45.1+CD45.2-) were transferred to NOD (CD45.1+CD45.2+) and proinsulin transgenic 
(CD45.1+CD45.2+) recipients and G9 Tmem were enumerated at defined time points. To control for 
background mAb staining, mice of each genotype that were not injected with G9 Tmem were 
analysed alongside test mice in each experiment. Mice that were not injected with G9 Tmem 
consistently displayed negligible CD45.1+CD45.2-Vβ6+CD8+-gated events. Despite proliferation of 
G9 Tmem in proinsulin transgenic recipients (Fig. 4.5), the total number of G9 Tmem in spleens of 
these recipients decreased over time (Fig. 4.6B). The total number of G9 Tmem from proinsulin 
transgenic recipients was significantly lower than NOD recipients in spleen at five and seven days 
after transfer (Fig. 4.6B). The total number of G9 Tmem remained low across time in both sdLN 
and pLN from proinsulin transgenic recipients (Fig. 4.6B). When the number of G9 Tmem was 
represented as a proportion of total CD8+ T cells, there was a reduction in the proportion of G9 
Tmem of total CD8+ T cells over time in spleen of both proinsulin transgenic and NOD recipients 
(Fig. 4.6C). This reduction in the proportion of G9 T cells of total CD8+ T cells in spleen was not 
observed when naïve G9 T cells were transferred (Fig. 3.3) and may be due to different trafficking 
properties of Tmem as a result of differential expression of CD62L. Seven days after transfer the 
proportion of G9 Tmem of total CD8+ T cells from proinsulin transgenic recipients was 
significantly lower than NOD recipients in spleen, sdLN and pLN (Fig. 4.6C). The proportion of G9 
Tmem of total CD8+ T cells remained low in sdLN and pLN of proinsulin transgenic recipients 
(Fig. 4.6C). Similarly to when CFSE was used to track G9 Tmem, no increase in the proportion of 
G9 Tmem of total CD8+ T cells was observed in pLN of NOD recipients at any time point when G9 
Tmem were identified based on differential CD45 expression (Fig. 4.6C). The population dynamics 
of G9 Tmem after transfer to proinsulin transgenic and NOD recipients indicate G9 Tmem are 
rapidly deleted in mice transgenically expressing proinsulin.  
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Figure 4.6- G9 Tmem are rapidly deleted after transfer to proinsulin transgenic recipients. 
(A) CFSE-labelled G9 Tmem (2x106) were transferred to B16A, NOD and proinsulin transgenic mice. 
Three days later, G9 Tmem (CFSE+CD8+Vβ6+) as a proportion of total CD8+ T cells in spleen, sdLN 
and pLN was determined using flow cytometry. (B, C) G9 Tmem (2x106, CD45.1+CD45.2-) were 
transferred to NOD (CD45.1+CD45.2+) and proinsulin transgenic (CD45.1+CD45.2+) mice. At times 
shown, total number of G9 Tmem (CD45.1+CD45.2-CD8+Vβ6+) (B) and G9 Tmem as a proportion of 
total CD8+ T cells (C) in spleen, sdLN and pLN were determined using flow cytometry. Data are 
pooled from at least two independent experiments at each time point. Each point represents a single 
mouse. (B, C) n=5 (day 1 and 5); n=6 (day 2 and 3); n= 9 (day 7). Error bars show S.D. One-way 
ANOVA followed by Tukey post-test. (**p<0.01, ****p<0.0001: NOD spl vs proIns Tg spl (B, C)). 
 
 
A 
C 
B 
103 
 
4.2.6 G9 Tmem persist in the absence of their cognate antigen 
In Chapter 3 it was demonstrated that the frequency of naïve G9 T cells slowly decreased 
over time after transfer to NOD recipients, possibly reflecting deletion induced by islet-derived 
insulin. It is possible that G9 Tmem, due to their more differentiated phenotype, may be less 
responsive to islet-derived insulin presentation and as such the frequency of G9 Tmem might 
remain stable after transfer to NOD recipients. To test this, CFSE-labelled G9 Tmem were 
transferred to B16A, NOD and proinsulin transgenic recipients and G9 Tmem were enumerated 
three weeks later. The total number of G9 Tmem from B16A recipients was significantly higher 
than NOD and proinsulin transgenic recipients for both spleen and sdLN (Fig. 4.7A). The total 
number of G9 Tmem was similar between B16A, NOD and proinsulin transgenic recipients in pLN 
(Fig. 4.7A). There was no significant difference in the total number of G9 Tmem between NOD and 
proinsulin transgenic recipients in spleen, sdLN and pLN (Fig 4.7A). When the proportion of G9 
Tmem of total CD8+ T cells was analysed, there was a higher proportion of G9 Tmem from B16A 
compared to NOD and proinsulin transgenic recipients in spleen, sdLN and pLN (Fig. 4.7B). There 
was a trend toward an increase in the proportion of G9 Tmem recovered from NOD compared to 
proinsulin transgenic recipients, although, this was not significant (Fig. 4.7B). The total cellularity 
of spleens from B16A recipients was significantly lower than both NOD and proinsulin transgenic 
recipients (Fig. 4.7C). There was also a trend toward lower cellularity of sdLN from B16A than 
NOD and proinsulin transgenic recipients (Fig. 4.7C), yet, this was not significant. This highlights 
the higher number of G9 Tmem in B16A recipients compared to NOD and proinsulin transgenic 
recipients despite reduced cellularity of organs in B16A recipients. These data indicate G9 Tmem 
are slowly deleted after transfer to NOD recipients. Since the frequency of G9 Tmem remained 
stable in B16A recipients, the slow deletion of G9 Tmem in NOD recipients might be due to islet-
derived insulin presentation. An important observation here is the complete absence of G9 Tmem 
three weeks after transfer to proinsulin transgenic recipients, further supporting the notion of rapid 
deletion of G9 Tmem in response to transgenic proinsulin expression.  
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Figure 4.7- Transferred G9 Tmem persist in B16A recipients.  
CFSE-labelled G9 Tmem (2x106) were transferred to B16A, NOD and proinsulin transgenic mice. 
Three weeks later, the total number of G9 Tmem (CFSE+CD8+Vβ6+) (A), G9 Tmem as a proportion of 
total CD8+ T cells (B) and the total number of cells (C) in spleen, sdLN and pLN were determined 
using flow cytometry. Data are pooled from two independent experiments. Each point represents a 
single mouse. Error bars show S.D. One-way ANOVA followed by Tukey post-test. (**p<0.01, 
****p<0.0001). 
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4.2.7 G9 Tmem do not infiltrate the pancreas after transfer to recipients  
Since G9 Tmem are post-activated CD8+ T cells which recognise an insulin-derived 
determinant, it is possible that G9 Tmem might preferentially migrate to the pancreas after transfer 
and this might underlie the decrease in number of G9 Tmem in secondary lymphoid organs of 
proinsulin transgenic recipients. To test this, G9 Tmem (CD45.1+CD45.2-) were transferred to NOD 
(CD45.1+CD45.2+) and proinsulin transgenic (CD45.1+CD45.2+) recipients and pancreas-
infiltrating leukocytes were analysed seven days later. The level of CD45.1 mAb background 
staining in pancreas was determined for NOD and proinsulin transgenic mice that were not injected 
with G9 Tmem (Fig. 4.8A). Seven days after transfer, no donor (G9) leukocytes were observed in 
pancreas of proinsulin transgenic or NOD recipients (Fig. 4.8A). A G9 mouse was included as a 
technical control for staining of CD45.1+CD45.2- cells in pancreas (Fig. 4.8A). There was no 
difference observed for the proportion of host-type pancreas-infiltrating leukocytes between NOD 
and proinsulin transgenic recipients (Fig. 4.8B). This might be due to 8-10 week old male NOD 
mice being used as recipients and these mice may be expected to have milder insulitis than older 
female NOD mice and as a result, fewer endogenous leukocytes might infiltrate the pancreas. The 
proportion of donor leukocytes of host-type leukocytes was not significantly different between 
NOD and proinsulin transgenic recipients in pancreas (Fig. 4.8C). Therefore the decrease in G9 
Tmem number after transfer to proinsulin transonic recipients is not due to G9 Tmem trafficking to 
pancreas. It is possible that islet inflammation, which is expected to be mild in the NOD recipients 
used, is a requirement for attracting transferred G9 Tmem to pancreas.  
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Figure 4.8 - G9 Tmem do not traffic to the pancreas in immune-replete NOD or proinsulin 
transgenic recipients.  
G9 Tmem (2x106, CD45.1+CD45.2-) were transferred to NOD (CD45.1+CD45.2+) and proinsulin 
transgenic (CD45.1+CD45.2+) mice (A). Seven days later, host (CD45.1+CD45.2+) leukocytes as 
proportion of live cells (B) and transferred (CD45.1+CD45.2-) leukocytes as a proportion of total 
leukocytes (C) in pancreas were determined using flow cytometry. Data are pooled from two 
independent experiments. FACS plots are representative of at least two individual mice. Each point 
represents a single mouse. Error bars show S.D. One-way ANOVA followed by Tukey post-test.  
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4.2.8 Transferred G9 Tmem maintain a memory-like phenotype in B16A and NOD recipients 
G9 Tmem persist in the absence of cognate antigen, but it is not known whether G9 Tmem 
retain a memory phenotype and whether this phenotype might differ between NOD (islet-derived 
insulin) and B16A (no antigen) recipients. To test this, CFSE-labelled G9 Tmem were transferred to 
B16A, NOD and proinsulin transgenic recipients and G9 Tmem phenotype was determined three 
weeks later. Prior to transfer, G9 Tmem comprise a mixed population of CD44hiCD62Lhi TCM and 
CD44hi CD62Llo TEM. Transferred G9 Tmem from sdLN of B16A recipients were predominantly 
CD44hi, in contrast to the host CD8+Vβ6+ T-cell population which was predominantly CD44lo (Fig. 
4.9A). The level of relevant isotype control mAb staining was low on both G9 Tmem and host 
CD8+Vβ6+ T cells (Fig. 4.9A), although the increased fluorescence observed for G9 Tmem might 
be expected due to CFSE labelling. Three weeks after transfer, G9 Tmem from both B16A and 
NOD recipients were predominantly CD44hi in spleen, sdLN and pLN (Fig. 4.9B). The phenotype 
of G9 Tmem after transfer to proinsulin transgenic recipients was not determined (Fig. 4.9B-D) as 
there were no G9 Tmem observed in spleen, sdLN or pLN three weeks after transfer, consistent 
with data described above (Fig. 4.7). The proportion of G9 Tmem expressing high levels of CD44 
and CD62L was similar between B16A and NOD recipients for spleen, sdLN and pLN (Fig. 4.9B). 
Similarly, the proportion of CD44hiCD62L- G9 Tmem in B16A recipients did not differ to NOD 
recipients (Fig. 4.9C). Therefore, the proportion of TEM- and TCM-like G9 Tmem after transfer to 
B16A and NOD recipients was similar to that observed prior to transfer, indicating in vitro-cultured 
G9 Tmem maintain a memory phenotype in vivo, consistent with a long-lived Tmem population.   
108 
 
 
 
 
 
 
 
s
p
l 
s
d
L
N
 
p
L
N
 
s
p
l 
s
d
L
N
 
p
L
N
 
s
p
l 
s
d
L
N
 
p
L
N
 
0
2 0
4 0
6 0
8 0
1 0 0
T
o
ta
l 
C
D
4
4
h
i
G
9
 T
m
e
m
 (
%
)
n .d . n .d . n .d .
B 1 6 A N O D p ro In s  T g
s
p
l 
s
d
L
N
 
p
L
N
 
s
p
l 
s
d
L
N
 
p
L
N
 
s
p
l 
s
d
L
N
 
p
L
N
 
0
2 0
4 0
6 0
8 0
1 0 0
C
D
4
4
h
i C
D
6
2
L
+
 G
9
 T
m
e
m
 (
%
)
B 1 6 A N O D p ro In s  T g
n .d . n .d . n .d .
 
s
p
l 
s
d
L
N
 
p
L
N
 
s
p
l 
s
d
L
N
 
p
L
N
 
 s
p
l 
s
d
L
N
 
p
L
N
 
0
2 5
5 0
7 5
1 0 0
C
D
4
4
h
i C
D
6
2
L
-  
G
9
 T
m
e
m
 (
%
)
n .d . n .d . n .d .
B 1 6 A N O D p ro In s  T g
  
B C 
D 
Figure 4.9 - Transferred G9 Tmem maintain a memory-like phenotype in B16A and NOD 
recipients.   
CFSE-labelled G9 Tmem (2x106) were transferred to B16A, NOD and proinsulin transgenic mice. 
Three weeks later, the proportion of CD44hi (B), CD44hiCD62L+ (C) and CD44hiCD62L- (D) G9 
Tmem (CFSE+CD8+Vβ6+) were determined using flow cytometry. Data are pooled from two 
independent experiments. Representative FACS plots showing CD44 and CD62L expression on 
transferred G9 Tmem and host CD8+Vβ6+ T cells in sdLN from B16A recipients (A). Each point 
represents a single mouse. Error bars show S.D. n.d.= not determined. One-way ANOVA followed by 
Tukey post-test.  
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4.2.9 G9 Tmem do not preferentially migrate to BM in recipients  
Since BM is an important site of TCM accumulation (Becker et al., 2005; Mazo et al., 2005), 
it is possible that transferred G9 Tmem, of which approximately 50% display a TCM-like phenotype, 
may preferentially home to this compartment in recipients. If so, this might explain the reduced 
number of G9 Tmem recovered from secondary lymphoid organs after transfer to proinsulin 
transgenic recipients (Fig. 4.6, 4.7). To test this, CFSE-labelled G9 Tmem were transferred to 
B16A, NOD and proinsulin transgenic recipients and G9 Tmem enumerated from BM three weeks 
later. The total number of G9 Tmem from BM of proinsulin transgenic recipients did not differ 
compared to NOD recipients (Fig. 4.10A). A higher total number and proportion of G9 Tmem 
within total CD8+ T cells was observed for BM of B16A recipients compared to both NOD and 
proinsulin transgenic recipients (Fig. 4.10A, B), consistent with the increased proportion of G9 
Tmem from other sites of B16A recipients at this time point (Fig. 4.7). Since B16A mice show 
reduced spleen cellularity than NOD and proinsulin transgenic mice (Fig. 4.7), it is possible that the 
cellularity of BM from B16A mice may be lower compared to that of wild type NOD mice. The 
total cellularity of BM from B16A recipients was similar to NOD and proinsulin transgenic 
recipients (Fig. 4.10C). This validates the increase in the total number of G9 Tmem in BM of B16A 
compared to NOD recipients, as this was not an artefact of differing BM cellularity. Since CFSE 
was used to track transferred G9 Tmem, it was possible that loss of G9 Tmem-gated events due to 
CFSE dilution could account for the reduced number of G9 Tmem from BM of NOD and proinsulin 
transgenic recipients (Fig. 4.10A, B).  
To confirm data in Figure 4.10, G9 Tmem were transferred to congenic NOD and proinsulin 
transgenic recipients (CD45.1+CD45.2+) as well as B16A recipients (CD45.1+CD45.2-). Three 
weeks later, G9 Tmem in BM were identified using both congenic markers and InsB15-23-loaded, 
H2-Kd-tetramer for NOD and proinsulin transgenic recipients and tetramer alone for B16A 
recipients. Similarly to data in Figure 4.10, the recovery of G9 Tmem was lower from BM of NOD 
and proinsulin transgenic recipients compared to B16A recipients, when G9 Tmem were identified 
with congenic markers (Fig. 4.11A, C) or tetramer (Fig. 4.11B, D). Despite variability, the 
proportion of G9 Tmem within total CD8+ T cells from BM of B16A recipients as identified with 
tetramer (Fig. 4.11B), was similar as identified with CFSE (Fig. 4.10B). Also, no difference in BM 
cellularity was observed between congenic NOD, congenic proinsulin transgenic and B16A 
recipients (Fig. 4.11C). These data exclude BM as a preferential site of deposition or reservoir for 
G9 Tmem after transfer to recipients, and this finding helps to reinforce the notion of G9 Tmem 
undergoing rapid deletion after transfer to proinsulin transgenic recipients.  
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  Figure 4.10- Increased recovery of CFSE-labelled G9 Tmem in BM of B16A recipients compared 
to NOD and proinsulin transgenic recipients. 
CFSE-labelled G9 Tmem (2x106) were transferred to B16A, NOD and proinsulin transgenic mice. 
Three weeks later, the total number of G9 Tmem (CFSE+CD8+Vβ6+) (A), G9 Tmem as a proportion of 
total CD8+ T cells (B) and the total number of cells (C) in BM were determined using flow cytometry. 
Data are pooled from two independent experiments. Each point represents a single mouse. Error bars 
show S.D. One-way ANOVA followed by Tukey post-test. (**p<0.01). 
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Figure 4.11- Few tetramer-binding G9 Tmem detected in BM of NOD and proinsulin transgenic 
recipients.  
G9 Tmem (2x106, CD45.1+CD45.2-) were transferred to B16A (CD45.1+CD45.2-), NOD 
(CD45.1+CD45.2+) and proinsulin transgenic (CD45.1+CD45.2+) mice. Three weeks later, the total 
number of G9 Tmem (CD45.1+CD8+Kd:Ins+Vβ6+ in B16A or CD45.1+CD45.2-CD8+Vβ6+ in NOD and 
proinsulin transgenic) (A), total number of G9 Tmem (CD45.1+CD8+Kd:Ins+Vβ6+) (B), G9 Tmem 
(CD45.1+CD8+Kd:Ins+Vβ6+ in B16A or CD45.1+CD45.2-CD8+Vβ6+ in NOD and proinsulin 
transgenic) as a proportion of total CD8+ T cells (C), G9 Tmem (CD45.1+CD8+Kd:Ins+Vβ6+) as a 
proportion of total CD8+ T cells (D) and the total number of cells (E) in BM were determined using 
flow cytometry. Data are pooled from two independent experiments. Each point represents a single 
mouse. Error bars show S.D. The dashed line represents the detection limit for Kd:Ins tetramer binding 
and shows the mean frequency of Kd:LLO (control) tetramer-binding CD8+ T cells. One-way ANOVA 
followed by Tukey post-test. (*p<0.05).  
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4.2.10 TCR down-regulation on transferred G9 Tmem is observed in proinsulin transgenic 
recipients 
Since naïve G9 T cells down-regulate TCR expression after transfer to proinsulin transgenic 
recipients, it is possible that G9 Tmem down-regulate TCR in a similar manner. To test this, G9 
Tmem were transferred to NOD and proinsulin transgenic recipients and TCR expression on G9 
Tmem was analysed at defined time points. G9 Tmem from proinsulin transgenic recipients 
displayed reduced Vβ6 expression compared to G9 Tmem from NOD recipients (Fig. 4.12A). As 
early as one day after transfer, the level of Vβ6 expression was lower for G9 Tmem from pLN in 
proinsulin transgenic recipients compared to NOD recipients (Fig. 4.12B). This reduction of Vβ6 
expression was maintained, and at seven days after transfer, G9 Tmem Vβ6 expression was 
significantly lower from proinsulin transgenic recipients compared to NOD recipients in spleen, 
sdLN and pLN (Fig. 4.12B). After transfer to NOD recipients, G9 Tmem Vβ6 expression was lower 
relative to the host CD8+Vβ6+ T-cell population as a result of in vitro activation of G9 Tmem 
during culture (Fig. 4.12B). To determine G9 Tmem Vβ6 expression after transfer to B16A 
recipients, CFSE-labelled G9 Tmem were transferred to B16A, NOD and proinsulin transgenic 
recipients and TCR expression on G9 Tmem analysed three days later. G9 Tmem Vβ6 expression 
was similar from B16A compared to NOD recipients (Fig. 4.12C). From proinsulin transgenic 
recipients, G9 Tmem displayed significantly lower Vβ6 expression compared to those from NOD 
and B16A recipients in spleen, sdLN and pLN (Fig. 4.12C). These data confirm G9 Tmem rapidly 
down-regulate TCR after transfer to proinsulin transgenic recipients. TCR down-regulation might 
indicate G9 Tmem are functionally inactivate after transfer to mice transgenically expressing 
proinsulin.  
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Figure 4.12 – TCR down-regulation by G9 Tmem after transfer to proinsulin transgenic 
recipients. 
G9 Tmem (2x106, CD45.1+CD45.2-) were transferred to NOD (CD45.1+CD45.2+) and proinsulin 
transgenic (CD45.1+CD45.2+) mice. (A) Vβ6 expression on G9 Tmem (CD45.1+CD45.2-CD8+Vβ6+) 
in sdLN from NOD and proinsulin transgenic recipients seven days after transfer. (B) At times shown, 
Vβ6 expression on G9 Tmem (CD45.1+CD45.2-CD8+Vβ6+) relative to host 
(CD45.1+CD45.2+CD8+Vβ6+) T cells in spleen, sdLN and pLN was determined using flow cytometry. 
(C) CFSE-labelled G9 Tmem (2x106) were transferred to B16A, NOD and proinsulin transgenic mice. 
Three days later, Vβ6 expression on G9 Tmem (CFSE+CD8+Vβ6+) in spleen, sdLN and pLN was 
determined using flow cytometry. Histograms are representative of nine mice from three independent 
experiments. Data are pooled from at least two independent experiments at each time point (B) and 
two independent experiments (C). n=5 (day 1 and 5); n=6 (day 2 and 3); n= 12 (day 7). Each point 
represents a single mouse. Error bars show S.D. One-way ANOVA followed by Tukey post-test. 
(*p<0.05, ****p<0.0001: NOD pLN vs proIns Tg pLN (B)). (***p<0.001 (C)). 
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4.2.11 Transferred G9 Tmem are unresponsive to InsB15-23 immunisation in proinsulin transgenic 
recipients 
Since the data presented to this point suggest G9 Tmem are deleted after transfer to 
proinsulin transgenic recipients and residual G9 Tmem exhibit reduced TCR expression, it is 
possible that the residual population of G9 Tmem in proinsulin transgenic recipients are 
unresponsive. To test this, G9 Tmem were transferred to B16A, NOD and proinsulin transgenic 
mice and seven days later recipients immunised with InsB15-23 (23 Gly)/poly I:C. Five days after 
immunisation, G9 Tmem were enumerated and IFN-γ production was determined using ELISPOT. 
Since B16A mice express the same CD45.1 allotype as G9 Tmem, InsB15-23-loaded, H2-K
d-tetramer 
was used to detect transferred G9 Tmem in recipients. There was a trend toward an increase in the 
total number of G9 Tmem in immunised B16A recipients compared to unimmunised B16A 
recipients, however, this was not significant (Fig. 4.13A). The total number of G9 Tmem and their 
proportion of total CD8+ T cells remained unchanged in NOD recipients after immunisation (Fig. 
4.13A, B). In proinsulin transgenic recipients, the total number of G9 Tmem and their proportion of 
total CD8+ T cells was low and did not differ following immunisation (Fig. 4.13A, B). The 
proportion of G9 Tmem within CD8+ T cells from B16A recipients was increased following 
immunisation (Fig. 4.13B). G9 Tmem were also identifiable in NOD and proinsulin transgenic 
recipients based on expression of CD45.1 and CD45.2. A similar pattern was observed when G9 
Tmem were identified using tetramer and congenic markers (Fig. 4.13C, D).  
Immunisation did not significantly alter the total cellularity of spleens for any strain (Fig. 
4.13E). The total cellularity of spleens from immunised B16A mice was significantly lower than 
immunised proinsulin transgenic mice (Fig. 4.13E). Immunised NOD recipients were 
normoglycemic at the time of cull and BGL were similar between immunised and unimmunised 
NOD recipients and age-matched NOD mice that were not injected with G9 Tmem (Fig. 4.13F). By 
ELISPOT, there appeared to be fewer IFN-γ-producing cells from proinsulin transgenic than NOD 
and B16A recipients (Fig. 4.13G). The number of IFN-γ-producing cells was increased in B16A 
recipients by immunisation but remained unchanged in NOD recipients following immunisation 
(Fig. 4.13H). In proinsulin transgenic recipients, there were very few IFN-γ-producing cells 
observed and this was unchanged following immunisation (Fig. 4.13H). The number of IFN-γ-
producing cells appeared to be lower from immunised proinsulin transgenic than immunised NOD 
recipients yet this was not significantly different (Fig. 4.13H). These data suggest G9 Tmem are 
responsive to InsB15-23 immunisation after transfer to B16A recipients, that is, in the absence of 
cognate antigen. In contrast to naïve G9 T cells, G9 Tmem did not respond to InsB15-23 
immunisation after transfer to NOD recipients. Importantly though, the response of G9 Tmem to 
immunisation was ablated after transfer to mice expressing transgenic proinsulin. 
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Figure 4.13- G9 Tmem recall response is ablated after transfer to proinsulin transgenic mice. 
G9 Tmem (2x106, CD45.1+CD45.2-) were transferred to B16A (CD45.1+CD45.2-), NOD 
(CD45.1+CD45.2+) and proinsulin transgenic (CD45.1+CD45.2+) mice. Seven days later, mice were 
injected with InsB15-23 (50µg) and poly I:C (100µg) i.p. or left unimmunised. Five days later, the total 
number of G9 Tmem (CD8+Kd:Ins+Vβ6+) (A), G9 Tmem (CD8+Kd:Ins+Vβ6+) as a proportion of total 
CD8+ T cells (B), the total number of G9 Tmem (CD45.1+CD8+Kd:Ins+Vβ6+ in B16A; 
CD45.1+CD45.2-CD8+Vβ6+ in NOD and proinsulin transgenic) (C), G9 Tmem 
(CD45.1+CD8+Kd:Ins+Vβ6+ in B16A; CD45.1+CD45.2-CD8+Vβ6+ in NOD and proinsulin transgenic) 
as a proportion of total CD8+ T cells (D) and the total number of spleen cells (E) in spleen were 
determined using flow cytometry. The non-fasting BGL (mM) of NOD mice was determined at time 
of cull and table shows mean±S.D (F). IFN-γ production in spleen was determined using ELISPOT 
(G, H). (G) Representative images from InsB15-23-stimulated wells. Data are from two independent 
experiments. Each point represents a single mouse. Error bars shown S.D. The dashed line shows the 
mean frequency of Kd:LLO (control) tetramer-binding CD8+ T cells. One-way ANOVA followed by 
Tukey post-test. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).  
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4.2.12 G9 Tmem do not accumulate in LN of proinsulin transgenic recipients following InsB15-23 
immunisation 
Since InsB15-23/poly I:C immunisation did not increase the number of G9 Tmem in spleen of 
NOD recipients, it is possible that G9 Tmem might have accumulated in LN which drain the site of 
immunisation instead. In light of this, as InsB15-23/poly I:C immunisation was administered i.p., an 
increase in G9 Tmem may have occurred in inguinal LN or pLN of immunised recipients which 
both drain the peritoneal cavity. To test this, G9 Tmem were transferred to B16A, NOD and 
proinsulin transgenic mice and seven days later recipients immunised with InsB15-23/poly I:C. Five 
days after immunisation, G9 Tmem were enumerated in spleen, brachial, inguinal and pancreatic 
LN as described above. There was no significant difference in the total number of G9 Tmem or 
their proportion of total CD8+ T cells in brachial LN of NOD recipients after immunisation (Fig. 
4.14B), consistent with the response observed in spleen (Fig. 4.14A). Despite the small number of 
mice analysed, the number of G9 Tmem remained unchanged in inguinal LN (Fig. 4.14C) and pLN 
(Fig. 4.14D) of NOD recipients following immunisation. No significant difference in the total 
number of G9 Tmem or their proportion of total CD8+ T cells was observed in brachial LN from 
B16A recipients (Fig. 4.14B). Importantly, in immunisation-draining and non-draining sites alike, 
the number and proportion of G9 Tmem was low and this remained unchanged following 
immunisation in proinsulin transgenic recipients (Fig. 4.14A-D). These findings suggest the pattern 
of G9 Tmem dynamics observed for spleen was similar in LN tissue. An important observation was 
that G9 Tmem did not expand in any lymphoid site in response to InsB15-23 immunisation.   
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Figure 4.14- G9 Tmem do not accumulate in LN of proinsulin transgenic recipients following 
InsB15-23 immunisation. 
G9 Tmem (2x106, CD45.1+CD45.2-) were transferred to B16A (CD45.1+CD45.2-), NOD 
(CD45.1+CD45.2+) and proinsulin transgenic (CD45.1+CD45.2+) mice. Seven days later, mice were 
injected with InsB15-23 (50µg) and poly I:C (100µg) i.p. or left unimmunised. Five days later, the total 
number of G9 Tmem (CD45.1+CD8+Kd:Ins+Vβ6+in B16A or CD45.1+CD45.2-CD8+Vβ6+ in NOD and 
proinsulin transgenic) (left) and G9 Tmem as a proportion of total CD8+ T cells (right) in spleen (A), 
brachical LN (B), inguinal LN (C) and pancreatic LN (D) were determined using flow cytometry. Data 
are from a single (pLN and inguinal LN, B16A recipients) or two (spleen and brachial LN) 
independent experiments. Each point represents a single mouse. Error bars shown S.D. The dashed 
line shows the mean frequency of Kd:LLO (control) tetramer-binding CD8+ T cells. One-way ANOVA 
followed by Tukey post-test. (*p<0.05, **p<0.01, ***p<0.001). 
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4.2.13 G9 Tmem are unresponsive to InsB15-23 immunisation twenty one days after transfer to 
proinsulin transgenic recipients 
Since G9 Tmem are unresponsive to InsB15-23/poly I:C immunisation in proinsulin 
transgenic recipients seven days after transfer, it is possible that this functional inactivation is not 
maintained and G9 Tmem responsiveness is re-instated. To test the longevity of G9 Tmem 
unresponsiveness, G9 Tmem were transferred to B16A, NOD and proinsulin transgenic mice and 
twenty one days later recipients immunised with InsB15-23/poly I:C. Five days after immunisation, 
G9 Tmem were enumerated using flow cytometry and IFN-γ production was determined using 
ELISPOT. Neither the total number of G9 Tmem nor their proportion of total CD8+ T cells was 
increased by immunisation in B16A, NOD or proinsulin transgenic recipients when G9 Tmem were 
identified using tetramer (Fig. 4.15A, B) and expression of congenic markers (Fig. 4.15C, D). 
Recovery of G9 Tmem was higher in B16A recipients than NOD and proinsulin transgenic 
recipients (Fig. 4.15A, B). Immunisation did not affect the total number of spleen cells for any 
strain but the total number of spleen cells was lower from immunised B16A recipients compared to 
immunised NOD and immunised proinsulin transgenic recipients (Fig. 4.15E). NOD recipients and 
age-matched NOD mice not injected with G9 Tmem were normoglycemic at the time of cull (Fig. 
4.15F). After immunisation, there appeared to be fewer IFN-γ-producing cells from NOD and 
proinsulin transgenic recipients compared to B16A recipients (Fig. 4.15E). The number of IFN-γ-
producing cells was not significantly altered by immunisation in B16A, NOD or proinsulin 
transgenic recipients (Fig. 4.15F). There was a trend toward an increased number of IFN-γ-
producing cells from immunised B16A recipients compared to immunised NOD and immunised 
proinsulin transgenic recipients, however, this was not significant (Fig. 4.15F). These data suggest 
G9 Tmem persist and remain functional in the absence of cognate antigen, as indicated by IFN-γ 
production, yet do not exhibit an increased response following InsB15-23 immunisation in B16A 
recipients. A second InsB15-23 immunisation may elicit a stronger response from transferred G9 
Tmem in B16A recipients. G9 Tmem, like naïve G9 T cells, are also unresponsive to InsB15-23 
immunisation twenty one days after transfer to NOD recipients. Particularly significant here is the 
complete functional unresponsiveness of G9 Tmem after transfer to proinsulin transgenic recipients, 
suggesting peripheral tolerance induction in G9 Tmem is maintained in mice transgenically 
expressing proinsulin.   
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Figure 4.15- G9 Tmem are functionally inactivate in proinsulin transgenic recipients.  
G9 Tmem (2x106, CD45.1+CD45.2-) were transferred to B16A (CD45.1+CD45.2-), NOD 
(CD45.1+CD45.2+) and proinsulin transgenic (CD45.1+CD45.2+) mice. Twenty-one days later, mice 
were injected with InsB15-23 (50µg) and poly I:C (100µg) i.p. or left unimmunised. Five days later, the 
total number of G9 Tmem (CD45.1+CD8+Kd:Ins+Vβ6+) (A), G9 Tmem (CD45.1+CD8+Kd:Ins+Vβ6+) as 
a proportion of total CD8+ T cells (B), the total number of G9 Tmem (CD45.1+CD45.2-CD8+Vβ6+ in 
NOD and proinsulin transgenic) (C), G9 Tmem (CD45.1+CD45.2-CD8+Vβ6+ in NOD and proinsulin 
transgenic) as a proportion of total CD8+ T cells (D) and the total number of spleen cells (E) were 
determined using flow cytometry. The non-fasting BGL (mM) of NOD mice was determined at time 
of cull and the table shows mean±S.D (F). The number of IFN-γ-producing cells in spleen of recipients 
was determined using ELISPOT (G, H). (G) Representative images from InsB15-23-stimulated wells. 
Data are from two independent experiments. Each point represents a single mouse. Error bars shown 
S.D. The dashed line shows the mean frequency of Kd:LLO (control) tetramer-binding CD8+ T cells. 
One-way ANOVA followed by Tukey post-test. (*p<0.05, **p<0.01, ****p<0.0001). 
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Table 4.1 Summary of Chapter 4   
 B16A NOD Proinsulin 
transgenic 
Proliferation No pLN only Yes, in all sites 
analysed 
Absolute number n/a Slow decrease (by 21 
days after transfer) 
Rapid decrease (by 7 
days after transfer) 
Proportion (of total 
CD8+ cells) 
Unchanged Accumulation in pLN 
(at day 3) followed by 
slow decrease in all 
sites analysed (by day 
21) 
Rapid decrease (by day 
7) 
TCR down-
regulation  
No No Yes 
IFN-γ production Yes Yes (at day 7 
following transfer) 
No 
Recall response  Yes No increase in G9 
Tmem number 
following 
immunisation 
No 
Figure 4.16 – Summary of main findings from Chapter 4.  
This table represents summarised data from Chapter 3. ‘Proliferation’ refers to Figure 4.5, ‘Absolute 
number’ and ‘proportion’ refer to Figure 4.6 and Figure 4.7, ‘TCR down-regulation’ refers to Figure 
4.12, ‘IFN-γ production’ and ‘Recall response’ refer to Figure 4.13 and Figure 4.15.   
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4.3 Discussion  
Induction of peripheral tolerance in naïve CD8+ T cells has been studied widely, whereas 
this has not been investigated as extensively for CD8+ Tmem. To an even lesser extent have studies 
examined tolerance induction in CD8+ Tmem specific for self-antigens in the context of 
autoimmune disease. In this chapter, transgenic expression of proinsulin in MHC class II+ APC as a 
means to induce peripheral tolerance in insulin-specific CD8+ Tmem was investigated. After 
activation with InsB15-23, G9 T cells rapidly transfer autoimmune diabetes to NOD.SCID recipients 
(Wong et al., 2009). Naïve G9 T cells are not diabetogenic and as such may be more amenable to 
tolerogenic signals in the periphery, due to being maintained in a naïve state (Fig. 3.1) in G9 mice 
despite expression of their cognate antigen, InsB15-23, in the thymus and the periphery. In the present 
study, G9 T cells were cultured in the presence of InsB15-23 and IL-2 for three days and IL-15 alone 
for a further two days. The resulting CD8+ T cells displayed a memory-like phenotype and secreted 
IFN-γ, consistent with TEM differentiation. It could therefore be hypothesized that G9 Tmem are 
less likely, compared to their naïve counterparts, to undergo peripheral tolerance induction after 
transfer to proinsulin transgenic mice. The data in this chapter, however, suggest transgenic 
expression of proinsulin provides robust tolerogenic signals to induce tolerance in a mixed 
population of insulin-specific TEM and TCM. 
G9 T cells were activated by InsB15-23 (23 Gly) in vitro, as indicated by CD69 up-regulation. 
Synchronously, an increase in FSC fluorescence was observed with addition of InsB15-23 (23 Gly), 
indicating blastogenesis, further validating activation of G9 T cells. Whilst there was no difference 
in the proportion of activated G9 T cells, a reduced concentration of the higher affinity APL InsB15-
23 (23 Val) was required for maximal G9 T-cell activation compared to stimulation with native 
InsB15-23 (23 Gly), consistent with a previous study (Wong et al., 2002). As a high-affinity 
TCR/peptide interaction (Hogquist et al., 1994), OT-I T cells and the agonist peptide OVA257-264 
was assessed in the present study. The kinetics of OT-I T cells in response to OVA257-264 stimulation 
was similar to previously published findings (Salmond et al., 2014), although the peptide 
concentration required for maximal T-cell activation was lower in the present study. This could be 
due to different stimulation periods, 18 hours in the present study compared to 4 hours in the study 
by Salmond et al. Overall, the outcomes of the peptide titration studies confirmed G9 T cells exhibit 
a low affinity for their cognate determinant from insulin.  
The method of generating a mixed population of insulin-specific CD8+ TEM and TCM 
employed here was based on widely-accepted protocols and has been validated for investigating 
antigen-specific effector/memory T-cell responses (Carrio et al., 2004; Klebanoff et al., 2005; 
Manjunath et al., 2001; Weninger et al., 2001). In vitro-cultured OT-I Tmem displayed similar 
kinetics compared to long-lived in vivo-generated OT-I Tmem in response to transgenic OVA 
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expression targeted to CD11chi DC (Kenna et al., 2008). G9 Tmem in the present study displayed a 
phenotype similar to that of OT-I T cells cultured under equivalent conditions (Kenna et al., 2008). 
Despite G9 Tmem displaying a similar phenotype to OT-I Tmem, it is possible that there would be 
differences in tolerance outcomes between the in vitro-generated G9 Tmem used in the present 
study and in vivo-generated G9 Tmem. To test whether this was the case, G9 T cells would be 
transferred to congenic B16A recipients, the B16A recipients immunised with InB15-23/poly I:C and 
six weeks later TEM and TCM sorted from recipients. These in vivo-generated G9 Tmem could then 
be transferred to recipients alongside with in vitro-generated G9 Tmem and analyses performed 
accordingly. It is possible that the more implicit signals available to G9 T cells during culture skew 
the ‘memory’ phenotype toward one more readily amenable to peripheral tolerance induction. The 
aforementioned experiment may address this. With regard to effector differentiation, G9 T cells 
displayed an activated, effector-like phenotype after stimulation with InsB15-23 and IL-2, expressing 
similar levels of CD44 and CD62L at day 3 of culture compared to OT-I T cells stimulated with 
OVA257-264 and IL-2 (Salmond et al., 2014). Salmond et al. reported little KLRG1 and IL-7Rα 
expression on the surface of OT-I CTL which was similar with the phenotype of G9 T cells at day 3 
of culture in the present study. Salmond et al. also reported intracellular expression of granzyme B 
by effector differentiated OT-I T cells. Unstimulated OT-I T cells were not included in the analysis 
by Salmond et al., therefore, background staining on naïve T cells, as observed for G9 T cells in 
Figure 4.3, cannot be conclusively ruled out. To skew effector G9 T cells present at day 3 toward a 
memory-like phenotype, T cells were cultured for a further two days in the presence of IL-15, since 
IL-15 has been shown to maintain the memory phenotype of CD8+ T cells in the absence of antigen 
(Liu et al., 2002). At the end of the culture period, in the absence of InsB15-23 and the presence of 
IL-15, G9 Tmem displayed reduced expression of co-inhibitory markers PD-1, LAG-3 and CTLA-
4, consistent with development from post-activated effector T cells to Tmem. Tmem represent a 
heterogenous population of TEM and TCM (Olson et al., 2013), therefore investigating the response 
of a mixed population of insulin-specific TEM and TCM to transgenic proinsulin expression was valid 
and physiologically relevant.  
It might be possible that a recently identified subset of TEM, termed tissue-resident effector 
memory T cells (TRM), play an important role in diabetes pathogenesis. TRM express CD69 and 
CD103, do not recirculate and have been identified in the intestinal epithelium and the epidermis of 
the skin (Carbone, 2015). One study indicated expression of CD69 and CD103 on TEM within the 
pancreas, potentially indicating the presence of TRM in this site (Casey et al., 2012). Since TRM 
represent a population of potentially long-lived TEM with potent effector function, pancreas-residing 
TRM may prove another barrier to an immunotherapeutic treatment for T1D. Another study 
demonstrated CD103 expression on CD8+ T cells was necessary for rejection of islet grafts (Feng et 
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al., 2002). Additional studies are required to further characterise and quantify potential pancreas-
residing TRM, then it may be possible to investigate the role of these TRM in the context of 
autoimmune diabetes and how this could be manipulated in a therapeutic approach.  
G9 Tmem proliferated to a lesser extent than naïve G9 T cells in pLN of NOD recipients. 
This is seemingly in contrast to the long-standing dogma that Tmem are more readily activated and 
responsive to antigen than their naïve counterparts (Curtsinger et al., 1998; Tanchot et al., 1997). 
There is recent evidence, however, to suggest this may not always hold true. Transferred naïve OT-I 
T cells proliferated to a greater extent than OT-I TCM in pLN of mice expressing OVA in the islets 
(Mehlhop-Williams & Bevan, 2014). This observation is analogous to the reduced proliferation of 
G9 Tmem, compared to naïve G9 T cells, in pLN of NOD recipients in the present study. Also, G9 
Tmem comprise approximately 60% TCM, which when considering TCM might proliferate less than 
naïve T cells in response to cross-presented antigen, may account for the reduced proliferation of 
G9 Tmem compared to naïve G9 T cells in response to islet-derived insulin. The evidence 
suggesting naïve T cells proliferate more so in response to limited amounts of antigen may hold true 
in the present study as young, male NOD were used as recipients and it might be expected that islet 
inflammation would be mild in these mice, and therefore a reduced co-stimulatory environment 
with presentation of insulin determinants compared to that of older female NOD mice. It might be 
possible that G9 Tmem proliferate to a greater extent in pLN of older, female NOD recipients 
compared to the young, male NOD recipients used. This is true for IGRP-reactive CD8+ T cells, as 
8.3 T-cell proliferation in pLN has been shown to be increased with the age of NOD recipients 
(Krishnamurthy et al., 2006). Work from the host laboratory suggests transfer of G9 Tmem to pre-
diabetic female NOD mice triggers accelerated β-cell damage and subsequent hyperglycaemia. 
Also, G9 Tmem secrete IFN-γ following in vitro InsB15-23 re-stimulation, which indicates rapid 
production of cytotoxic mediators with less antigen requirement, that is, in the absence of InsB15-23 
immunisation, than naïve G9 T cells. Programming of G9 thymocytes during thymic selection in the 
presence of thymic insulin presentation may account for the reduced G9 Tmem response observed 
in response to islet-derived insulin presentation. Despite the extensive use of TCR transgenic CD8+ 
T-cell models to investigate peripheral T-cell tolerance, a pertinent issue that is not addressed is the 
effect of thymic selection in the presence of cognate antigen on the CD8+ T cell. Data from the 
present study indicate targeting proinsulin expression to MHC class II+ APC induces rapid deletion 
and unresponsiveness in insulin-specific CD8+ Tmem, and this was despite thymic selection of G9 
thymocytes in the presence of insulin antigen.  
The reduced recall ability of G9 Tmem (Fig. 4.13) compared to naïve G9 T cells (Fig. 3.12) 
following InsB15-23 immunisation was somewhat unexpected when the robust IFN-γ response of G9 
Tmem in B16A recipients (Fig. 4.4) was considered. Naïve G9 T cells mounted, albeit a weak, 
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recall response in immunised NOD, but not B16A, recipients (Fig. 3.12). G9 Tmem, however, 
mounted a robust recall response indicated by increased production of IFN-γ in B16A recipients 
following InsB15-23 immunisation. In contrast, no increase in IFN-γ production was observed for 
NOD recipients following immunisation. The robust recall response of G9 Tmem, compared to 
naïve G9 T cells, in B16A recipients could be explained by priming of G9 T cells during culture, 
suggesting G9 T cells require more than a single round of priming to respond to InsB15-23 
immunisation. The absence of G9 Tmem expansion in NOD recipients after immunisation might 
have been a result of low G9 Tmem proliferation in response to islet-derived insulin. It is possible 
that the increased PD-1 expression by G9 Tmem, compared to naïve G9 T cells, inhibited the G9 
Tmem recall response in the present study, and this could be elucidated by blocking PD-1 in the G9 
Tmem adoptive transfer setting. An important point to be taken from defining the G9 Tmem 
dynamics in response to InsB15-23 immunisation is the absence of G9 Tmem expansion after transfer 
to proinsulin transgenic recipients in any site investigated, indicating the residual population of G9 
Tmem in proinsulin transgenic recipients are functionally inactive.  
Differences in the recall ability of Tmem subsets might explain variation in the recall ability 
of naïve G9 T cells compared to G9 Tmem in the present study. Due to the increased recovery of 
transferred G9 Tmem in spleen, compared to LN, this was the site of analysis for recall response 
experiments and TEM are predominantly found in spleen compared to LN (Brinkman et al., 2013). 
TCM expand in number in response to immunisation while TEM proliferate little but produce 
cytolytic mediators (Olson et al., 2013). While applying such analyses as in the present study to a 
mixed population of Tmem is physiologically relevant in the context of autoimmunity, there is the 
possibility that interpretation of Tmem responses to immunisation may be skewed, that is, 
expansion in TCM, for example, might be concealed by the reduction of TEM. At twenty one days 
after transfer, there was no difference in the proportion of TEM-like and TCM-like G9 Tmem in 
B16A and NOD recipients, it is unknown whether this would be the same at earlier time points. It is 
plausible that in spleens of B16A recipients, G9 TEM and TCM might comprise a different proportion 
compared to that in spleens of NOD recipients due to islet-derived insulin presentation modulating 
G9 Tmem trafficking into and out of the spleen in NOD recipients. This may account for the 
different responses of G9 Tmem to InsB15-23 immunisation observed for NOD and B16A recipients. 
Studies employing soluble peptide administration as a means of T-cell tolerance induction 
have shown different outcomes depending on the dose and affinity of peptide used. Using clone 4 T 
cells, it was shown that administration of a Kd-HA super agonist resulted in unresponsiveness of 
transferred clone 4 T cells (Smith et al., 2014). Unresponsive clone 4 T cells expressed high levels 
of PD-1 and the number of clone 4 T cells in spleen was similar to PBS-treated controls. In contrast, 
clone 4 T cells were deleted in recipient mice after administration of a weak agonist APL of HA. 
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After treatment with a weak agonist APL, clone 4 T cells expressed lower levels of PD-1 and were 
less frequent in spleen than those treated with native peptide, which may be indicative of T-cell 
deletion. However, a lower dose of strong agonist peptide was used as a comparison to the weak 
agonist peptide, that is, 1µg and 10µg, respectively, in the study by Smith et al. and the difference 
in peptide dose may have affected the T-cell tolerance outcomes observed. Therefore, this study 
suggests different T-cell tolerance outcomes are possible depending on the strength of TCR/peptide-
MHC interactions. Clone 1 T cells differ from clone 4 T cells in that they express a transgenic HA-
specific TCR cloned from CD8+ T cells recovered from mice expressing HA in the islets and 
thymus (Lyman et al., 2005) and thus express a low-affinity TCR. Clone 1 T cells are similar to G9 
T cells in that both T cells have undergone thymic selection in the presence of their cognate antigen. 
Most clone 1 T cells were deleted following HA-peptide administration recipients, yet a population 
of clone 1 T cells expressing PD-1 persisted after peptide administration, potentially indicating 
unresponsiveness and this was in contrast to the complete deletion of clone 4 T cells following 
weak agonist peptide administration. While PD-1 has been examined on T cells with regard to 
unresponsiveness, PD-1 is increased on CD8+ T cells after activation and PD-1 expression has been 
implicated in shaping the Tmem population. It has been shown that PD-1 expression may inhibit 
conversion of TCM to TEM (Charlton et al., 2013), and in the absence of PD-1, homeostatic 
expansion of CD4+ T cells resulted in a skew toward TEM-like phenotype (Charlton et al., 2015). 
Overall, the data from Smith et al. suggest T cells with low-affinity TCR may undergo inefficient 
tolerance induction in response to peptide administration. The response of clone 1 T cells to peptide 
administration can be contrasted to the robust, effective tolerance observed for low-affinity G9 
Tmem in recipient mice over-expressing proinsulin, emphasising the different tolerance outcomes 
between peptide antigen administration and when antigen is targeted to MHC class II-expressing 
APC.  
IL-7 is a crucial cytokine for CD8+ Tmem survival (Tan et al., 2002) and in some settings 
IL-7 can promote autoreactive T-cell expansion (Calzascia et al., 2008). Blocking IL-7Rα was 
shown to not only prevent but also reverse hyperglycemia in NOD mice (Lee et al., 2012a). IL-7Rα 
blockade favoured PD-1 up-regulation on effector T cells using a BDC2.5 T-cell adoptive transfer 
model and PD-1 involvement was further implicated as PD-1 blockade reversed normoglycemia in 
IL-7Rα blockade-cured NOD mice. Similarly, Penaranda et al. demonstrated reversal of 
hyperglycemia in NOD mice by IL-7Rα blockade and PD-1 was implicated in this reversal also 
(Penaranda et al., 2012). The number of Tmem within pLN was not reduced after anti-IL-7Rα 
treatment, but the ability of Tmem to produce IFN-γ and to transfer diabetes to NOD.SCID mice 
was impaired, consistent with inhibition afforded by PD-1 expression rather than a deletional 
mechanism. In the context of islet transplantation, blocking IL-7Rα protected allogeneic islet grafts 
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from rejection in streptozotocin (STZ)-induced diabetic mice (Mai et al., 2014). Yet again, 
protection was associated with reduced T-cell IFN-γ production and PD-1 expression. Therefore, 
inhibiting Tmem responses is beneficial in impeding diabetes development in NOD mice. From the 
perspective of immunotherapy development, however, a more targeted, antigen-specific approach 
would be favourable and as such, the present study has demonstrated insulin-specific CD8+ Tmem 
are rapidly inactivated when proinsulin is expressed under control of an MHC class II promoter.  
A clinical trial has tested whether depletion of TEM in recent-onset T1D patients had any 
effect on disease progression (Rigby et al., 2013). In this study, a dimeric fusion protein, alefacept, 
was used to target CD2-expressing TEM and was shown to deplete TEM more readily than TCM. 
Rigby et al. rationalised that this was a more selective method of pathogenic T-cell depletion, with 
less widespread immunosuppression than general immune suppressive agents such as cyclosporine. 
At one year follow-up, alefacept-treated patients showed a reduction in CD4+ TEM and TCM 
populations and reduced CD8+ TCM compared to placebo-treated patients, while CD4
+Foxp3+ Treg 
were unaltered. Most encouragingly, insulin use had decreased as a result of alefacept treatment. An 
issue not thoroughly addressed in the study by Rigby et al. was maintenance of protective 
immunity, and assessment of patient responses to common viral pathogens may have elucidated 
this, at least to some extent. These immunological and metabolic outcomes suggest targeting TEM 
and TCM populations using a therapy which maintains Treg may be a useful approach for treatment 
of T1D. Therefore, taking the notion of ‘selective therapy’ one step further and deleting 
diabetogenic TEM and TCM in a β cell antigen-specific manner might allow for interruption of 
pathogenic islet autoimmunity without compromising protective immunity. 
Overall, this chapter investigated peripheral tolerance induction in insulin-specific CD8+ 
Tmem. A method of generating G9 Tmem was established using in vitro culture and verified by 
analysis of phenotypic markers. G9 Tmem were shown to proliferate extensively in proinsulin 
transgenic recipients while the number of G9 Tmem recovered from secondary lymphoid organs 
rapidly decreased. The remaining population of G9 Tmem in proinsulin transgenic recipients was 
minimal and displayed reduced TCR expression than those in NOD recipients. Similarly to naïve 
G9 T cells, G9 Tmem did not expand or produce IFN-γ in response to InsB15-23 immunisation in 
proinsulin transgenic recipients. These observations in proinsulin transgenic recipients are 
consistent with the rapid in activation of OT-I Tmem in MII.OVA mice. In NOD recipients, G9 
Tmem waned slowly overtime in secondary lymphoid organs and prior to this contraction, G9 
Tmem produced IFN-γ without InsB15-23 immunisation. In the absence of cognate antigen, that is, in 
B16A recipients, the number of G9 Tmem was maintained and G9 Tmem produced IFN-γ twenty 
one days after transfer. Therefore, insulin-specific CD8+ TCM and TEM are rapidly inactivated after 
transfer to mice which transgenically express proinsulin under control of an MHC class II promoter, 
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consistent with the induction of peripheral tolerance. Since transgenic expression of proinsulin 
induces rapid inactivation in naïve and memory G9 T cells, it would be logical to then determine the 
effect on diabetes development of introducing tolerogenic proinsulin expression in non-transgenic 
NOD mice. The following chapter will examine the effect of proinsulin-encoding HSPC/BM 
transfer on diabetes development in sub-lethally conditioned NOD recipients.  
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4.4 Future directions 
This chapter has addressed tolerance induction in CD8+ Tmem specific for an important islet 
antigen, insulin. Since male NOD mice develop insulitis and subsequent autoimmune diabetes to a 
reduced extent than female, it may be possible that reduced islet inflammation in male NOD 
recipients would alter the response of G9 Tmem to islet-derived insulin presentation. It is important 
to address the effect of increased islet inflammation, as seen in pre-diabetic female NOD mice, on 
the slow deletion of G9 Tmem. To test this, G9 Tmem could be transferred to male and female 
NOD recipients at ages, that represent different, defined stages of diabetes development and then 
effector function assessed. Furthermore, G9 Tmem proliferation in pLN of NOD mice was reduced 
compared to naïve G9 T cells. Since a proportion of G9 Tmem expressed PD-1 prior to transfer, this 
may explain the reduced proliferation of G9 Tmem to islet-derived insulin presentation and the 
involvement of PD-1 could be examined by blocking PD-1 or PD-L1 in NOD recipients. G9 Tmem 
expression of PD-1 may also explain the reduced recall response to immunisation of G9 Tmem 
compared to naïve G9 T cells. PD-1/PD-L1 blockade and immunisation might elucidate whether 
this is the case. Finally, G9 Tmem displayed effector function as demonstrated by IFN-γ 
production, therefore, G9 Tmem may contribute to diabetes progression in NOD mice. To test this, 
G9 Tmem would be transferred to male and female NOD and proinsulin transgenic recipients and 
6-8 weeks later, just prior to diabetes onset, pancreas and secondary lymphoid organs could be 
analysed for β-cell antigen-specific CD8+ T cells as indicators of islet autoimmunity.  
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Chapter 5 
Transfer of proinsulin-encoding BM and IL-2/αIL-2 complex alter 
diabetes development in an age-dependent manner 
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5.1 Introduction 
The previous chapter investigated tolerance induction in G9 Tmem. Since the potentially 
diabetogenic T cells were rapidly inactivated after transfer to mice expressing transgenic proinsulin, 
the question is raised whether introducing tolerogenic proinsulin expression and, as a consequence, 
tolerance to insulin would affect diabetes development in non-transgenic NOD mice. OT-I T cells 
are inactivated in non-transgenic recipients after OVA-encoding BM transfer (Coleman et al., 
2013). BM transfer is, therefore, a means to possibly instate the tolerogenicity of transgenic 
proinsulin expression in non-transgenic NOD recipients. Antigen-encoding BM/HSPC transfer 
might represent a clinical approach to developing an immunotherapy which requires cognate T-cell 
inactivation.  
Re-placing the haematopoietic compartment of NOD mice by transfer of allogeneic BM 
from non-autoimmune-prone BALB/c mice prevents autoimmune diabetes (Ikehara et al., 1985). In 
addition, transfer of purified, allogeneic HSC protects NOD mice from diabetes after lethal 
irradiation (Beilhack et al., 2003). Therefore, diabetes protection by means of allogeneic HSC 
transplantation suggests an immunological re-set from a diabetogenic repertoire to one tolerant to β-
cell antigens is possible. Transplantation of allogenic BM/HSPC poses substantial risks such as 
highly toxic conditioning regimens, graft rejection and graft-versus-host disease (GVHD) [reviewed 
in (Leventhal et al., 2013; Ramadan & Paczesny, 2015)]. Transplantation of autologous HSPC/BM, 
however, might negate at least some risks associated with such toxic procedures. Transfer of 
autologous, mobilised HSPC after sublethal, yet relatively high dose, irradiation (800cGy) protected 
6-week old NOD recipients from autoimmune diabetes and this protection was attributed to 
expansion of Foxp3+ Treg (Kared et al., 2006). Re-setting of the diabetogenic immune compartment 
and subsequent protection from diabetes can be achieved even when autoimmune-prone NOD 
HSPC are transferred, suggesting the conditioning regimen itself affords protection from diabetes 
progression. In humans, transplantation of autologous HSC has proved to be one of the few 
efficacious therapies, in terms of metabolic outcome, for recent-onset T1D patients. Voltarelli et al. 
demonstrated that transplantation of autologous, mobilised HSC to T1D patients conditioned with 
high-dose cyclophosphamide and anti-thymocyte globulin resulted in insulin independence for a 
proportion of patients (Voltarelli et al., 2007). Immunologically, there was a reduction in the 
humoral response to GAD while metabolically, an increase in C-peptide was observed in HSC-
transplanted patients. Similarly, Li et al. demonstrated reduced exogenous insulin usage and 
increased C-peptide in a cohort of recent-onset Chinese T1D patients (Li et al., 2012). These 
promising human trials exemplify transplantation of autologous HSC as a means to overcome 
established β-cell autoimmunity. However, results from these trials suggest relapse is mostly 
inevitable, which might indicate a requirement for long-lasting immune tolerance to completely 
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reverse T1D. Ideally, such immune tolerance would be β-cell antigen-specific, directly impeding 
diabetogenic autoimmunity without compromising protective, anti-pathogen immune responses. 
Antigen-specific immunotherapy would be preferred to non-specific immunosuppression, such as 
anti-CD3 mAb therapy, that has been previously trialed in mice (Chatenoud et al., 1994) and 
humans (Keymeulen et al., 2010b), due to safety considerations such as EBV re-activation and T-
cell cytokine release, of particular consideration in the context of T1D due to the young age of 
onset. 
Since antigen-specific therapy represents a means to inactivate diabetogenic T-cell 
responses without compromising protective immunity, the question is raised as to which β-cell 
antigen might be targeted for tolerance induction. The notion of insulin as the primary antigen in 
autoimmune diabetes in NOD mice is exemplified by the fact that NOD mice in which proinsulin 
expression is under control of an MHC class II promoter are protected from insulitis and diabetes 
development (French et al., 1997). Whereas transgenic over-expression of other important β-cell 
antigens, IGRP (Krishnamurthy et al., 2006) and GAD65 (Jaeckel et al., 2003), does not protect 
NOD mice from diabetes. When proinsulin is transgenically expressed, the inherently diabetogenic 
repertoire of the NOD mouse is most likely regulated centrally and peripherally from birth, perhaps 
even in utero, instigating robust protection from autoimmune events that underlie diabetes 
development. Transfer of proinsulin-encoding HSPC to immune-ablated NOD mice protected from 
diabetes (Chan et al., 2006; Steptoe et al., 2003). The use of a conditioning regimen, required to 
create ‘space’ for HSPC reconstitution, that ablated the diabetogenic immune repertoire of NOD 
mice meant the transferred HSPC completely re-established the immune compartment, resulting in 
protection from diabetes. In an immune-ablated recipient, the pathogenic T cells have been cleared 
by the irradiation, therefore antigen-expressing APC, derived from transferred HSPC, are not 
required to actively induce T-cell tolerance in this setting. Considering T1D, when correctly 
managed, is generally not fatal, it is especially pertinent to ensure patient safety before any 
immunotherapy might be adopted clinically. Therefore, given the potential tolerogenic capacity of 
transgenic proinsulin expression to inactivate naïve and memory insulin-specific CD8+ T cells, it is 
advantageous to determine the efficacy of proinsulin-encoding BM/HSPC transfer on impeding 
diabetes development when performed under reduced intensity, immune-preserving conditions. 
Using Treg to impede β-cell autoimmunity in NOD mice has been achieved through various 
approaches including generation of an immunosuppressed, Treg-favoured environment (Battaglia et 
al., 2006), modulation of APC to promote Treg function (Richer et al., 2012) and recruitment of 
Treg to islets (Montane et al., 2011). A complex of IL-2 and an anti-IL-2 mAb, JES6-1, specifically 
expands Treg (Webster et al., 2009) and ameliorates hyperglycemia in diabetic NOD mice 
(Grinberg-Bleyer et al., 2010). It is plausible that expanding Treg synchronously with transfer of 
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proinsulin-encoding BM/HSPC might induce or expand (pro)insulin-specific Treg, mediating 
insulin-specific regulation as well as bystander suppression toward other β-cell specificities. An 
example of a combination therapy based on similar principles employed the T-cell modulator γ-
aminobutyric acid (GABA) and proinsulin administration which showed synergistic efficacy to 
restore glycemic control in recent-onset diabetic NOD mice (Tian et al., 2014). This combination 
therapy led to generation of antigen-specific Treg, inhibition of pathogenic T cells and regeneration 
of β cells, while there was minimal effect of either therapy individually. A similar effect was 
observed with combination therapy involving GAD65 and GABA which increased survival of islet 
grafts in diabetic NOD mice (Tian et al., 2011). These studies emphasise the potential of 
combinatory approaches which boost Treg and supply antigen, to synergise and induce tolerance 
which results in a disease-relevant outcome. Therefore, this chapter assesses whether coupling Treg 
expansion with proinsulin-encoding BM/HSPC transfer will enhance the tolerogenicity of 
BM/HSPC transfer to instate tolerance to β-cell antigens and inhibit diabetes development.  
In this chapter, I investigate the effect of introducing transgenic proinsulin expression on 
diabetes development in wild type NOD recipients. Firstly, donor-type leukocyte development was 
assessed in recipients of proinsulin transgenic BM after low-dose irradiation. Secondly, the efficacy 
of an IL-2/αIL-2 complex to expand Treg was assessed in NOD mice. Finally, proinsulin transgenic 
BM/HSPC were transferred to NOD mice at defined ages and diabetes incidence was assessed to 
determine the disease stage at which proinsulin-encoding BM/HSPC transfer altered diabetes 
development. IL-2/αIL-2 complex was administered to BM/HSPC recipients to determine whether 
this therapy synergises with tolerogenic BM/HSPC transfer.  
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5.2 Results 
5.2.1 BM from proinsulin transgenic mice is not rejected after transfer to sublethally irradiated 
NOD mice 
It has been shown that BM encoding a neo-antigen is susceptible to immune-mediated 
rejection if the neo-antigen is expressed ubiquitously or in components of BM, such as HSC, that 
are required for engraftment under immune-preserving conditions (Eixarch et al., 2009; Rosenzweig 
et al., 2001). One means to prevent rejection of antigen-encoding BM is to restrict neo-antigen 
expression to differentiated APC using APC-specific promoters which protects the engrafting 
components, that is, HSPC, from antigen-specific immune destruction. In C57BL/6 mice, HSC 
transiently express MHC class II and MHC class II-promoter controlled OVA expression in HSC 
lead to their immune rejection after transfer (Coleman et al., 2013). Such immune rejection might 
also occur after transfer of proinsulin transgenic BM, if the proinsulin expressed from the MHC 
class II promoter used becomes a target for immune attack. To test this in NOD mice where 
proinsulin-specific T-cell responses are likely present, CD45 congenic NOD mice (CD45.1-
CD45.2+) were irradiated (300cGy) and proinsulin transgenic (CD45.1+CD45.2-) or NOD 
(CD45.1+CD45.2-) BM transferred. Development of donor-type leukocytes was assessed in 
peripheral blood at defined time points and in spleen six weeks after transfer as an indicator of 
donor BM engraftment.  
The proportion of donor-type cells in peripheral blood increased in a time-dependent manner 
after transfer of BM (Fig. 5.1A). Donor-type leukocyte development was marginally higher in 
recipients of NOD compared to proinsulin transgenic BM at two and four weeks after transfer but 
this difference was not observed at six weeks after transfer of BM (Fig. 5.1A). This suggests, 
perhaps, a more rapid development of NOD compared to proinsulin transgenic-derived leukocytes, 
but that engraftment, once established, was overall similar. Donor-type DC, B cells and myeloid 
cells all increased in a time-dependent manner in recipients, and this did not differ between 
recipients of NOD and proinsulin transgenic BM (Fig. 5.1B-D). Notably, donor-type CD8+ and 
CD4+ T cells increased more slowly than other cell subsets but was similar for recipients of 
proinsulin transgenic and NOD BM (Fig. 5.1E, F). To validate observations from peripheral blood, 
the frequency of donor-type leukocytes was compared between peripheral blood and spleen. Six 
weeks after transfer of BM, the proportion of donor-type leukocytes was somewhat lower in spleen 
than peripheral blood for both recipients of proinsulin transgenic and NOD BM, but overall there 
was no difference in the frequency of donor-type leukocytes in spleen between recipient groups 
(Fig. 5.2A). The proportion of donor-type myeloid cells was marginally lower in spleen than blood 
of recipients of proinsulin transgenic BM, yet this was not different in recipients of NOD BM (Fig. 
5.2D). There was no significant difference between spleen and peripheral blood in the proportion of 
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other donor-derived leukocyte subsets at this time point (Fig. 5.2B, C, E, F) nor was there a 
difference between recipients of proinsulin transgenic and NOD BM for each cell subset analysed 
(Fig. 5.2B-F). There was a trend toward a decreased donor-type B cells and myeloid cells in spleen 
compared to peripheral blood of proinsulin transgenic and NOD BM recipients (Fig. 5.2C, D). 
While not significant, this might account for the reduced proportion of donor-type leukocytes in 
spleen compared to peripheral blood of BM recipients (Fig. 5.2A). However, a substantial level 
(greater than 50%) of donor chimerism was still observed in spleen of recipients of proinsulin 
transgenic and NOD BM (Fig. 5.2A). 
The engraftment studies described above indicate that BM expressing MHC class II 
promoter-controlled proinsulin was not rejected in recipients which differs from that observed for 
BM expressing OVA under control of an MHC class II promoter. HSC from C57BL/6 mice 
transiently express MHC class II which resulted in priming of OVA transgene-specific T-cell 
responses and subsequent rejection of OVA-encoding BM when OVA was expressed under an 
MHC class II promoter (Coleman et al., 2013). It is possible that HSC from NOD mice do not 
express MHC class II, thereby permitting the observed engraftment of proinsulin transgenic BM in 
wild type NOD recipients. To test this, surface expression of MHC class II, I-Ag7, was determined 
on various mature and progenitor cell subsets within non-transgenic NOD BM. A small proportion 
of lin-c-kit+ progenitor cells expressed I-Ag7 (Fig. 5.3). A similar trend for I-Ag7expression was 
observed on the less differentiated c-kit+sca-1+ and c-kit+sca-1+CD135- populations (Fig. 5.3). With 
the caveat of minimal cells in the lin-c-kit+sca-1+CD135-CD48-CD150+ long-term repopulating 
HSC (LT-HSC) population to analyse, there appeared to be a small shift in the level of I-
Ag7expression relative to isotype control (Fig. 5.3). These results indicate HSC in NOD mice may 
express MHC class II, particularly in the LT-HSC population, which might lead to expression of the 
proinsulin II transgene by LT-HSC. In this experiment the only control for I-Ag7 mAb binding was 
the level of relevant isotype control staining. To more stringently control for non-specific binding of 
the anti-I-Ag7 mAb, and to allow for more accurate interpretation of these data, I-Ag7 expression 
was assessed on known MHC class II-expressing and MHC class II-negative mature cell 
populations. CD11chi DC and CD19+B220+ B cells served as positive controls for MHC class II 
expression as both DC and B cells express MHC class II in NOD mice (De Riva et al., 2013). I-Ag7 
expression was observed on a substantial proportion of B cells and DC within NOD BM (Fig. 5.3). 
On the other hand, T cells do not express MHC class II and were used to assess the level of non-
specific binding of the anti-I-Ag7 mAb. As expected, both CD3+CD4+ and CD3+CD8+ T cells 
displayed nominal I-Ag7expression compared to B cells and DC (Fig. 5.3).With regard to progenitor 
cell subsets in experiment 2, low I-Ag7 expression by lin-c-kit+ progenitors cells was observed when 
compared to the isotype control (Fig. 5.3). Similarly, only a very small proportion of cells from the 
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less differentiated subsets displayed I-Ag7 expression (Fig. 5.3). When LT-HSC were analysed, a 
marginal increase in I-Ag7 expression was observed relative to the isotype control (Fig. 5.3). Due to 
variation observed between two individual experiments, further investigation is required regarding 
I-Ag7 expression by HSPC from NOD mice. However, these data are to some extent consistent with 
the study by Coleman et al. demonstrating MHC class II expression on LT-HSC in C57BL/6 mice. 
It should also be noted that directly measuring expression of the proinsulin transgene using PCR 
could be used in conjunction with antibody-mediated detection of MHC class II to ascertain 
whether proinsulin transgene expression by HSC occurs in this setting and if so, why this proinsulin 
transgene expression precludes immune rejection of transferred BM/HSPC facilitated by low-dose 
irradiation.  
Transfer of proinsulin transgenic and NOD BM after low-dose irradiation allows for a high 
level of donor-type leukocyte development, particularly in APC subsets, presumably as a result of 
effective engraftment. The similarity in the frequency of donor-type leukocytes observed in blood 
and spleen validates using peripheral blood to assess donor engraftment. The evidence suggests 
HSPC from NOD mice might express MHC class II but this needs to be investigated further. These 
data demonstrate BM encoding proinsulin under control of an MHC class II promoter is not rejected 
in wild type NOD recipients after low-dose irradiation and thus BM transfer provides a means to 
instate the potentially tolerogenic capacity of transgenic proinsulin expression to wild type NOD 
recipients.   
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Figure 5.1 – No difference in donor-type leukocyte development in peripheral blood from 
recipients of proinsulin transgenic and NOD BM. 
NOD.CD45.2 (CD45.1-CD45.2+) mice were irradiated (300cGy) prior to transfer of 2x107 bulk BM 
cells from NOD (CD45.1+CD45.2-, blue) or proinsulin transgenic (CD45.1+CD45.2-, red) mice. At 
indicated time points, the proportion of donor-type (CD45.1+CD45.2-) total donor cells (A), DC 
(CD11chi) (B), B cells (B220+) (C), myeloid cells (CD11b+) (D), CD8+ T cells (E) and CD4+ T cells 
(F) were determined in peripheral blood using flow cytometry. Data are pooled from two independent 
experiments. n=4-5. Error bars show S.D. Two-way ANOVA followed by Bonferroni post-test. 
(**p<0.01: proIns Tg vs NOD). 
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Figure 5.2 – Substantial donor-type leukocyte development in spleen from recipients of NOD 
and proinsulin transgenic BM.  
NOD.CD45.2 (CD45.1-CD45.2+) mice were irradiated (300cGy) prior to transfer of 2x107 bulk BM 
cells from NOD (CD45.1+CD45.2-) or proinsulin transgenic (CD45.1+CD45.2-) mice. Six weeks later, 
the proportion of donor-type (CD45.1+CD45.2-) total donor cells (A), DC (CD11chi) (B), B cells 
(B220+) (C), myeloid cells (CD11b+) (D), CD8+ T cells (E) and CD4+ T cells (F) were determined in 
peripheral blood and spleen using flow cytometry. Data are pooled from two independent experiments. 
Each point represents a single mouse. One-way ANOVA followed by Tukey post-test. Error bars show 
S.D. (*p<0.05, **p<0.01, ***p<0.001). 
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Figure 5.3 – HSPC from NOD BM express variable levels of MHC class II.  
BM from NOD mice was harvested and I-Ag7 expression on mature, lin-positive leukocyte subsets and 
HSPC was determined using flow cytometry. (A) Gating strategy of HSPC populations in descending 
order of reduced differentiation and (B) I-Ag7 (solid line) and isotype (dashed line) expression on 
CD3+CD4+ T cells, CD3+CD8+ T cells, B220+CD19+ B cells, CD11c+CD19- DC, lin+c-kit- mature BM 
cells, lin-c-kit+ HPC, lin-c-kit+sca-1+ HSC, lin-c-kit+sca-1+CD135- HSC and lin-c-kit+sca-1+CD135-
CD48-CD150+ LT-HSC. Data are from two independent experiments. 
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5.2.2 IL-2/αIL-2 complex expands Treg in spleen and LN of NOD mice 
Transfer of proinsulin-encoding BM as an approach to induce insulin-specific CD8+ T-cell 
tolerance in NOD mice might be benefited by concurrently enhancing Treg activity. Treatment with 
a cytokine/antibody complex comprised of IL-2 and the anti-IL-2 mAb, JES-61 (IL-2/αIL-2), 
expands Treg in C57BL/6 mice (Webster et al., 2009). To determine whether Treg are expanded 
and the dynamics of this in NOD mice, IL-2/αIL-2 complex or PBS was administered to NOD mice 
for three consecutive days and the total number, frequency and phenotype of Treg analysed in 
spleen and LN at defined time points. Little change was observed in the total number of 
CD4+FoxP3+ Treg or their proportion of total CD4+ T cells in spleen after one or two days of IL-
2/αIL-2 treatment (Fig. 5.4A, B). However, three days after the third and final administration of IL-
2/αIL-2, the number of CD4+FoxP3+ Treg and their proportion of CD4+ T cells in spleen was 
increased almost two-fold over PBS-treated mice (Fig. 5.4A, B). The total number and proportion 
of Treg of total CD4+ T cells peaked at this time and remained elevated for at least four days after 
treatment (Fig. 5.4A, B). As expected, neither the number nor proportion of Treg were altered in 
PBS-treated mice (Fig. 5.4A, B).  
In LN, little change was observed in the total number and proportion of Treg after two days 
of IL-2/αIL-2 treatment (Fig. 5.4C, D). An increase in the total number of Treg was observed on the 
final day of IL-2/αIL-2 treatment and the number of Treg peaked two days after cessation of 
treatment (Fig. 5.4C). The increase in Treg number was transient, and by four days after cessation 
of treatment the number of Treg in LN of IL-2/αIL-2-treated mice returned to the level observed in 
PBS-treated mice (Fig. 5.4C). The number and proportion of Treg in LN was not altered in PBS-
treated mice (Fig. 5.4C, D). In LN of IL-2/αIL-2-treated mice, the proportion of Treg of total CD4+ 
T cells was increased at one day after cessation of treatment and this increase was maintained until 
at least four days after treatment (Fig. 5.4D). The pattern of Treg expansion, defined as a proportion 
of total CD4+ T cells, was similar in LN and spleen, although the proportion of Treg in the total 
CD4+ T cell population was lower in LN than in spleen (Fig. 5.4B, D). These data confirm Treg 
expansion in spleen and LN of NOD mice after treatment with IL-2/αIL-2 and this may represent a 
therapeutic option in NOD mice to expand Treg, which might also act synergistically with transfer 
of proinsulin-encoding BM to protect autoimmune-prone NOD mice from diabetes development.  
 
 
140 
 
0 1 2 3 4 5 6
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0 *********
D a y
F
o
x
p
3
+
 T
r
e
g
/s
p
le
e
n
 (
x
1
0
-3
)
0 1 2 3 4 5 6
0
1 0
2 0
3 0 *** *** *** ***
D a y
F
o
x
p
3
+
 T
r
e
g
(%
 o
f 
to
ta
l 
C
D
4
+
T
 c
e
ll
s
)
P B S
IL -2 / I l-2
 
 
0 1 2 3 4 5 6
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
D a y
F
o
x
p
3
+
 T
r
e
g
/L
N
 (
x
1
0
-3
)
****
0 1 2 3 4 5 6
0
5
1 0
1 5
D a y
F
o
x
p
3
+
 T
r
e
g
(%
 o
f 
to
ta
l 
C
D
4
+
 T
 c
e
ll
s
) * *** *** ***
 
  
A B 
C D 
Figure 5.4 - Foxp3+ Treg expansion in spleen and LN of NOD mice following IL-2/αIL-2 complex 
treatment.  
NOD mice were injected with IL-2/αIL-2 or PBS i.p. for three consecutive days. At indicated time 
points, the total number of CD4+FoxP3+ Treg (A, C) and their proportion of total CD4+ T cells (B, D) 
in spleen (A, B) and LN (C, D) were determined using flow cytometry. Data are from 1-2 experiments 
at each time point, n=4-7. Error bars show S.D. Two-way ANOVA followed by Bonferroni post-test. 
(*p<0.05, **p<0.01, ***p<0.001 between IL-2/αIL-2 and PBS). 
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5.2.3 IL-2/αIL-2 complex enhances Treg expression of CD25, Foxp3 and other markers indicative 
of suppressive function  
Next, the phenotype of IL-2/αIL-2-expanded Treg was assessed as an indicator of Treg 
function. Increased CD25 and Foxp3 expression by Treg is observed following IL-2/αIL-2 
treatment (Webster et al., 2009) and increased expression of these markers has been associated with 
increased suppressive function (Wan & Flavell, 2007). Similarly, increased expression of TNFRII, 
glucocorticoid-induced TNFR-related receptor (GITR), LAG-3, and CD103 have been associated 
with suppressive function Treg (Chen et al., 2008b; Huang et al., 2004; McHugh et al., 2002; 
Zabransky et al., 2012). Since IL-2/αIL-2 complex expands Treg, it might be expected that this 
increase would be due to induction of peripheral iTreg, rather than an increase in emergence of 
thymic-derived nTreg. Expression of the transcription factor, helios, is a marker of nTreg (Singh et 
al., 2015; Thornton et al., 2010). To determine the phenotype of IL-2/αIL-2-expanded Treg, NOD 
mice were treated with IL-2/αIL-2 or PBS for three consecutive days and Treg phenotype was 
analysed two days later. 
CD25 expression by CD4+Foxp3+ Treg from spleen and LN was significantly higher in IL-
2/αIL-2-treated mice than in PBS-treated controls (Fig. 5.5A). Foxp3 expression by Treg was 
increased in spleen following IL-2/αIL-2 treatment, but Foxp3 expression was not significantly 
altered in LN (Fig. 5.5B). As expected, most CD4+Foxp3+ Treg in spleen and LN expressed GITR, 
and the proportion of GITR-expressing Treg was not altered by IL-2/αIL-2 treatment (Fig. 5.5C). 
However, the level of GITR expression by Treg from spleen and LN was significantly increased in 
response to IL-2/αIL-2 treatment (Fig. 5.5D). The proportion of Treg from spleen and LN 
expressing LAG-3 remained unchanged after IL-2/αIL-2 treatment (Fig. 5.5E). The proportion of 
TNFRII-expressing Treg was increased in IL-2/αIL-2-treated mice compared to PBS-treated mice 
for spleen, yet remained unchanged in LN (Fig. 5.5F). The proportion of Treg from spleen and LN 
expressing CD103 was increased after IL-2/αIL-2 treatment (Fig. 5.5G). Finally, the proportion of 
Treg expressing helios in spleen and LN did not differ between IL-2/αIL-2-treated and PBS-treated 
mice (Fig. 5.5H). 
These data are in agreement with increased expression of CD25 and Foxp3 following IL-
2/αIL-2 treatment and constitutive GITR expression by Treg observed in other studies (McHugh et 
al., 2002; Webster et al., 2009). The fact that IL-2/αIL-2 treatment did not alter the proportion of 
helios-expressing Treg might indicate IL-2/αIL-2-expanded Treg are iTreg, rather than nTreg, 
although there is conjecture as to whether helios is an exclusive marker of nTreg (Gottschalk et al., 
2012). The increase in CD25, Foxp3, GITR, CD103 and TNFRII expression by Treg in IL-2/αIL-2-
treated mice may indicate an increase in suppressive function.    
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Figure 5.5 – Enhanced Treg expression of CD25, Foxp3, GITR, TNFRII and CD103 following 
IL-2/αIL-2 complex treatment. 
NOD mice were injected with IL-2/αIL-2 or PBS i.p. for three consecutive days. On day 4 of 
treatment, the phenotype of CD4+Foxp3+ Treg in spleen and LN was determined using flow cytometry. 
(A) CD25 MFI, (B) Foxp3 MFI, (C) GITR+ Treg (%) (D) GITR MFI, (E) helios+ Treg (%), (F) LAG-
3+ Treg (%), (G) TNRFII+ Treg (%) and (H) CD103+ Treg (%). Data are pooled from two independent 
experiments. Each point represents single mouse. Error bars show S.D. One-way ANOVA followed by 
Tukey post-test. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
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5.2.4 IL-2/αIL-2 complex increases the frequency of non-Treg immune cell populations 
The IL-2/αIL-2 complex generated with the anti-IL-2 mAb, JES6-1, has been shown to be 
selective for Treg in C57BL/6 mice (Webster et al., 2009) due to enhanced signalling through the 
high-affinity IL-2Rα, CD25. In contrast, the anti-IL-2 mAb, S4B6, promotes signalling though IL-
2Rβ (CD122) leading to expansion of CD8+ Tmem and NK cells (Boyman et al., 2006). It is 
possible that the selectively of IL-2/JES6-1 complex for Treg is different in NOD mice and other 
non-Treg cell populations might be expanded also. Expansion of potentially pathogenic, IL-2-
responsive cell types such as CD8+ T cells, NK and NKT cells after IL-2/αIL-2 treatment might be 
detrimental in the context of proinsulin transgenic BM transfer. To test the effect of IL-2/JES6-
1complex on non-Treg cell subsets, NOD mice were injected with IL-2/αIL-2 or PBS daily for three 
consecutive days and lymphocyte populations were analysed two or three days after the final IL-
2/αIL-2 administration.  
The total number and proportion of CD8+ T cells of total leukocytes was not altered by IL-
2/αIL-2 treatment in spleen or LN (Fig. 5.6A, B). The total number and proportion of CD8+ TCM of 
total CD8+ T cells remained unchanged after IL-2/αIL-2 treatment in spleen and LN (Fig. 5.6C, D). 
However, the total number and proportion of CD8+ TEM of total CD8
+ T cells was significantly 
higher in IL-2/αIL-2-treated mice compared to PBS-treated mice in spleen, yet remained unchanged 
in LN (Fig. 5.6E, F). NK and NKT cells were defined in the present study by expression of CD49b, 
as NOD mice do not express NK1.1 (Baxter et al., 1997). As such, the total number and proportion 
of NKT cells of total leukocytes was increased following IL-2/αIL-2 treatment in spleen, but not in 
LN (Fig. 5.7A, B). Similarly, the total number and proportion of NK cells of total leukocytes was 
higher in spleen of IL-2/αIL-2-treated mice compared to PBS-treated mice, but not in LN (Fig. 
5.7C, D). An increase in the total number and proportion of CD11chi DC in spleen was observed in 
response to IL-2/αIL-2 treatment, yet these parameters were not affected in LN (Fig. 5.7E, F). 
Finally, the total number of B cells in spleen and LN did not differ significantly between IL-2/αIL-
2-treated and PBS-treated mice (Fig. 5.7G). Interestingly, the proportion of B cells from spleen was 
significantly lower after IL-2/αIL-2 treatment, but remained unchanged in LN (Fig. 5.7H). It is 
possible that IL-2/αIL-2 treatment increased the cellularity of spleen, however, there was no 
significant difference between spleen cellularity in IL-2/αIL-2-treated (57.0x106±12.7) and PBS-
treated (40.0x106±9.9) mice. These data suggest treatment with IL-2/JES6-1 complex not only 
expands Treg, but also non-Treg cell populations including CD8+ TEM, NK- and NKT-like cells as 
well as DC in NOD mice.  
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Figure 5.6 – Expansion of CD8+ TEM in spleen following IL-2/αIL-2 complex treatment. 
NOD mice were injected with IL-2/αIL-2 or PBS i.p. for three consecutive days. On day 5 or 6 of 
treatment, the total number of CD8+ T cells (A), CD8+ T cells as a proportion of total leukocytes (B), 
the total number of CD44hiCD62Lhi CD8+ TCM (C), CD8
+ TCM as a proportion of total CD8
+ T cells 
(D), the total number of CD44hiCD62Llo CD8+ TEM (E) and CD8
+ TEM as a proportion of total CD8
+ T 
cells (F) were determined in spleen and LN using flow cytometry. Data are pooled from two 
independent experiments. Each point represents a single mouse. Error bars show S.D. One-way 
ANOVA followed by Tukey post-test. (*p<0.05, **p<0.01). 
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Figure 5.7 – Expansion of NKT cells, NK cells and DC in IL-2/αIL-2-treated mice. 
NOD mice were injected with IL-2/αIL-2 or PBS i.p. for three consecutive days. On day 5 or 6 of 
treatment, the total number (left panel) and their proportion of total leukocytes (right panel) of 
TCRβ+CD49b+ NKT cells (A, B), CD3-CD49b+ NK cells (C, D), CD11chi DC (E, F) and B220+ B 
cells (G, H) were determined in spleen and LN using flow cytometry. Data are pooled from two 
independent experiments. Each point represents a single mouse. Error bars show S.D. One-way 
ANOVA followed by Tukey post-test. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
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5.2.5 Transfer of proinsulin transgenic BM alters diabetes development in an age-dependent manner 
Since transferred G9 T cells are inactivated in proinsulin transgenic recipients, it is possible 
that transfer of proinsulin-encoding BM to NOD recipients might inactivate host diabetogenic 
insulin-specific CD8+ T cells, preventing further β-cell damage and subsequently protecting NOD 
recipients from diabetes. To identify the therapeutic window in which instating tolerogenic 
proinsulin expression protects from diabetes development, NOD mice at defined disease stages 
were used as recipients of BM (In't Veld, 2014). In 16-week old, pre-diabetic NOD mice β-cell 
autoimmunity is well-established and destructive, and these mice would possess the minimum 
functional β-cell mass to maintain normoglycemia. It is possible that transfer of proinsulin 
transgenic BM at this disease stage might prevent further β-cell damage, thereby inhibiting 
progression to hyperglycemia. In 10-week old NOD mice substantial insulitis, that is, immune cell 
infiltration in the islets, would be expected and it might be possible that proinsulin-encoding BM 
transfer at this disease stage would prevent recipients developing overt diabetes. NOD mice at 6-
weeks of age show evidence of immune cells surrounding and infiltrating the pancreatic islets, and 
it may be possible to prevent destructive insulitis and diabetes by intervening at this disease stage. 
Also, expanding Treg concurrently might help to promptly suppress inflammation to allow for 
mature proinsulin-encoding APC derived from transferred BM to induce T-cell tolerance. To test 
the effect of proinsulin-encoding BM transfer and Treg expansion on diabetes development at 
different stages of islet autoimmunity, 16-, 10- and 6-week old NOD mice were irradiated (300cGy) 
prior to transfer of NOD or proinsulin transgenic BM with or without IL-2/αIL-2 administration. 
Diabetes incidence was assessed commencing one week after BM transfer, for 16-week old 
recipients, or at approximately 80 days of age for 6- and 10-week old recipients.  
Development of diabetes did not differ between 16-week old recipients of proinsulin 
transgenic BM and NOD BM (Fig. 5.8A). While minor changes were apparent, no significant 
differences were observed between groups (Fig. 5.8A) While low-dose irradiation without BM 
transfer appeared to reduce diabetes incidence compared to untreated NOD mice, statistical 
significance was not reached due to low number of replicates in the 300cGy/no BM group (Fig. 
5.8A). It should be noted that the untreated mice represent a cumulative cohort of female NOD mice 
run concurrently with BM transfer experiments. As such, the onset of diabetes development in this 
untreated cohort was prior to BM transfer in experimental mice (indicated by the red arrow), and all 
experimental mice were negative for glycosuria prior to irradiation and BM transfer. Whilst there 
were no significant differences observed between treatment or control groups based on analysis 
using a log-rank test, there was a very noticeable trend toward an increase in diabetes incidence for 
10-week old recipients of proinsulin transgenic BM compared to NOD BM (Fig. 5.8B). IL-2/αIL-2 
treatment did not alter diabetes incidence for recipients of proinsulin transgenic BM and NOD BM 
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(Fig. 5.8B). Similarly to recipients at 16 weeks of age, low-dose irradiation without BM transfer 
appeared to reduce diabetes incidence in 10-week old NOD mice compared to untreated NOD mice, 
yet this was not significant (Fig. 5.8B). Diabetes incidence was significantly increased in 6-week 
old recipients of proinsulin transgenic BM compared to recipients of NOD BM (Fig. 5.8C). Despite 
the increased penetrance of diabetes in recipients of proinsulin transgenic BM, the time of diabetes 
onset in this group was relatively similar to that of recipients of NOD BM and untreated NOD mice 
(Fig. 5.8C). A noticeable trend was observed in that diabetes incidence appeared to be increased for 
IL-2/αIL-2-treated recipients of NOD BM compared to PBS-treated recipients of NOD BM treated, 
however, this was not significant (Fig. 5.8C). No such trend was observed for IL-2/αIL-2-treated 
recipients of proinsulin transgenic BM (Fig. 5.8C). The diabetes incidence was similar between 
untreated and 300cGy/no BM groups (Fig. 5.8C).  
In recipients of proinsulin transgenic BM, diabetes development was not altered at 16 
weeks, while there was a noticeable trend towards an increase in diabetes incidence at 10 weeks and 
this increased diabetes incidence was significant at 6 weeks. It is possible that the increased diabetes 
penetrance is due to priming of an immune response by the proinsulin transgene. It might be 
expected that this would be more prominent in younger NOD recipients due to the predominance of 
insulin specificities at this stage (Wong et al., 1999). On the other hand, transfer of NOD BM 
appeared to impede diabetes development more so in younger NOD recipients, which is consistent 
with an increased repertoire of potentially diabetogenic immune cells present in transferred BM of 
older NOD mice. Low-dose irradiation without transfer of BM might be more effective in inhibiting 
diabetes development when performed in older NOD mice, suggesting established diabetogenic 
responses evident at the pre-diabetic stage may be cleared by irradiation resulting in reduced 
diabetes incidence. Therefore, transfer of proinsulin transgenic BM facilitated by low-dose 
irradiation affects diabetes development in an age-dependent manner. 
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Figure 5.8 – Proinsulin transgenic BM increases the penetrance of diabetes when transferred to 
6-week old NOD recipients. 
Sixteen- (A), ten- (B) and six-week old (C), non-diabetic female NOD mice were irradiated (300cGy) 
and 2x107 NOD or proinsulin transgenic BM cells transferred. One group were irradiated without BM 
transfer and another group left untreated. Recipients of NOD and proinsulin transgenic BM were 
injected with IL-2/αIL-2 or PBS i.p. on day 0, 1 and 2 after transfer. Mice were screened for glycosuria 
weekly commencing one week after transfer (A) or at approximately 80 days of age (B, C). Diabetes 
was confirmed by two consecutive weekly readings of non-fasting BGL>12mM. Survival curves 
showing overall diabetes incidence (A-C). Data are pooled from at least three independent 
experiments. Log-rank (Mantel-Cox) test. (**p<0.01: NOD BM vs proIns Tg BM). 
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5.2.6 Donor-type leukocyte development is observed in peripheral blood from 6-week old NOD 
recipients of proinsulin transgenic HSPC  
 Clinically, transfer of HSPC is now more widely used due to the ease of harvesting blood 
derived CD34+ cells in patients compared to bulk BM aspirate (Deotare et al., 2015). Furthermore, 
transfer of HSPC negates the effect of transferring potentially diabetogenic immune cells residing 
within bulk BM, which might have been a confounding factor in interpretation of experiments using 
transfer of BM. Also, transfer of HSPC, rather than BM, meant age-mismatched NOD donors could 
be used in future experiments as harvesting BM from NOD mice younger than 6 weeks of age could 
be technically challenging. It is possible, however, that effects of transfer might differ depending on 
whether HSPC or BM was transferred. To test this, 6-week old NOD mice were irradiated (300cGy) 
prior to transfer of NOD or proinsulin transgenic HSPC. Development of donor-type leukocytes 
was assessed in peripheral blood six weeks after transfer.  
Lin-c-kit+ HSPC (CD45.1+CD45.2+), that were congenically distinct from recipients 
(CD45.1+CD45.2), were sorted to a high purity using FACS (Fig. 5.9A, B). Six weeks after 
irradiation and transfer of HSPC, there were fewer peripheral blood leukocytes in recipients of both 
NOD and proinsulin transgenic HSPC compared to unirradiated NOD mice but the total number of 
leukcoytes was similar for recipients of both NOD and proinsulin transgenic HSPC (Fig. 5.10A). 
This indicates recipients remain lymphopenic for at least six weeks following low-dose irradiation. 
The total number of donor-type DC, B cells, myeloid and T cells in peripheral blood did not differ 
between recipients of NOD and proinsulin transgenic HSPC (Fig. 5.10B-F). Similarly, there was no 
significant difference in the overall proportion of donor-type leukocytes between recipients of NOD 
and proinsulin transgenic HSPC (Fig. 5.11A). At six weeks after transfer, the overall proportion of 
donor-type leukocytes was lower in recipients of HSPC (approximately 40%, Fig. 5.11A) than in 
recipients of bulk BM (approximately 60%, Fig. 5.1A). No significant differences were observed 
for the proportion of donor-type cell subsets between recipients of NOD and proinsulin transgenic 
HSPC (Fig. 5.11B-F). The proportion of donor-type myeloid and T cells appeared to be higher in 
recipients of bulk BM (Fig. 5.1D-F) compared to recipients of HSPC (Fig. 5.11D-F), which may 
account for the reduced donor-type development in recipients of HSPC compared to BM. 
Importantly, development of donor-type APC subsets, DC and B cells, was similar between 
recipients of HSPC (Fig. 5.11B, C) and BM (Fig. 5.1B, C). 
These data demonstrate substantial development of mature leukocyte populations derived 
from both NOD and proinsulin HSPC in peripheral blood of recipients after low-dose irradiation. It 
should be noted that due to the nature of these long-term diabetes incidence studies, donor-type 
leukocyte development was not confirmed in lymphoid tissue, however, data in Figure 5.2 
demonstrated donor-type leukocyte development in peripheral blood was similar to spleen under 
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like conditions. This finding confirms HSPC transfer as a valid means to introduce transgenic 
proinsulin expression to wild type NOD recipients without the confounding factor of transferring 
mature immune cells as for transfer of bulk BM. 
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NOD proIns Tg 
94.5±4.0 93.7±2.6 
Figure 5.9 – High purity of FACS-sorted HSPC from NOD and proinsulin transgenic BM. 
HSPC (lin-c-kit+) from BM of NOD and proinsulin transgenic were sorted using FACS. (A) 
Representative FACS plots of lin- and c-kit-stained bulk BM (‘Pre-sort’, top panel) and sorted HSPC 
(‘Post-sort, bottom panel)  from NOD and proinsulin transgenic mice, (B) Final proportion of lin-c-kit+ 
HSPC of live (PI-) cells from NOD and proinsulin transgenic mice, mean ± S.D. Dot plots (A) are 
representative of seven independent experiments.  Data in table (B) are pooled from seven independent 
experiments. 
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Figure 5.10 – No difference in donor-type leukocyte development between sublethally irradiated 
recipients of NOD and proinsulin transgenic HSPC.  
Five- to six-week old NOD (CD45.1+CD45.2-) mice were irradiated (300cGy) and 2x105 NOD 
(CD45.1+CD45.2+) or proinsulin transgenic (CD45.1+CD45.2+) purified HSPC transferred. Six weeks 
later, the total number of total leukocytes (A) and the total number of donor-type (CD45.1+CD45.2+) 
DC (B), B cells (C), myeloid cells (D), CD8+ T cells (E) and CD4+ T cells (F) in peripheral blood 
were determined using flow cytometry. Data are pooled from two independent experiments. Each 
point represents a single mouse. Error bars shows S.D. One-way ANOVA followed by Tukey post-test 
(A) or student’s t-test (B-F). (***p<0.001). 
 
A B 
C D 
E F 
Overall DC 
Myeloid cells B cells 
CD4+ T cells CD8+ T cells 
153 
 
N O D p r o In s  T g
0
2 0
4 0
6 0
8 0
1 0 0
T
o
ta
l 
d
o
n
o
r
 c
e
ll
s
 (
%
)
n .s .
N O D p r o In s  T g  
0
2 0
4 0
6 0
8 0
1 0 0
D
o
n
o
r
 D
C
 (
%
)
n .s .
 
N O D p r o In s  T g  
0
2 0
4 0
6 0
8 0
1 0 0
D
o
n
o
r
 B
 c
e
ll
s
 (
%
)
n .s .
N O D p r o In s  T g  
0
2 0
4 0
6 0
8 0
1 0 0
D
o
n
o
r
 m
y
e
lo
id
 c
e
ll
s
 (
%
)
n .s .
 
N O D p r o In s  T g
0
2 0
4 0
6 0
8 0
1 0 0
D
o
n
o
r
 C
D
8
+
 c
e
ll
s
 (
%
)
n .s .
N O D p r o In s  T g  
0
2 0
4 0
6 0
8 0
1 0 0
D
o
n
o
r
 C
D
4
+
 c
e
ll
s
 (
%
)
n .s .
 
  
A B 
C D 
E F 
Figure 5.11 – No difference in donor-type leukocyte development between sublethally irradiated 
recipients of NOD and proinsulin transgenic HSPC. 
Five- to six-week old NOD (CD45.1+CD45.2-) mice were irradiated (300cGy) and 2x105 NOD 
(CD45.1+CD45.2+) or proinsulin transgenic (CD45.1+CD45.2+) purified HSPC transferred. Six weeks 
later, the proportion of donor-type (CD45.1+CD45.2+) total cells (A), DC (B), B cells (C), myeloid 
cells (D), CD8+ T cells (E) and CD4+ T cells (F) in peripheral blood were determined using flow 
cytometry. Data are pooled from two independent experiments. Each point represents a single mouse. 
Error bars shows S.D. Student’s t-test.  
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5.2.7 Transfer of proinsulin transgenic HSPC does not increase diabetes penetrance in 6-week old 
NOD recipients 
In order to compare incidence studies using BM transfer with incidence studies using HSPC 
transfer, diabetes incidence was assessed for 6-week old NOD recipients of NOD and proinsulin 
transgenic HSPC. Similarly to transfer of bulk BM, the age diabetes onset was not affected by 
transfer of proinsulin transgenic or NOD HSPC when compared to untreated NOD mice (Fig. 
5.12A). The overall incidence was similar between recipients of NOD and proinsulin transgenic 
HSPC compared to untreated NOD mice (Fig. 5.12A). Unlike transfer of proinsulin transgenic BM 
(Fig. 5.8C), transfer of proinsulin transgenic HSPC did not alter diabetes development in 6-week 
old NOD recipients (Fig. 5.12A). Quantifying the level of donor-type leukocytes in peripheral blood 
from recipients of HSPC allowed for exploration of the relationship between the level of donor-type 
leukocyte development and the age of diabetes onset. There was no correlation between donor-type 
leukocyte development and the age of diabetes onset for recipients of NOD HSPC (Fig. 5.12B). 
Interestingly, there was a negative correlation between the proportion of donor-type leukocytes and 
the age of diabetes onset for recipients of proinsulin transgenic HSPC (Fig. 5.12B). Since the 
overall diabetes incidence was similar in HSPC recipients at 6 weeks of age and untreated NOD 
mice, diabetes incidence following transfer of BM and HSPC can be compared between NOD 
recipients at different ages. However, as diabetes incidence was not increased following proinsulin 
transgenic HSPC transfer, the increased penetrance of diabetes following transfer of proinsulin-
encoding BM to 6-week old NOD recipients was BM-dependent. 
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Figure 5.12 – Transfer of proinsulin-encoding HSPC does not increase the penetrance of 
diabetes in 6-week old NOD recipients.  
Five- to six-week old female NOD mice were irradiated (300cGy) and 2x105 NOD or proinsulin 
transgenic purified HSPC transferred. One group was left untreated. Mice were screened weekly for 
glycosuria commencing at approximately 80 days of age. Diabetes was confirmed by two consecutive 
weeks of non-fasting BGL>12mM. (A) Survival curve showing diabetes incidence. (B) Correlation of 
the proportion of donor-type leukocytes in peripheral blood 6 weeks after HPC transfer and the age of 
diabetes onset shown with linear regression. Data are pooled from two independent experiments. Each 
point represents a single mouse. Log-rank (Mantel-Cox) test (A) and Pearson correlation (B). 
(*p<0.05: proIns Tg HPC (B)). 
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5.2.8 Increased donor-type leukocyte development in 3-week old recipients of proinsulin transgenic 
compared to NOD HSPC  
Since transfer of proinsulin-encoding HSPC did not alter diabetes incidence when 
performed in 6-week old NOD recipients, it is possible that transferring proinsulin transgenic HSPC 
to NOD recipients prior to the onset of insulitis may protect from diabetes development. To test 
this, 3-week old NOD mice were irradiated (300cGy) and NOD or proinsulin transgenic HSPC 
transferred. Development of donor-type leukocytes in peripheral blood was assessed six weeks after 
transfer. The total number of leukocytes in peripheral blood of recipients was significantly lower 
than unirradiated NOD mice but was not different between recipients of NOD and proinsulin 
transgenic HSPC, with or without IL-2/αIL-2 treatment (Fig. 5.13A). The total number of donor-
type DC, B cells, myeloid and T cells did not differ significantly between recipients of proinsulin 
transgenic and NOD HSPC (Fig. 5.13B-F). The proportion of donor-type leukocytes was higher for 
PBS-treated recipients of proinsulin transgenic compared to NOD HSPC (Fig. 5.14A). The 
proportion of donor-type DC, CD8+ and CD4+ T cells was higher in PBS-treated recipients of 
proinsulin transgenic compared to NOD HSPC, while IL-2/αIL-2 treatment reduced development of 
these cell subsets for recipients of proinsulin transgenic HSPC (Fig. 5.14B, E, F). In recipients of 
proinsulin transgenic HSPC, the proportion of donor-type B cells was higher compared to recipients 
of NOD HSPC and this remained unchanged by IL-2/αIL-2 treatment (Fig. 5.14C). The proportion 
of donor-type myeloid cells was higher in recipients of proinsulin transgenic compared to NOD 
HSPC and this was unchanged by IL-2/αIL-2 treatment (Fig. 5.14D). These data demonstrate 
development of donor-type leukocytes following transfer of HSPC to 3-week old NOD recipients. 
Interestingly, a higher level of donor-type leukocyte development was observed for recipients of 
proinsulin transgenic than NOD HSPC and may indicate increased expression of potentially 
tolerogenic proinsulin expression. Also in recipients of proinsulin transgenic HSPC, IL-2/αIL-2 
treatment inhibited development of donor-type DC and T cells.   
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Figure 5.13 – Substantial donor-type leukocyte development in 3-week old recipients of NOD 
and proinsulin transgenic HSPC. 
Three-week old NOD (CD45.1+CD45.2-) mice were irradiated (300cGy) and 1x105 NOD 
(CD45.1+CD45.2+) or proinsulin transgenic (CD45.1+CD45.2+) purified HSPC transferred. HSPC 
recipients were injected with IL-2/αIL-2 complex or PBS i.p. on day 0, 1 and 2 of transfer. Six weeks 
later, the total number of total leukocytes (A) and the total number of donor-type (CD45.1+CD45.2+) 
DC (B), B cells (C), myeloid cells (D), CD8+ T cells (E) and CD4+ T cells (F) in peripheral blood 
were determined using flow cytometry. Data are pooled from three independent experiments. Each 
point represents a single mouse. Error bars shows S.D. One-way ANOVA followed by Tukey post-
test. (***p<0.001). 
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Figure 5.14 – Increased donor-type leukocyte development in 3-week old, PBS-treated recipients 
of proinsulin transgenic HSPC compared to NOD HSPC.  
Three-week old NOD (CD45.1+CD45.2-) mice were irradiated (300cGy) and 1x105 NOD 
(CD45.1+CD45.2+) or proinsulin transgenic (CD45.1+CD45.2+) purified HPC transferred. HPC 
recipients were injected with IL-2/αIL-2 complex or PBS i.p. on day 0, 1 and 2 of transfer. Six weeks 
later, the proportion of donor-type (CD45.1+CD45.2+) total cells (A), DC (B), B cells (C), myeloid 
cells (D), CD8+ T cells (E) and CD4+ T cells (F) in peripheral blood were determined using flow 
cytometry. Data are pooled from three independent experiments. Each point represents a single mouse. 
Error bars shows S.D. One-way ANOVA followed by Tukey post-test. (*p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001). 
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5.2.9 IL-2/αIL-2 expands host-type CD25+CD4+ T cells in peripheral blood from recipients of 
proinsulin transgenic HSPC 
The data presented in Figure 5.4 indicated CD4+CD25+Foxp3+ Treg expanded 1-2 days after 
IL-2/αIL-2 treatment in NOD mice. It is not known whether IL-2/aIL-2 treatment expands Treg 
following low-dose irradiation, and whether Treg expansion, if evident, is maintained. To test this, 
recipients of HSPC were treated with IL-2/αIL-2 or PBS for three consecutive days starting at the 
time of HSPC transfer. Six weeks later, CD25-expressing CD4+ and CD8+ T cells in peripheral 
blood were enumerated. The total number of CD25-expressing donor-type CD4+ T cells and their 
proportion of host CD4+ T cells remained unchanged following IL-2/αIL-2 treatment in recipients 
of NOD and proinsulin transgenic HSPC (Fig. 5.15A, C). The number of host-type CD25-
expressing CD4+ T cells was higher in recipients of NOD HSPC than recipients of proinsulin 
transgenic HSPC, although, this did not differ significantly with IL-2/αIL-2 treatment (Fig. 5.15B). 
In recipients of proinsulin transgenic HSPC, the proportion of host-type CD25-expressing CD4+ T 
cells increased after IL-2/αIL-2 treatment, yet this remained unchanged in recipients of NOD HSPC 
(Fig. 5.15D). In the CD8+ T cell compartment, the total number of donor- and host-type 
CD25+CD8+ T cells remained unchanged after IL-2/αIL-2 treatment in both recipients of proinsulin 
transgenic and NOD HSPC (Fig. 5.17E, F). Similarly, the proportion of donor- and host-type 
CD25+CD8+ T cells did not differ between recipients of proinsulin transgenic and NOD HSPC 
treated with IL-2/αIL-2 or PBS (Fig. 5.17G, H). Some points require consideration for interpretation 
of these data. Initial timecourse studies analysed Treg expansion in secondary lymphoid organs, it is 
possible that responses in peripheral blood do not reflect those observed in spleen and LN. In 
addition, CD25 expression alone does accurately identify Treg as conventional T cells up-regulate 
CD25 upon activation (Williams et al., 2006). However, no difference in the frequency of CD25-
expressing CD8+ T cells was observed after IL-2/αIL-2 treatment, which may perhaps indicate the 
increase in the proportion of host-type CD25+CD4+ T cells in recipients of proinsulin transgenic 
HSPC represents a specific expansion of Treg.  
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Figure 5.15– Expansion of host-type CD25+CD4+ T cells in recipients of proinsulin transgenic HSPC 
following IL-2/αIL-2 treatment.  
Three-week old NOD (CD45.1+CD45.2-) mice were irradiated (300cGy) and 1x105 NOD 
(CD45.1+CD45.2+) or proinsulin transgenic (CD45.1+CD45.2+) purified HPC transferred. HPC recipients 
were injected with IL-2/αIL-2 complex or PBS i.p. on day 0, 1 and 2 of transfer. Six weeks later, the total 
number of donor-type (CD45.1+CD45.2+) CD25+CD4+ T cells (A), total number of host-type 
(CD45.1+CD45.2-) CD25+CD4+ T cells (B), donor-type CD25+CD4+ T cells (% of host CD4+) (C), host-type 
CD25+CD4+ T cells (% of host CD4+) (D), total number of donor-type CD25+CD8+ T cells (E), total number 
of host-type CD25+CD8+ T cells (F), donor-type CD25+CD8+ T cells (% of donor CD8+) (G), host-type 
CD25+CD8+ T cells (% of host CD8+) (H) were determined in peripheral blood using flow cytometry. Data 
are pooled from two independent experiments. Each point represents a single mouse. Error bars shows S.D. 
One-way ANOVA followed by Tukey post-test. (*p<0.05, **p<0.01, ***p<0.001). 
A 
P B S IL -2 / IL -2 P B S IL -2 / IL -2
0
5
1 0
1 5
H
o
s
t 
C
D
4
+
C
D
2
5
+
 (
%
 o
f 
C
D
4
+
)
p ro In s  T gN O D
*
*
P B S IL -2 / IL -2 P B S IL -2 / IL -2
0
5
1 0
1 5
D
o
n
o
r
 C
D
2
5
+
C
D
4
+
 (
%
 o
f 
C
D
4
+
)
p ro In s  T gN O D
n .s .
n .s .
P B S IL -2 / IL -2 P B S IL -2 / IL -2
0 .0 0 0
0 .0 0 5
0 .0 1 0
0 .0 1 5
0 .0 2 0
0 .0 2 5
D
o
n
o
r
 C
D
2
5
+
 C
D
4
 c
e
ll
s
 (
x
1
0
-3
)
p ro In s  T gN O D
n .s .
n .s .
P B S IL -2 / IL -2 P B S IL -2 / IL -2
0 .0 0
0 .0 2
0 .0 4
0 .0 6
0 .0 8
H
o
s
t 
C
D
2
5
+
 C
D
4
 c
e
ll
s
 (
x
1
0
-3
)
p ro In s  T gN O D
**
n .s .
n .s .
P B S IL -2 / IL -2 P B S IL -2 / IL -2
0
2
4
6
8
1 0
D
o
n
o
r
 C
D
2
5
+
 C
D
8
 c
e
ll
s
 (
%
) n .s . n .s .
p ro In s  T gN O D
P B S IL -2 / IL -2 P B S IL -2 / IL -2
0
1
2
3
H
o
s
t 
C
D
2
5
+
 C
D
8
 c
e
ll
s
 (
%
)
p ro In s  T gN O D
n .s .
n .s .
P B S IL -2 / IL -2 P B S IL -2 / IL -2
0 .0 0 0
0 .0 0 1
0 .0 0 2
0 .0 0 3
0 .0 0 4
0 .0 0 5
D
o
n
o
r
 C
D
2
5
+
 C
D
8
 c
e
ll
s
 (
x
1
0
-3
)
p ro In s  T gN O D
n .s .
n .s .
P B S IL -2 / IL -2 P B S IL -2 / IL -2
0 .0 0 0
0 .0 0 2
0 .0 0 4
0 .0 0 6
0 .0 0 8
H
o
s
t 
C
D
2
5
+
 C
D
8
 c
e
ll
s
 (
x
1
0
-3
)
***
p ro In s  T gN O D
n .s . n .s .
C 
E 
G 
B 
D 
F 
H 
Host-type Donor-type 
CD4+ T cells 
CD8+ T cells 
161 
 
5.2.10 IL-2/αIL-2 treatment reduces diabetes incidence in 3-week old recipients of NOD HSPC 
To test the effect on diabetes development of proinsulin transgenic HSPC transfer to NOD 
recipients prior to the onset of insulitis (In't Veld, 2014), 3-week old NOD mice were irradiated 
(300cGy), NOD or proinsulin transgenic HSPC transferred and diabetes incidence was assessed. 
The time of diabetes onset was similar for recipients of proinsulin transgenic and NOD HSPC 
compared to untreated NOD mice, with the exception of the somewhat delayed onset observed for 
IL-2/αIL-2-treated NOD HSPC recipients (Fig. 5.16A). IL-2/αIL-2 treatment reduced the overall 
incidence of diabetes for recipients of NOD HSPC compared to untreated NOD mice (Fig. 5.16A). 
There appeared to be a reduction in diabetes incidence for IL-2/αIL-2-treated recipients of 
proinsulin transgenic HSPC compared to untreated NOD mice, yet, this was not significant (Fig. 
5.16A) There was no correlation between donor-type leukocyte development and the age of 
diabetes onset for neither recipients of NOD nor proinsulin transgenic HSPC (Fig. 5.16B). These 
data suggest transfer of proinsulin-encoding HSPC to 3-week old NOD recipients did not alter 
diabetes development. However, treatment of recipients of NOD HSPC with IL-2/αIL-2 complex 
reduced diabetes development. Since IL-2/αIL-2 complex was not administrated in the absence of 
low-dose irradiation and HSPC transfer, it is not known whether this protective effect would be 
mediated by IL-2/αIL-2 complex alone, although, this could be explored in the future.  
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Figure 5.16 – IL-2/αIL-2 complex reduced diabetes incidence in 3-week old recipients of NOD 
HSPC. 
Three-week old NOD (CD45.1+CD45.2-) mice were irradiated (300cGy) and 1x105 NOD 
(CD45.1+CD45.2+) or proinsulin transgenic (CD45.1+CD45.2+) purified HSPC transferred. HSPC 
recipients were injected with IL-2/αIL-2 complex or PBS i.p. on day 0, 1 and 2 of transfer. One group 
was left untreated. Mice were screened weekly for glycosuria commencing at approximately 80 days 
of age. Diabetes was confirmed by two consecutive weeks of BGL>12mM. (A) Survival curve 
showing diabetes incidence. (B) Correlation of the proportion of donor-type leukocytes in peripheral 
blood 6 weeks after HPC transfer and the age of diabetes onset shown with linear regression. Data are 
pooled from three independent experiments. Each point represents a single mouse. Log-rank (Mantel-
Cox) test (A) and Pearson correlation (B). (**p<0.01: NOD HPC + IL-2/αIL-2 vs untreated). 
 
 
A 
B 
Irradiation + 
HPC transfer 
0 1 0 0 2 0 0 3 0 0
0
2 0
4 0
6 0
8 0
A g e  o f o n s e t
T
o
ta
l 
d
o
n
o
r
 c
e
ll
s
 (
%
)
p ro In s  T g  H P C
N O D H P C
r= 0 .4 6
r= 0 .7 6
163 
 
5.2.11 Donor-type leukocytes develop after transfer of NOD and proinsulin transgenic HSPC to 3-
day old recipients 
Since transfer of proinsulin-encoding HSPC to 3-week old NOD recipients did not protect 
from diabetes development, it might be possible that transfer of proinsulin transgenic HSPC to 
neonatal NOD recipients will enable development of potentially tolerogenic, proinsulin-expressing 
APC at a very early stage in diabetes progression. To test this, 3-day old NOD mice were irradiated 
(300cGy) and NOD or proinsulin transgenic HSPC transferred intrahepatically. Development of 
donor-type leukocytes was assessed in peripheral blood was assessed six weeks after transfer. 
Similar to 3- (Fig. 5.13A) and 6-week old (Fig. 5.10A) NOD recipients, 3-day old recipients of 
HSPC showed significantly lower total numbers of leukocytes in peripheral blood compared to 
unirradiated NOD mice at six weeks after irradiation and HSPC transfer (Fig. 5.17A). The total 
number of donor-type DC, B cells, myeloid cells and T cells did not differ significantly between 
recipients of NOD and proinsulin transgenic HSPC (Fig. 5.17B-F). Similarly, no significant 
difference was observed for the proportion of donor-type leukocytes between recipients of NOD 
and proinsulin transgenic HSPC (Fig. 5.18A). Donor-type leukocyte development was lower for 3-
day old recipients (approximately 20%, Fig. 5.18A) compared to 3- (approximately 40%, Fig. 
5.14A) and 6-week old recipients (approximately 40%, Fig. 5.11A). A higher degree of variability 
in the proportion of donor-type leukocytes was observed between replicates in the proinsulin 
transgenic HSPC group, which may indicate recipients express varying amounts of transgenic 
proinsulin (Fig. 5.18A). No significant differences were observed in the proportions of donor-type 
DC, B cells, myeloid cells or T cells between recipients of NOD and proinsulin transgenic HSPC 
(Fig. 5.18B-F). These data confirm development of donor-type leukocytes in 3-day old recipients of 
both NOD and proinsulin transgenic HSPC. Therefore, by 6 weeks of age, recipients of proinsulin 
transgenic HSPC may express transgenic proinsulin at level sufficient to prevent diabetes 
development. However, due to time constraints, recipients of NOD and proinsulin transgenic HSPC 
were approximately 120-days old at completion of this thesis. Therefore, no solid conclusions can 
be drawn as yet regarding the effect of low-dose irradiation and transfer of proinsulin-encoding and 
NOD HSPC in 3-day old NOD recipients. 
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Figure 5.17 – Similar donor-type leukocyte development in sublethally irradiated 3-day old 
recipients of NOD and proinsulin transgenic HSPC. 
Three-day old NOD (CD45.1+CD45.2-) mice were irradiated (300cGy) and 2x104 NOD 
(CD45.1+CD45.2+) or proinsulin transgenic (CD45.1+CD45.2+) purified HSPC transferred. Six weeks 
later, the total number of total leukocytes (A) and the total number of donor-type (CD45.1+CD45.2+) 
DC (B), B cells (C), myeloid cells (D), CD8+ T cells (E) and CD4+ T cells (F) in peripheral blood 
were determined using flow cytometry. Data are pooled from two independent experiments. Each 
point represents a single mouse. Error bars shows S.D. One-way ANOVA followed by Tukey post-test 
(A) and student’s t-test (B-F). (*p<0.05). 
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Figure 5.18 – Similar donor-type leukocyte development in sublethally irradiated, 3-day old 
recipients of NOD and proinsulin transgenic HSPC. 
Three day old NOD (CD45.1+CD45.2-) mice were irradiated (300cGy) and 2x104 NOD 
(CD45.1+CD45.2+) or proinsulin transgenic (CD45.1+CD45.2+) purified HSPC transferred. Six weeks 
later, the proportion of donor-type (CD45.1+CD45.2+) total cells (A), DC (B), B cells (C), myeloid 
cells (D), CD8+ T cells (E) and CD4+ T cells (F) in peripheral blood were determined using flow 
cytometry. Data are pooled from two independent experiments. Each point represents a single mouse. 
Error bars shows S.D. Student’s t-test. 
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Table 5.1 Summary of BM/HSPC transfer experiments in Chapter 5 
  
   
Age of recipients 
Cells 
transferred 
Strain Treatment 16 weeks 10 weeks 6 weeks 3 weeks 
Bulk BM NOD + PBS n.s. n.s. n.s. n/a 
+ IL-2/αIL-2 n.s. n.s. n.s. n/a 
Proinsulin 
transgenic 
+ PBS n.s. n.s. Diabetes 
incidence 
increased 
n/a 
+ IL-2/αIL-2 n.s. n.s. n.s. n/a 
Sorted lin- 
c-kit+ HSPC 
NOD + PBS n/a n/a n.s. n.s. 
+ IL-2/αIL-2 n/a n/a n/a n.s. 
Proinsulin 
transgenic 
+ PBS n/a n/a No 
change 
from 
untreated 
NOD 
mice 
n.s. 
+ IL-2/αIL-2 n/a n/a n/a Diabetes 
incidence 
decreased 
Figure 5.19 – Summary of main findings from BM/HSPC transfer experiments in Chapter 5. 
‘Bulk BM’ refers to Figure 5.8, ‘Sorted lin-c-kit+ HSPC’ refers to Figure 5.12 and Figure 5.16. n.s. 
denotes no significant change in diabetes incidence, while n/a denotes that the indicated groups were 
not included in experiments.    
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5.3 Discussion 
 The previous two chapters have demonstrated tolerance induction in naïve and memory 
insulin-specific CD8+ T cells after transfer to mice transgenically expressing proinsulin, 
respectively. Since insulin-reactive CD8+ T cells might be primary contributors to β-cell destruction 
in NOD mice, it is possible that inducing tolerance in these diabetogenic T cells could protect 
susceptible mice from disease development. It has been shown that proinsulin-encoding HSPC 
transfer can protect NOD mice from autoimmune diabetes after myeloblative conditioning (Chan et 
al., 2006; Steptoe et al., 2003). The highly intensive conditioning used eliminates most of the 
pathogenic immune cell pool and reconstitution of the immune system occurs from transferred 
proinsulin-encoding HSPC. It remains to be addressed whether, and at which stage of disease, 
introducing potentially protective, proinsulin-encoding APC will be sufficient to inactivate the 
existing insulin-specific T-cell population and whether this will protect from diabetes development. 
In a clinical setting, only the mildest level of conditioning would be acceptable due to the not 
immediately life threatening nature of T1D and the young age of onset. Therefore, work in this 
chapter sought to determine the feasibility of such as approach in an experimental setting.  
 Since immune responses are mounted toward ubiquitously-targeted antigen, leading to 
rejection of BM encoding ubiquitously-targeted antigen (Coleman et al., 2013), targeting antigen 
using cell-specific promoters might overcome rejection of gene-modified donor BM. Proinsulin-
encoding HSPC are not rejected in recipients subjected to high levels of γ-radiation (950 or 650cGy, 
respectively) (Chan et al., 2006; Steptoe et al., 2003). Given BM from MII.OVA mice is rejected 
when transferred to non-transgenic recipients after low dose irradiation (Coleman et al., 2013), it 
was possible that HSPC/BM from proinsulin transgenic mice would be rejected in a similar manner 
in wild type NOD recipients. In fact, proinsulin-encoding BM/HSPC were not rejected in non-
transgenic NOD recipients, implying proinsulin transgenic HSC were not subjected to the same 
anti-transgene immune response as MII.OVA HSC. Evidence for immunogenicity of gene-modified 
cells in transplantation and gene therapy is provided by studies employing known-immunogenic 
foreign antigens such as green fluorescent protein (GFP) (Eixarch et al., 2009) and OVA 
(Brockstedt et al., 1999) or virus-derived antigens such as herpes simplex virus tyrosine kinase 
(Berger et al., 2006). The inherent immunogenicity of the transgene may determine the likelihood 
of graft rejection (Carpentier et al., 2015). (Pro)insulin is a self-antigen which might explain the 
acceptance of proinsulin-encoding BM/HSPC in the present study. Furthermore, the CD8+ T cell 
immunodominant epitope of OVA binds to MHC class I with high affinity, in contrast to the low-
affinity MHC class I binding of (pro)insulin-derived peptides, in particular InsB15-23. The difference 
in affinity of OVA and (pro)insulin may affect the ability of the transgene to prime a CTL response 
capable of rejecting antigen-encoding HSPC, which may account for the acceptance of proinsulin 
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transgenic BM and HSPC in the present study. Despite the ‘self’ nature of insulin, insulin is 
immunogenic in NOD mice (Lamont et al., 2014; Wong et al., 2009), BALB/c mice (Abiru et al., 
2001) and T1D-susceptible humans (Kent et al., 2005; Yang et al., 2014), as such, immunogenicity 
might not be the single determining factor in immune-mediated rejection of gene-modified HSPC, 
particularly in the context of self-antigens and autoimmunity.  
While IL-2/αIL-2 treatment expanded CD4+Foxp3+ Treg in the present study, similar to 
reports with C57BL/6 mice (Webster et al., 2009), there also appeared to be expansion of 
potentially pathologic CD8+ TEM and NK-like cells, which has been observed in studies using 
another anti-IL-2 mAb, S4B6, in C57BL/6 mice (Boyman et al., 2006). It is possible that IL-2 
signalling defects in NOD mice (Yamanouchi et al., 2007) may account for the more promiscuous 
selectivity of IL-2/JES6-1 in NOD compared to C57BL/6 mice. There is the caveat that CD49b was 
used to identify NK- and NKT-like cells in NOD mice in the present study. While CD49b has been 
used to define NK and NKT cells in NK1.1-negative strains, such as BALB/c (Arase et al., 2001) 
and NOD (Gonzalez et al., 2001a), others have demonstrated CD49b-defined NKT cells are not 
equivalent to CD1d-tetramer-defined NKT cells (Pellicci et al., 2005). Therefore, a more robust 
method for identifying NK and NKT cells would be to use α-galactosylceramide-loaded, CD1d-
tetramer, or NK1.1-congenic NOD mice. NOD mice have a deficiency of NKT cells (Baxter et al., 
1997) and it is thought that this deficiency is crucial for autoimmune diabetes to progress (Yang et 
al., 2001). Activated NKT cells have been shown to inhibit both spontaneous autoimmune diabetes 
(Naumov et al., 2001) and adoptively transferred diabetes (Chen et al., 2005). The apparent increase 
in NKT cells observed in the present study following IL-2/αIL-2 may be beneficial in inhibiting 
diabetes development. The involvement of NK cells is less clear, with evidence to suggest NK cells 
are protective (Lee et al., 2008), disease-promoting (Poirot et al., 2004) or unnecessary for diabetes 
development (Beilke et al., 2012), depending on the model used. With regard to the effect of IL-
2/αIL-2 treatment on CD8+ T cells, expansion of TEM may be expected following IL-2/αIL-2 
treatment, as effector CD8+ T cells are dependent on IL-2 [reviewed in (Boyman & Sprent, 2012)] 
and there was no way of differentiating between effector T cells and true TEM by expression of 
CD44 and CD62L as used in the present study. In addition, Treg and non-Treg cell expansion may 
differ when IL-2/αIL-2 is administered in conjunction with low-dose irradiation and HSPC/BM 
transfer. It is plausible that low-dose irradiation leads to an inflammatory environment in which 
different immune cell subsets become more responsive to IL-2 signalling. Indeed, increased IL-2 
signalling from treatment with a stimulatory IL-2/αIL-2 complex drives OVA-specific CD8+ T cells 
toward autoimmunity (Waithman et al., 2008). Expansion of CD8+ TEM and NK-like cells following 
IL-2/αIL-2 treatment might be exacerbated by lymphopenia following low-dose irradiation and this 
may further contribute to diabetogenicity. In contrast, expansion of NKT-like cells may be 
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beneficial in aiding the regulation of diabetogenic cells. Since the primary outcome of BM/HSPC 
transfer experiments in the present study was overall diabetes incidence, the effect of expanding 
individual IL-2/αIL-2-responsive cell subsets was not investigated. It is possible that the outcomes 
of IL-2/αIL-2 treatment observed in the present study were due to changes in the balance of IL-2 
responsive regulatory and pathogenic cell subsets at different disease stages. Further dissection of 
the cellular response to IL-2/αIL-2 following low-dose irradiation is required to confirm population 
dynamics and how this effects diabetes incidence in recipients.  
 In a therapeutic setting, low-dose IL-2 treatment in recent-onset diabetic NOD mice has 
been shown to reverse hyperglycemia, but not insulitis, in approximately 60% of treated mice 
(Grinberg-Bleyer et al., 2010). Treatment in pre-diabetic NOD mice was associated with an 
increased frequency of islet-infiltrating CD4+Foxp3+ Treg with enhanced expression of CD25, 
Foxp3, CTLA-4 and GITR. Interestingly, low-dose IL-2 did not further increase Treg frequency in 
islets of diabetic NOD mice but enhanced CD25 and Foxp3 expression. These findings suggest low-
dose IL-2 is beneficial in new-onset diabetic NOD mice by increasing suppressive function of islet-
infiltrating Treg rather than Treg expansion. Grinberg-Bleyer et al. demonstrated benefit of IL-2 
treatment in inflammatory sites, in that reduced IFN-γ production by CD8+ T cells was observed in 
pancreas, which may explain the inhibition of progression from insulitis to overt diabetes. In the 
present study, diabetes incidence appeared to be slightly reduced when IL-2/αIL-2 complex was 
coupled with transfer of NOD BM to 16-week old recipients. It is not known which cell subsets are 
expanded by IL-2/αIL-2 complex in the context of irradiation-induced lymphopenia, which persists 
for at least 6 weeks. Compounding the potential effect of lymphopenia on IL-2/αIL-2 treatment is 
the introduction of antigen, that is, proinsulin, by way of proinsulin-encoding BM/HSPC transfer. 
This could prime insulin-specific Treg and/or effector T cells that could either regulate or exert 
effector function, respectively. Utilisation of peptide-loaded tetramers in combination with 
intracellular transcription factor and cytokine analysis could help dissect this further. Interestingly, 
IL-2/αIL-2 treatment was most beneficial in 3-week old recipients of NOD and proinsulin 
transgenic HSPC compared to other disease stages. Defects in Treg survival have been 
demonstrated in 6-week old NOD mice (Tang et al., 2008) and IL-2/αIL-2 treatment might 
overcome this survival defect at this early disease stage, rendering the Treg suppressive, leading to 
reduced diabetes incidence in 3-week old recipients. Also, at this early disease stage, there are 
possibly fewer activated, and thus IL-2 responsive, effector T cells that may be permissive to 
expansion following IL-2/αIL-2 treatment, and conversely, T cells are less permissible to regulation 
later in diabetes development (You et al., 2005). Both factors may account for increased IL-2/αIL-2 
efficacy in early diabetes development and for reduced efficacy at later stages of disease in the 
present study. While timecourse experiments (Fig 5.4) showed the dosing regimen used in the 
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present study was sufficient to expand Treg in NOD mice, it is not known whether greater 
expansion of Treg would be required to inhibit diabetes development. Greater and/or more 
prolonged expansion of Treg using IL-2/αIL2 complex might be achieved through staggering the 
dose over the first few weeks following BM/HSPC transfer and/or by administering IL-2/αIL2 
complex over more than three days. In human T1D, low-dose IL-2 preferentially increases the 
frequency of and CD25, CTLA-4 and GITR expression by Treg (Rosenzwajg et al., 2015). 
Furthermore, IFN-γ production by proinsulin- and GAD65-specific T cells was generally reduced in 
IL-2-responsive patients. It should be noted that the increase in Treg frequency was transient was 
returned to baseline levels at a time relative to IL-2 dosage. The transience of Treg expansion may 
underpin the lack of metabolic efficacy in IL-2 trials in human T1D (Hartemann et al., 2013). It has 
been noted that a longer dosing regimen may increase efficacy and as such a trial testing this in 
recent-onset children is underway (ClinicalTrials.gov Identifier: NCT01862120). Similarly, in the 
present study Treg expansion following IL-2/αIL-2 treatment was not sustained and may account 
for inefficacy when administered to older NOD recipients.  
A potential benefit of combining a Treg-boosting therapy with transfer of proinsulin-
encoding BM/HSPC, as employed in the present study, is expansion of insulin-specific Treg. 
Hyperglycemia was reversed in recent-onset NOD mice after treatment with an anti-CD3 mAb and 
intranasal administration of human proinsulin II B24-C36 peptide (Bresson et al., 2006). While 
InsB9-23-stimulated CD4
+CD25+ T cells derived from InsB9-23-immunised NOD mice prevented 
diabetes development in an adoptive transfer setting (Mukherjee et al., 2003). Indeed, Treg 
displaying a phenotype indicative of suppressive function were expanded by IL-2/αIL-2 complex in 
NOD mice at early stages of diabetes pathogenesis in the present study. To test the suppressive 
function of IL-2/anti-IL2 complex expanded Tregs, sorted CD4+CD25hi T cells could be sorted from 
treated and untreated NOD mice. The ability of these cells to suppress autologous CD25- T cells 
stimulated with anti-CD3, for example, could be examined in vitro. Or, the proliferation of CFSE-
labelled G9 (or 8.3, IGRP-specific CD8+) T cells in response to peptide immunisation could be 
analysed in recipients that have been treated, or not, with IL-2/αIL2 complex as an in vivo approach. 
Generation of suppressive Treg in an autoimmune, inflammatory environment is challenging. To 
overcome this immune dysregulation, Kasagi et al. employed low-dose irradiation (200cGy) in 
combination with transfer of phagocytic cells and GAD65 peptide to induce GAD65-specific Treg 
which prevented further hyperglycemia in recently diabetic NOD mice (Kasagi et al., 2014). The 
fact that hyperglycemic NOD mice did not return to normoglycemia suggests the GAD65-specific 
Treg were regulating the established response without impeding the pathogenic process. There is 
evidence for β-cell regeneration succeeding Treg-mediated regulation (Diaz-de-Durana et al., 2013; 
Luo et al., 2005). If β-cell regeneration was occurring in the study by Kasagi et al., it may be 
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expected that BGL in ‘cured’ mice would decrease. By design, the BM/HSPC transfer experiments 
in the present study did not track BGL over time. In 16-week old recipients it might have been 
possible that BM transfer coupled with IL-2/αIL-2 treatment reduced hyperglycemia more so than 
recipients of BM alone, potentially by regulating established autoimmunity.  
Targeting antigen to fixed APC induces peripheral tolerance in cognate T cells (Turley & 
Miller, 2007). As such, targeting insulin in this manner reversed hyperglycemia in recently diabetic 
NOD mice but this effect was not observed with GAD65 peptides or the IGRP peptide mimetope, 
NRP-V7 (Fife et al., 2006). Hyperglycemic remission was ablated by administration of an anti-PD-
L1 mAb, but Treg involvement in this setting was PD-L1-independent, indicating Treg alone did 
not mediate diabetes protection in this setting. Although, NOD mice have been shown to harbor 
anergic T cells which recognise InsB10-23, suggesting anergy may be broken in certain 
circumstances (Pauken et al., 2013). Furthermore, splenocytes coupled with both InsB9-23 and 
InsB15-23 significantly reduced diabetes incidence compared to sham-coupled splenocytes when 
injected into 4-5 week old NOD mice (Prasad et al., 2012). Reduced diabetes incidence was not 
observed in mice when IGRP206-214, GAD65509-524 or GAD65524-543 peptides were used. There was 
robust protection from insulitis in NOD mice treated with InsB9-23-coupled splenoctyes and Treg 
were again implicated in this protection. These data are consistent with the primacy of anti-insulin 
responses in autoimmune diabetes and tolerance induction to insulin is necessary for preventing 
diabetes development.  
Inducing tolerance to insulin by administration of a plasmid DNA vaccine encoding 
preproinsulin II delayed diabetes development in hyperglycemic NOD mice (Solvason et al., 2008). 
Delayed diabetes development was preproinsulin II-dependent as no effect was observed when the 
DNA vaccine encoded preproinsulin I, consistent with observations in transgenic mice over-
expressing proinsulin II (French et al., 1997) and mice lacking proinsulin I (Moriyama et al., 2003). 
In human T1D, weekly administration of a DNA plasmid encoding proinsulin reduced the 
frequency of proinsulin-specific CD8+ T cells (Roep et al., 2013). This immunological outcome was 
also associated with conservation of C-peptide in proinsulin plasmid treated-patients and connects 
the reduction of pathogenic mediators with metabolic improvement. These studies suggest deleting 
(pro)insulin-specific T cells may be an effective means to impede diabetes development. The 
transiency of antigen presentation derived from plasmid DNA is disadvantageous for long-term 
tolerance induction. Due to the multipotency of HSPC, the tolerogenic capacity of transgenic 
antigen expression can be passed on to progeny APC, thus generating a long-lived, renewing source 
of APC able to induce tolerance to cognate T cells, in theory, indefinitely. From these plasmid DNA 
studies, reduction of insulin-reactive CD8+ T cells might be an indicator of efficacy in autoimmune 
diabetes immunotherapy. On the other hand, studies in which whole insulin or insulin peptides were 
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administered implicate Treg induction as crucial for impediment of diabetes development in NOD 
mice (Bergerot et al., 1999; Fousteri et al., 2010). Similar trials in human T1D patients 
demonstrated that administration of insulin protein did not lead to a sustained metabolic benefit 
(Chaillous et al., 2000; Skyler et al., 2005). Therefore, deletion of antigen-reactive CD8+ T cells 
might be required for observable metabolic benefit in human T1D, rather than exclusively inducing 
Treg. It is possible that an effective immunotherapy will be capable of β-cell antigen-specific T-cell 
deletion in addition to Treg induction, synergistically creating a robustly tolerogenic environment to 
impede diabetes development.  
In another gene-therapy approach, targeting InsB9-23 to hepatocytes using a lentiviral vector 
(LV) protected 90% of NOD mice from diabetes (Akbarpour et al., 2015). This protection was not 
observed when the LV encoded OVA or when InsB9-23 expression was ubiquitously targeted. 
Interestingly, InsB9-23- and OVA-specific CD8
+ T cells were primed following transfer of InsB9-23- 
or OVA-encoding LV constructs, respectively. Despite robust production of IFN-γ by these primed 
CD8+ T cells, hepatocytes expressing either antigen were not rejected, as indicated by high vector 
copy number. In contrast, there was significantly lower copy number of LV vector in liver when 
either transgene was ubiquitously targeted. It is known that targeting delivery of transgene-
expressing cells to the liver may protect from immune-mediated rejection (Follenzi et al., 2004; 
Mingozzi et al., 2003), probably due to effective T-cell tolerance following activation in liver 
(Benseler et al., 2011; Bowen et al., 2004). The authors suggest targeting antigen expression to APC 
in NOD mice is immunostimulatory, due to the CTL response primed after transfer of ubiquitously 
targeted InsB9-23, this is contrasted to driving antigen expression from the hepatocyte-specific 
enhanced transthyretin (ET) promoter. However, CTL were primed in response to ET-promoted 
transgene also. Despite the elicitation of InsB9-23-specific CTL, InsB9-23 expression in hepatocytes 
induced Foxp3+ Treg expansion, particularly evident in pLN, which mediated protection from 
diabetes. It was shown that a dose of an anti-CD3 mAb alongside the InsB-encoding LV construct 
was required to reverse hyperglycemia in recently diabetic NOD mice. This suggests reduction of 
pathogenic T cells is still required to mediate diabetes reversal and highlights the benefit of a 
therapy which specifically depletes pathogenic T cells. These efficacious studies of Treg-dependent 
tolerance induction to insulin emphasise the ability of antigen-specific Treg to negate established 
islet autoimmunity, which at late stages of disease may be reliant mainly on bystander suppression 
than a direct effect on insulin-specific T cells as other β cell-antigen specificities are prominent at 
this stage. 
Studies demonstrating efficacy of tolerance induction to insulin and its effect on diabetes 
development raise the question as to why a similar effect was not observed following transfer of 
proinsulin-encoding HSPC/BM in the present study. Perhaps the tolerogenicity of proinsulin-
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encoding BM is altered after transfer to recipients facilitated by low-dose irradiation, in that APC 
may present proinsulin-derived determinants in an immunostimulatory, rather than tolerogenic, 
capacity. Data from the host laboratory indicates inactivation of transferred G9 T cells occurs in 
recipients of proinsulin-encoding BM, suggesting transgenic proinsulin expression remains 
tolerogenic, at least for TCR transgenic G9 T cells, in the context of low-dose irradiation and BM 
transfer. However, the impact of low-dose irradiation and BM transfer may alter the host immune 
repertoire of NOD recipients in a different manner than is indicated by the G9 T-cell adoptive 
transfer model. That is, the polyclonal repertoire of the NOD mouse would include insulin-reactive 
CD8+ T cells with varying TCR affinities, insulin-reactive CD4+ T cells and T cells potentially 
responsive to modified insulin-derived epitopes, and the response of such T cells to transgenic 
proinsulin expression is not known. The notion of critical checkpoints in progression to diabetes 
might help explain the processes involved here (Andre et al., 1996; Hoglund et al., 1999). An 
important observation in the present study is the similarity in time of diabetes onset between 
different treatment groups within experiments but also between experiments, when BM/HSPC were 
transferred to recipients at different disease stages. It might be expected that if an overt anti-insulin 
CTL response was primed, which may be expected more so following transfer of proinsulin 
transgenic BM than HSPC due to mature proinsulin-expressing APC residing in BM, diabetes onset 
might mimic that seen for diabetogenic T-cell adoptive transfer (Wong et al., 2009) and diabetes 
might ensue soon thereafter. Rapid diabetes onset was not observed even in 6-week old recipients of 
proinsulin transgenic BM, in which overall diabetes incidence was increased compared to recipients 
of NOD BM. Also, T cells may reside in BM from proinsulin transgenic mice that are tolerant to 
insulin in proinsulin transgenic mice, but in the context of lymphopenia in BM recipients may 
become activated and contribute to the increased diabetes penetrance observed in 6-week old 
recipients of proinsulin transgenic BM. Therefore, at least the initial checkpoint was not overcome 
earlier as a result of proinsulin-encoding BM transfer in 6-week old NOD recipients. Evidence for 
dysfunctional antigen presentation as a checkpoint following proinsulin transgenic BM transfer may 
be the higher diabetes incidence in recipients of proinsulin transgenic BM compared to proinsulin 
transgenic HSPC. This perhaps suggests mature APC presenting proinsulin-derived determinants 
residing in BM, but not purified HSPC, mediate events underlying this increased diabetes incidence. 
The fact that proinsulin transgenic BM transfer to 10- and 16- week old recipients did not increase 
diabetes incidence might be a result of the prominence of the anti-insulin response in 6-week old 
NOD recipients (Trudeau et al., 2003). Another point favouring the failure of regulatory 
checkpoints, rather than direct priming of an anti-insulin CTL response, in 6-week old recipients of 
proinsulin transgenic BM is the engraftment of proinsulin transgenic BM (Fig. 5.1) and HSPC (Fig. 
5.10). If anti-insulin CTL were primed, rejection of proinsulin-encoding BM/HSPC might be 
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expected. It is possible that a diabetogenic anti-insulin T-cell response may not recognise and 
destroy proinsulin-encoding APC derived from donor BM/HSPC. Therefore, insulitis may develop 
‘normally’ in recipients of proinsulin-encoding BM but once insulitis has become destructive, the 
checkpoint preventing the descent to hyperglycemia is less effective than in recipients of NOD BM. 
Interestingly, IL-2/αIL-2 treatment in 6-week old recipients of NOD BM also leads to increased 
diabetes incidence similar to recipients of proinsulin transgenic BM. This suggests a similar 
breakdown of checkpoint regulation, plausibly due to an IL-2/αIL-2-mediated effect on insulin-
reactive T cells, which are prominent in 6-week old NOD mice, or other potentially diabetogenic 
immune cells. Some evidence suggests lymphopenia, observed in the present study, is detrimental 
for tolerance induction due to the reduced recovery of Treg (Kaminitz et al., 2010), although, other 
studies have suggested Treg are less susceptible to irradiation-induced apoptosis (Qu et al., 2010a; 
Qu et al., 2010b). The effect of irradiation-induced lymphopenia may contribute to the different 
effects of proinsulin-encoding BM/HSPC transfer on diabetes development at different disease 
stages.  
Due to epitope spreading (Ott et al., 2004; Tian et al., 2006), it might be expected that 
inducing tolerance to insulin at a late stage of diabetes progression would not completely resolve 
established islet autoimmunity. Inactivating insulin-specific T cells may remain beneficial even at 
late time points in diabetes pathogenesis as it may ease the autoimmune pressure on β cells, perhaps 
maintaining metabolic activity, without complete reversal of hyperglycemia. As proinsulin-
encoding BM transfer did not alter established diabetes pathogenesis in the present study, targeting 
the range of known β-cell antigens, might prove capable of reversing diabetes development. Once 
the islet autoimmune response is reversed, remaining β cells may regenerate (Dor et al., 2004; Teta 
et al., 2007), and islet transplantation (Al-Adra et al., 2012; Okitsu et al., 2001) or β-cell 
replacement (Lawandi et al., 2015) strategies could be employed more readily for further metabolic 
improvement.  
In conclusion, this chapter demonstrated the ability of HSPC from mice expressing 
proinsulin under control of an MHC class II promoter to engraft in wild type NOD mice facilitated 
by low-dose irradiation. Expansion of CD4+Foxp3+ Treg was observed in NOD mice following 
treatment with an IL-2/αIL-2 complex. These IL-2/αIL-2-expanded Treg expressed higher levels of 
markers associated with Treg suppression including CD25, Foxp3, GITR and TNFRII. Expansion 
of CD8+ TEM and NK-like cells was also observed following IL-2/αIL-2 treatment. Transfer of 
proinsulin-encoding BM to 10- and 16-week old non-transgenic NOD recipients did not alter 
diabetes development. When proinsulin-encoding BM was transferred to 6-week old NOD 
recipients, diabetes incidence was increased compared to recipients of NOD BM. Transfer of 
proinsulin-encoding HSPC resulted in substantial donor-type leukocyte development in peripheral 
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blood of 6-week old NOD recipients, yet, this had no effect on diabetes development. Interestingly, 
IL-2/αIL-2 treatment reduced diabetes incidence in 3-week old recipients of NOD HSPC. Finally, 
proinsulin-encoding HSPC were transferred to 3-day old NOD mice, but due to time constraints, the 
outcome of diabetes incidence studies was yet to be determined. Data within this chapter suggests 
proinsulin-encoding BM transfer facilitated by low-dose irradiation and treatment with an IL-2/αIL-
2 complex alter diabetes development in an age-dependent manner.  
  
176 
 
5.4 Future directions 
For further progress with regard to Treg expansion, the immune cell population dynamics 
following IL-2/αIL-2 treatment in the context of low-dose irradiation would need to be further 
dissected to determine the potentially beneficial and deleterious effects of IL-2/αIL-2 on diabetes 
progression. Since diabetes incidence in 6-week old recipients of proinsulin-encoding BM was 
higher than in recipients of proinsulin-encoding HSPC, transfer of proinsulin-encoding HSPC to 10- 
and 16-week old NOD recipients would address whether this different effect of BM or HSPC 
transfer is disease stage-dependent. Since IL-2/αIL-2 treatment was most beneficial in 3-week old 
NOD recipients of HSPC, it might be possible that IL-2/αIL-2 would be beneficial also in 3-day old 
NOD recipients. To test this, 3-day old NOD recipients of proinsulin-encoding HSPC could be 
treated with IL-2/αIL-2. To determine the tolerogenic capacity of proinsulin-encoding BM/HSPC 
transfer, β cell-specific T cells might be tracked in recipients using β-cell antigen peptide-loaded 
tetramers. The phenotype of tetramer-binding cells, for example, expression of TCR, CD44 and PD-
1, could be determined as indicators of activation status and tolerance induction. Finally, in a 
broader approach, the effect of targeting multiple β-cell antigens, such as IGRP, GAD65 and ChgA 
together with insulin, to prevent diabetes development could be explored. It may be possible that 
inducing tolerance to multiple β-cell antigens increases the therapeutic window of intervention to 
potentially inactivate the predominant diabetogenic T-cell specificities which may prevent further 
β-cell damage and arrest general islet inflammation, which would be advantageous, particularly in 
human T1D.  
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Chapter 6 
Concluding remarks 
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6.1 Concluding remarks 
T1D results from autoimmune destruction of insulin-producing β cells. CD8+ T cells 
recognizing β-cell antigens are important contributors to this autoimmune process through direct 
lysis of β cells and proinflammatory cytokine production. The current treatments for T1D are daily 
injections of exogenous insulin and in some cases, islet transplantation. However, neither 
exogenous insulin nor islet transplantation mediate the underlying cause of T1D, that is, pathogenic 
islet autoimmunity, and as a result complications can arise from imperfect glycemic control and 
recurrent autoimmunity can destroy newly-transplanted islets. Therefore, there is a need for an 
immunotherapy to antigen-specifically inactivate β-cell antigen-specific CD8+ T cells, without 
compromising protective immunity. Targeting antigen expression to professional APC rapidly 
inactivates cognate CD8+ T cells (Kenna et al., 2010). Since insulin is the primary β-cell antigen 
responsible for autoimmune diabetes in NOD mice (French et al., 1997; Nakayama et al., 2005), the 
present study sought to determine whether targeting proinsulin expression to MHC class II-
expressing APC induces peripheral tolerance in insulin-specific CD8+ T cells. Also, I examined the 
effect of targeted transgenic proinsulin expression on diabetes development in NOD mice after 
BM/HSPC transfer facilitated by low-dose irradiation.  
Data presented in Chapter 3 and 4 demonstrated that the robustly tolerogenic nature of 
antigen expression under control of an MHC class II promoter, previously described in a model 
employing a foreign model antigen, OVA (Kenna et al., 2010), translated to a diabetes-relevant, β-
cell antigen, insulin, in an autoimmune-prone setting. Both naïve and memory G9 T cells 
proliferated extensively prior to undergoing rapid deletion after transfer to mice expressing 
transgenic proinsulin. Remaining G9 T cells in proinsulin transgenic recipients were functionally 
inactive. Interestingly, the frequency of G9 T cells waned over time after transfer to NOD recipients 
in that, by twenty one days after transfer, the number of G9 T cells was significantly lower in NOD 
recipients compared to B16A recipients. It is possible that transferred G9 T cells circulate to pLN, 
encounter insulin presentation and undergo deletion in NOD recipients. It has been demonstrated 
that cross-presentation of OVA in pLN was required for deletion of OT-I T cells (Kurts et al., 
1999). Using models with other antigens, it has been demonstrated that defects in CD8+ T-cell 
tolerance pathways exist in NOD mice. For example, clone 4 T cells on the NOD background 
proliferated and accumulated in pLN of HA transgenic mice (Martinez et al., 2005), while IGRP-
specific CD8+ T-cell accumulation was reduced in NOD mice congenic for protective genetic loci 
(Hamilton-Williams et al., 2012; Hamilton-Williams et al., 2010). Since NOD mice share several 
risk genes with human T1D, it is plausible that such tolerance defects exist in human T1D and 
demonstrating tolerance induction in autoimmune-prone NOD mice might indicate that targeting 
antigen expression using an MHC class II promoter would overcome tolerance defects observed in 
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human T1D also. The response of G9 T cells, characterised by slow deletion and, possibly effector 
function, after transfer to NOD recipients in the present study provided direct comparison to the 
rapid inactivation of transferred G9 T cells in proinsulin transgenic recipients. The mechanism 
underlying rapid inactivation of cognate CD8+ T cells in response to antigen expression under 
control of an MHC class II promoter remains to be precisely elucidated. It is possible that the dose 
of antigen is important, or the MHC class II promoter targets antigen expression to a robustly 
tolerogenic APC subset. Rapid inactivation of β-cell antigen-specific T cells without transient 
effector function would be desirable in terms of a T1D immunotherapy as β-cell damage by T cells 
undergoing tolerance induction would be detrimental for metabolic function in T1D patients 
(Lachin et al., 2014).  
As both naïve and memory G9 T cells were rapidly inactivated after transfer to mice 
expressing proinsulin under control of an MHC class II promoter, the effect on diabetes 
development of introducing potentially tolerogenic proinsulin expression to non-transgenic NOD 
mice was investigated in an immunotherapeutic approach. NOD mice at defined ages, that represent 
distinct stages of diabetes pathogenesis, were used as recipients of BM/HSPC to investigate the 
window in which targeting insulin might impede diabetes development. BM from mice expressing 
transgenic proinsulin engrafted to high levels in non-transgenic NOD recipients when transferred 
after conditioning with low-dose irradiation. This was in contrast to the immune rejection of BM 
from MII.OVA mice in non-transgenic C57BL/6 recipients (Coleman et al., 2012). Therefore, in 
NOD mice, BM/HSPC transfer represents a means to instate tolerogenic proinsulin expression in 
non-transgenic mice. Transfer of proinsulin transgenic BM to 6-week old NOD recipients resulted 
in increased diabetes penetrance compared to transfer of NOD BM. If this increase in diabetes 
penetrance was the result of priming an overt anti-proinsulin transgene CTL response, it might be 
expected that diabetes onset would be earlier in recipients of proinsulin transgenic compared to 
NOD BM, but this was not the case. Also, an increase in diabetes penetrance was not observed 
when proinsulin-encoding HSPC were transferred in the present study, suggesting the breakdown of 
critical checkpoints in diabetes progression following transfer of proinsulin transgenic BM was 
dependent on proinsulin-encoding cells present in the transferred BM. Transfer of proinsulin-
encoding HSPC facilitated by high dose irradiation (650-950cGy) protects NOD mice from diabetes 
development (Chan et al., 2006; Steptoe et al., 2003), indicating irradiation de-bulks the immune 
system of potentially diabetogenic cells. The important contribution of conditioning is highlighted 
in the case of transplantation of autologous HSPC in T1D patients (Li et al., 2012; Voltarelli et al., 
2007), where conditioning acted as an immune re-set, resulting in enhanced β-cell function. Yet, 
this response was transient, as reconstitution of the immune compartment was derived from 
autologous HSPC which are inherently defective and prone to autoimmunity. Targeting antigen 
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expression using an MHC class II promoter to HSPC might overcome this transiency by generating 
a self-renewing population of antigen-expressing APC to inactivate diabetogenic T cells in an 
antigen-specific manner, thus removing the drivers of β-cell destruction. Furthermore, general 
immunosuppression, which might be an outcome from high-intensity conditioning for 
transplantation of HSPC, is an undesired consequence which led to the cessation of T1D clinical 
trials using non-specific immune modulators including cyclosporine (Bougneres et al., 1988; Stiller 
et al., 1984) and anti-CD3 mAb (Keymeulen et al., 2010a). Therefore, it would be highly desirable 
for transfer of antigen-encoding HSPC to be facilitated by low-dose conditioning, preserving 
protective immunity. This will be challenging, since immune responses can be mounted toward 
transgenes (Carpentier et al., 2015; Eixarch et al., 2009), although data in the present study indicate 
proinsulin-encoding HSPC were not rejected in sublethally irradiated NOD mice. However, lower 
dose conditioning may be achievable as efficacy of antigen-encoding HSPC transfer would not rely 
solely on the re-set of the immune system from high-dose conditioning but active T-cell tolerance 
induction imparted by antigen-expressing APC.  
Translating antigen-encoding HSPC transfer from transgenic mouse models to human T1D 
patients would require viral, posssibly lentivial (Bigger & Wynn, 2014), transduction of autologous 
HSPC that could generate a self-renewing population of potentially tolerogenic antigen-expressing 
APC after engraftment. Gene therapy approaches to (re)introduce absent or defective gene products 
have been trialed in patients with genetic disorders including Wiskott-Aldrich syndrome and X-
linked adrenoleukodystrophy (Aiuti et al., 2013; Cartier et al., 2009). Recent advances with LV 
which target receptors expressed by LT-HSC in humans, such as CD105 and CD133, which 
resulted in a high level of transduction in granulocyte-colony stimulating factor (G-CSF)-mobilised 
CD34+ cells (Brendel et al., 2015; Kays et al., 2015), might benefit such an immunotherapeutic 
approach by potentially facilitating high levels of transgene expression in recipients. There are 
obvious considerations for application of such an approach including the fidelity of tolerogenic 
antigen expression, that is, ensuring antigen expression remains tolerogenic even in the presence of 
inflammatory stimuli, defining an optimal conditioning regimen allowing for high levels of 
transduced cell engraftment within safe parameters, and general safety considerations of using LV.  
Most β-cell antigen-specific immunotherapeutic approaches to date have involved nasal, 
oral, subcutaneous or intramuscular administration of peptide, including those from insulin, IGRP 
and GAD65. Peptide immunotherapies generally reply on induction of regulation including Treg as 
the means of tolerance induction (Hjorth et al., 2011). While protection from diabetes development 
has been observed in NOD mice treated with β-cell peptides (Bresson et al., 2006; Daniel & 
Wegmann, 1996; Tian et al., 1996), generally, these findings did not translate to human T1D and if 
efficacy was observed, this was transient (Ludvigsson et al., 2011; Pozzilli et al., 2000; Skyler et al., 
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2005). Since defects have been observed in human T1D with regard to Treg (Brusko et al., 2005; 
Jailwala et al., 2009; Lindley et al., 2005), it might be possible that relying solely on induction of 
regulation is ineffective for adequate control of diabetogenic responses. Actively deleting β cell-
specific T cells might be a more robust means to impede islet autoimmunity by elimination of 
contributors to β-cell destruction and proinflammatory cytokine production. Inducing regulation 
concurrently with T-cell deletion might provide the opportunity to halt further β-cell damage due to 
Treg by-stander suppression. Administration of a proinsulin-encoding plasmid DNA vaccine led to 
deletion of proinsulin-specific CD8+ T cells and an increase in C-peptide compared to placebo 
(Roep et al., 2013), while treatment alefacept (Rigby et al., 2013) showed deletion of CD8+ and 
CD4+ Tmem and increased C-peptide levels. Therefore, deleting CD8+ T cells in human T1D is 
feasible and appears to benefit residual β-cell function.  
Another important consideration in the development of an antigen-specific immunotherapy 
in T1D is the occurrence of epitope spreading. T-cell responses toward insulin are required for 
diabetes development in NOD mice (French et al., 1997; Moriyama et al., 2003; Nakayama et al., 
2005) and priming of T cells recognising other β-cell antigens, including IGRP and GAD65, are 
primed downstream of the anti-insulin response (Krishnamurthy et al., 2006; Prasad et al., 2012). 
Due to the primacy of anti-insulin responses in autoimmune diabetes in the NOD mouse, work in 
this thesis sought to determine whether inducing tolerance to insulin could impede diabetes 
development. Since transfer of proinsulin-encoding HSPC transfer might only impede diabetes 
development when performed in very young recipients, it might be possible that inducing tolerance 
to multiple β-cell antigens would widen the window for intervention to alter diabetes development. 
An approach in which several myelin-associated peptides coupled to peripheral blood mononuclear 
cells (PBMC) has been trialed in human MS patients indicating such an approach is safe and 
reduces antigen-specific T-cell responses (Lutterotti et al., 2013). However, a multiple-peptide 
therapy showed reduced efficacy in preventing syngeneic islet graft rejection in NOD mice 
compared to InsB9-23 therapy alone (Fousteri et al., 2015). Therefore, more preclinical studies in 
NOD mice using multiple peptides are required to determine the feasibility of such a therapy in 
autoimmune diabetes. 
It is becoming increasingly evident that a ‘cure’ for T1D will incorporate therapies to 
modulate the immune system along with strategies to maintain or enhance β-cell function and this 
would provide a multi-pronged approach to address both the immunological and metabolic 
components of T1D. Constant, tolerogenic antigen presentation would be an attractive approach to 
purge the diabetogenic T-cell repertoire, and might also maintain T-cell tolerance by continuously 
inactivating autoreactive T cells recently emerged from the thymus. There is evidence to suggest the 
diagnosis of T1D encapsulates multiple disease types such as absence of autoantibodies at diagnosis 
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and heterogeneity in C-peptide preservation (Gianani et al., 2010). Furthermore, there is evidence to 
suggest some T1D patients may retain some form of β-cell functionality long after T1D diagnosis 
(Keenan et al., 2010). Inactivating β cell-specific T-cell responses might be beneficial even after 
T1D diagnosis in that remaining β-cell mass might be preserved and β-cell function may be restored 
following inactivation of diabetogenic T-cell responses (Krogvold et al., 2015), thereby reducing 
the risk of complication development and islet graft survival might be increased in the absence of 
recurrent autoimmunity. While prevention of T1D with an immunotherapy to induce diabetogenic 
T-cell tolerance would be ideal, treatment of patients with established disease might be beneficial 
also.  
Despite extensive studies using preclinical animal models and clinical trials in human T1D, 
an immunotherapy to halt diabetes progression, within the parameters of tolerable side-effects, in 
human patients has remained elusive. However, recent studies have yielded promising results by 
means of depleting diabetogenic T cells in recent-onset T1D patients. Therefore, the demonstration 
of rapid deletion of insulin-specific CD8+ Tmem by transgenic expression of proinsulin in this 
thesis has potential implications in developing immunotherapeutic approaches toward T1D and may 
provide insight to help overcome issues associated with current therapeutic approaches including 
transient efficacy and impaired protective immunity. 
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